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ABSTRACT 
Activating mutations of the kras proto-oncogene are found in more than 90 % of 
human pancreatic ductal adenocarcinoma (PDAC) and can result in increased 
activity of the NF-κB pathway, leading to constitutive production of pro-
inflammatory cytokines such as TNF-α. Pancreatic cancer progression occurs 
through a series of pre-invasive lesions, pancreatic intraepithelial neoplasias (PanIN 
lesions), which progress into invasive carcinoma.  
 
The aim of this thesis is to understand the autocrine role of TNF-α produced by pre-
malignant epithelial cells in pancreatic tumour progression. This cytokine has already 
been shown to be involved in the progression of cancer. The major hypothesis 
therefore tested was that TNF-α secreted by pre-malignant epithelial cells promotes 
the early stages of pancreatic carcinogenesis by sustaining an inflamed 
microenvironment.  
 
In the spontaneous kras+/LSL-G12D; pdx1-cre mouse model of pancreatic cancer, 
concomitant genetic deletion of the TNF-α/IKK2 pathway substantially delayed 
pancreatic cancer progression and resulted in downregulation of the classical Notch 
target genes hes1 and hey1. Cell lines from the different PanIN bearing mice were 
established and used to dissect the cooperation between TNF-α/IKK2 and Notch 
signalling during PanIN progression. Optimal expression of Notch target genes was 
induced upon TNF-α stimulation of the canonical NF-κB signalling pathway, in 
cooperation with basal Notch signals. Mechanistically, TNF-α stimulation resulted in 
phosphorylation of histone H3 at the hes1 promoter and this signal was lost upon ikk2 
genetic deletion. HES1 suppressed the expression of pparg, which encodes for the 
anti-inflammatory nuclear receptor PPAR-γ. Thus, crosstalk between TNF-α/IKK2 
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and Notch sustained an intrinsic inflammatory profile of the transformed cells. The 
treatment of PanIN bearing mice with rosiglitazone, a PPAR-γ agonist, also delayed 
PanIN progression.  
 
A malignant cell-autonomous, low-grade inflammatory process was shown to operate 
from the very early stages of kras-driven pancreatic carcinogenesis, which may 
cooperate with the Notch signalling pathway to promote pancreatic cancer 
progression. 
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1.1 Cancer and inflammation 
1.1.1 Cancer 
The latest statistical figures show a decrease in cancer incidence and death rates in 
the United States in 2008. This has been achieved after many years of research, 
improved diagnostic and treatment options, further understanding of the mechanisms 
and better prevention and screening throughout the populations. In this same year, 
cancer accounted for 14 % of all deaths worldwide. Lung, breast and colorectal 
cancers are the most commonly diagnosed whereas lung, stomach, liver and 
pancreatic cancers remain the most lethal (Ferlay et al., 2010). 
 
Cancer is a multifactorial disease characterised by an uncontrolled division of cells 
and the ability of these to spread, either by direct growth into adjacent tissues 
through invasion, or by migration into distant sites, also called metastasis. Cancer 
initiation is due to genetic alterations that can be induced by external factors, such as 
chemicals, or internal factors, such as spontaneous mutations or recombination 
events, leading to the deregulation of critical pathways such as cell proliferation and 
cell death.  
 
The most common genetic alterations found in cancers are activating mutations 
within proto-oncogenes or loss of function mutations within genes encoding for 
tumour suppressor proteins (Mathers 2007). Conversion of proto-oncogenes into 
oncogenes can be due to point mutations, which lead to a constitutively active protein 
(such as KRAS versus KRASG12D) (O'Hagan and Heyer 2011) or it can result from 
chromosomal translocations, which usually modify the regulation of the gene 
expression or create new fusion proteins. The chromosomal translocation between 
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chromosomes 22 and 9 in humans is commonly found in patients with chronic 
myelogenous leukaemia and results in the production of the BCR-ABL fusion protein 
(Druker 2008).  
 
Most tumour suppressor genes encode proteins involved in the regulation of cell 
proliferation, inhibiting directly or not the progression of the cell cycle following 
DNA damage and/or stress signals (Sherr 2004). For example, loss of function of 
CDKN2, a cyclin-kinase inhibitor that regulates cell cycle progression, is found in 
various cancers (Kamb et al., 1994). The tumour suppressor protein p53 is also 
frequently mutated in cancer, preventing its main functions of activating DNA repair 
and inducing growth arrest or apoptosis from occurring (Soussi and Lozano 2005).  
 
In 2000, Hanahan and Weinberg proposed that most cancers exhibit six hallmarks, 
corresponding to the deregulation of six biological processes: evasion of apoptosis, 
sustained angiogenesis, limitless replicative potential, tissue invasion and metastasis, 
insensitivity to anti-growth signals and self-sufficiency in growth signals (Hanahan 
and Weinberg 2000) (Figure 1.1 A). However, genetic alterations alone are not 
sufficient to fully account for these characteristics. The role of an inflammatory 
microenvironment, including the role of the tumour microenvironment and its 
components, has been suggested as the 7th hallmark of cancer (Mantovani 2009). In 
2011, Hanahan and Weinberg proposed a revised version of the hallmarks of cancer, 
including two new emerging hallmarks: deregulation of cellular metabolism and 
avoidance of immune destruction (Hanahan and Weinberg 2011) (Figure 1.1 B). 
Two enabling characteristics have also been added as they facilitate the emergence of 
the hallmarks of cancer mentioned above: genome instability and tumour-promoting 
inflammation (Hanahan and Weinberg 2011) (Figure 1.1 B).  
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Figure 1.1: Hallmarks of cancer 
The diagrams represent the hallmarks of cancer described by Hanahan and Weinberg. (A) The six 
original hallmarks of cancer were evasion of apoptosis, tissue invasion and metastasis, insensitivity to 
growth inhibitors, self-sufficiency in growth signals, limitless replicative potential and sustained 
angiogenesis. (B) The revised version of these hallmarks includes two new emerging hallmarks: 
deregulation of cellular metabolism and avoidance of immune destruction and two enabling 
characteristics: genome instability and tumour-promoting inflammation (Hanahan and Weinberg 
2011). Adapted from (Hanahan and Weinberg 2011).  
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1.1.2 Inflammation 
Following tissue injury (physical, chemical or microbiological), inflammation is the 
first response mediated by many molecules and the influx of innate immune cells. 
This non-specific response is usually temporary, and lasts until its resolution: the 
repair of the damaged tissue. Macrophages and neutrophils are the main players 
involved during the acute phase. Tissue-resident innate immune cells are activated 
and secrete a cascade of signalling molecules (mainly cytokines and chemokines) to 
recruit more innate immune cells, such as monocytes and neutrophils, until 
resolution. If the inflammation process occurs in a tissue capable of regeneration, 
tissue damage will be negligible. However, if the tissue is unable to regenerate, the 
resolution of inflammation will be associated with scarring and fibrosis (Stramer et al., 
2007). If the injury is persistent, or if the acute phase is dysregulated, this short-term 
response can lead to chronic inflammation (Philip et al., 2004).  
 
This failure of resolution of inflammation has been associated with cancer and 
tumours were once described as wounds that do not heal (Dvorak 1986). It is now 
well established and accepted that inflammation can be a promoter of malignancy 
(Balkwill and Mantovani 2001; Hanahan and Weinberg 2011). 
1.1.3 Links between inflammation and cancer 
Cancer-related inflammation was first observed and implied by Rudolph Virchow in 
1864 (Virchow 1864). Since then, it has been suggested that chronic inflammation 
can promote cancer initiation and that inflammatory cells are recruited by the cancer 
cells to support tumour growth and progression (Aggarwal et al., 2006; Balkwill and 
Mantovani 2001; Balkwill et al., 2005; Coussens and Werb 2002; Kuper et al., 2000; 
Mantovani et al., 2008; Rakoff-Nahoum 2006). Inflammation is now considered as an 
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enabling characteristic facilitating malignant growth (Figure 1.1 B) (Hanahan and 
Weinberg 2011). 
 
This link is also supported by epidemiological data, where 20 % of all cancers are due 
to infectious agents (Hausen 2006). For example, chronic inflammation induced by 
Helicobacter pylori infection increases the risk of gastric cancer (Zabaleta 2012). Other 
infectious agents such as viruses also play a role in carcinogenesis. For example, 
persistent infection with human papilloma virus (HPV) induces the expression of the 
E6 and E7 viral proteins, which can inactivate tumour suppressor proteins such as 
p53 and therefore support constant cell proliferation. 95 % of cervix cancers are due 
to HPV infection (Saha et al., 2010). Epstein-Barr virus (EBV) and hepatitis B virus 
(HBV) infections are often associated with lymphoma and hepatocellular carcinoma 
respectively. Integration of the HBV DNA into the host DNA can induce 
transformation of the cells via genetic alterations such as amplification, deletion, 
translocation or duplication, further affecting different signalling pathways (Saha et 
al., 2010).  
 
The table below summarises and illustrates the cause-effect relationship between 
chronic inflammation and cancer in different clinical situations (Table 1.1).  
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Table 1.1: The relationship between chronic inflammation and cancer 
Table describes some examples of inflammatory agents and stimuli associated with malignant diseases. 
Adapted from (Balkwill and Mantovani 2001; Porta et al., 2011). 
 
Two pathways have been described to explain the link between inflammation and 
cancer: the intrinsic and the extrinsic pathways (Mantovani et al., 2008) (Figure 1.2). 
The intrinsic pathway occurs downstream of genetic events such as oncogene 
activation or loss of tumour suppressors, whereas the extrinsic pathway is activated 
in the context of infections or inflammatory conditions. In both cases, a variety of 
inflammatory mediators are produced and the inflammatory response is activated and 
regulated through transcription factors such as nuclear factor κB (NF-κB), hypoxia 
inducible factor 1 alpha (HIF1α) and signal transducer and activator of transcription 
3 (STAT3). Activation of the pathways associated with these transcription factors in 
tumour cells leads to increased secretion of cytokines and chemokines, allowing the 
recruitment of immune cells such as macrophages and neutrophils. This cytokine rich 
milieu activates inflammatory pathways in these cells as well as in the stroma, 
therefore generating a positive feedback loop, “fuelling” the inflammation process and 
response. 
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Figure 1.2: Extrinsic and intrinsic pathways linking inflammation and cancer 
Two pathways are involved in the connection between inflammation and cancer: the extrinsic 
pathway, with an inflammatory origin such as infections; and the intrinsic pathway, usually triggered 
by oncogene activations. In both cases, inflammatory pathways are activated (NF-κB, HIF1α and 
STAT3) and inflammatory mediators are released to recruit and activate immune cells. The positive 
feedback loop generated creates a cancer-related inflammatory microenvironment. Adapted from 
(Mantovani et al., 2008).  
 
Triggers involved in these inflammatory signalling pathways are pattern recognition 
receptors [mainly Toll-like receptors (TLR) recognising pathogen-associated 
molecular patterns (PAMP)], cytokines, cycloxygenase-2 (COX2) (involved in the 
synthesis of lipid inflammatory mediators such as prostaglandin), the transcription 
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factor NF-κB (discussed in more details in section 1.3), oxidative stress (leading to 
the production of reactive oxygen species and inducing DNA damage) and finally 
hypoxia inducible factors (HIF) that regulate pathways according to the oxygen 
levels (Balkwill and Mantovani 2001; Porta et al., 2011). The combination of these 
factors contributes to the creation of a cancer-related inflammatory 
microenvironment.  
 
Overall, any type of inflammation appears to predispose to cancer development as for 
pancreatitis and pancreatic cancer (Greer and Whitcomb 2009). It has been 
demonstrated that both intrinsic (kras mutation) and extrinsic (pancreatitis) 
inflammation could accelerate the initiation and progression of pancreatic ductal 
adenocarcinoma (Morris et al., 2010b).  
1.1.4 Tumour microenvironment 
The important role of the tumour microenvironment for tumour progression and 
metastasis was first proposed by Dr Stephen Paget (Paget 1989). He hypothesised 
that cancer cells could be assimilated as “seeds” that required the appropriate 
environment (“soil”) to proliferate. This “seed and soil” hypothesis is still topical and 
the microenvironment is now considered as a therapeutic target (Albini and Sporn 
2007). The tumour microenvironment, also called the stroma, is composed of an 
extracellular matrix and a non-malignant cell compartment of fibroblasts, immune 
cells and blood vessels surrounding the tumour. Its role in tumour progression and 
angiogenesis involves crosstalk with the tumour cells (Figure 1.3).  
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Figure 1.3: The tumour microenvironment 
Tumour cells are surrounded by a rich and dense stroma composed of an extracellular matrix (ECM), 
fibroblasts, immune cells, blood and lymphatic vessels. Bone marrow-derived cells are the precursors 
for the circulating immune cells, which can be recruited by the tumour cells to support tumour growth. 
Adapted from (Joyce and Pollard 2009; Kalluri and Zeisberg 2006). 
 
The tumour microenvironment evolves and is shaped by the cancer cells in a process 
that mimics wound healing in normal homeostasis. Such remodelling involves the 
secretion of mediators such as cytokines, chemokines and growth factors by the 
cancer cells to activate other signalling pathways in an autocrine and/or paracrine 
manner. These signals lead to constant stimulation of cell proliferation, mobility or 
invasion, which contribute to the generation of a supporting environment for tumour 
growth, progression and metastasis (Pietras and Ostman 2010). The main growth 
factors which control the composition of the stroma are hepatocyte growth factor 
(HGF), insulin-like growth factor (IGF), epidermal growth factor (EGF) and 
transforming growth factor beta (TGF-β). This dynamic process is constantly 
amplified over time. Moreover, hypoxic conditions develop in the core of the tumour, 
contributing to the activation of additional signalling pathways (Ide et al., 2006; 
Mahadevan and Von Hoff 2007). 
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1.1.4.1 Extracellular matrix  
The extracellular matrix (ECM) provides structural support for the different cells 
within the tumour microenvironment. The main components of the ECM are 
proteoglycans, hyaluronan and fibrous proteins such as collagen, fibronectin and 
fibrin (Dvorak et al., 2011).  
1.1.4.2 Cancer-associated fibroblasts  
Fibroblasts are widely distributed in tissues and play a role in maintaining their 
homeostasis. Fibroblasts are highly heterogeneous and no specific markers have been 
described to characterise them in vivo, although fibroblast specific protein 1 (FSP1) is 
believed to be an accurate marker (Kalluri and Zeisberg 2006) (Table 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2: Fibroblast markers 
Table describes various fibroblast markers, detailing their function as well as expression on different 
fibroblast types and also on other cells (Kalluri and Zeisberg 2006). 
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When tissues are injured, residential fibroblasts differentiate into myofibroblasts in 
response to paracrine signals. These cells, considered to be an intermediate between 
fibroblasts and smooth muscle cells, contribute to wound healing and undergo 
apoptosis once the tissue is repaired (Li and Wang 2009). The induction of 
myofibroblasts can also cause organ fibrosis, which enhances the risk of cancer 
development (Desmouliere et al., 2004; Radisky et al., 2007). Myofibroblasts are 
found in the reactive tumour stroma and are also called cancer-associated fibroblasts 
(CAFs). 
 
CAFs represent a very heterogeneous population in the tumour microenvironment 
and there is no consensus in the markers used to characterise them (Sugimoto et al., 
2006). Furthermore, their origin still remains elusive. CAFs may derive from multiple 
resident precursors such as endothelial cells, smooth muscle cells and myoepithelial 
cells (Tomasek et al., 2002; Willis et al., 2006). According to other studies, they may 
originate from bone marrow-derived stem cells (Brittan et al., 2002; Direkze et al., 
2004). In this context, the circulating precursors migrate into the wound and 
contribute to the wound healing process. 
 
The role of CAFs in the stroma of many different cancers is more and more topical, in 
particular their contribution to tumour growth and progression (Mueller and Fusenig 
2004). Several studies have shown they can promote tumour neoangiogenesis (Dong 
et al., 2004; Orimo and Weinberg 2006) or that they contribute to the provision of a 
suitable microenvironment for cancer cells (Koukourakis et al., 2006). However, their 
exact role is not clearly defined and appears to be context- and tissue-dependant. 
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Although CAFs were originally considered as quiescent cells, they are now regarded 
as key players for tumour growth, angiogenesis and metastasis as they represent an 
important source of pro-tumorigenic signals (Kalluri and Zeisberg 2006; Ostman and 
Augsten 2009). They can secrete growth factors such as vascular endothelial growth 
factor (VEGF) and stromal cell-derived factor 1 (SDF-1/CXCL12). CXCL12 allows 
the recruitment of endothelial progenitor cells, thus promoting tumour 
neoangiogenesis (Dong et al., 2004; Orimo and Weinberg 2006). In addition, it has 
been shown in colorectal cancer that CAFs and cancer cells have different metabolic 
pathways and that CAFs were able to use the toxic products generated by the cancer 
cells to provide and generate a suitable microenvironment for cancer cell growth and 
survival (Koukourakis et al., 2006). 
 
A study performed by Spaeth et al. demonstrated that mesenchymal stem cells 
present in the tumour microenvironment can differentiate into CAF-like cells (Spaeth 
et al., 2009). This was observed in a murine xenograft model with human ovarian 
cancer cells combined with human mesenchymal stem cells. In the arising tumours, 
cells expressing CAF markers, such as fibroblast activation protein (FAP) and FSP1 
(see Table 1.2), were identified and tumour growth was enhanced (Spaeth et al., 
2009). 
 
In mouse models of skin, breast and pancreatic tumours, CAFs express a pro-
inflammatory gene signature, which contributes to the support of tumour growth by 
enhancing neovascularisation and the recruitment of immune cells. These tumour-
promoting effects are abolished upon inhibition of the transcription factor NF-κB, 
suggesting an important role in tumour progression for this inflammatory signalling 
pathway in stromal cells (Erez et al., 2010).  
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As described in Table 1.2, FAP is one of the fibroblast markers and FAP+ stromal 
cells have been characterised and identified in different tumour models, including 
Lewis lung carcinoma. FAP+ cell population is heterogeneous, sharing mesenchymal 
and/or immunological markers, and represents 2 % of the tumour cells in Lewis lung 
carcinoma model (Kraman et al., 2010). The depletion of FAP+ cells in mice with 
established Lewis lung carcinoma induces necrosis and this biological process is 
mediated by IFN-γ and TNF-α. Cell lines derived from PDAC bearing 
krasG12Dtrp53R172H mice (see section 1.2.8.2) have been used in a subcutaneous model 
and the depletion of FAP+ cells after establishement of the tumours has also been 
associated with tumour regression. In these two models, FAP+ stromal cells have 
been described as important mediators for immune suppression, therefore supporting 
tumour growth (Kraman et al., 2010). 
1.1.4.3 Immune cells 
1.1.4.3.1 Tumour immune surveillance and immunoediting 
The inflammation process triggered in response to tissue injury allows the 
recruitement of leukocytes attracted by the chemokines, cytokines and growth factors 
released by the injured cells (see section 1.1.2). The immune system can also 
efficiently identify and eliminate damaged or transformed cells by a process called 
tumour immune surveillance. The discovery of this immune reaction originates from 
the observation that immunodeficient mice develop more spontaneous tumours than 
immunocompetent animals, but also that they are more susceptible to carcinogen-
induced tumour formation. A role for IFN-γ was initially identified in the tumour 
immune surveillance process as mice lacking IFN proteins are more susceptible to 
chemically-induced carcinogenesis (Dighe et al., 1994; Kaplan et al., 1998). In 
addition, mice deficient in adaptive immune cells (B cells and T cells) are also more 
susceptible to tumour formation (Shankaran et al., 2001). A large number of studies 
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have been performed and have revealed that all components of the immune system 
are required for tumour immune surveillance and tumour suppression [reviewed in 
(Vesely et al., 2011)].  
 
This anti-tumour response requires tumour-specific antigens, which are recognised 
by tumour-specific T cell precursors. Naïve T lymphocytes present in the lymph 
nodes and spleen can be activated by direct presentation of these antigens by the 
transformed cells in the case of haematopoietic malignancies or following metastasis 
of solid tumours. In most cases however, presentation of tumour specific antigen to 
naïve T cells requires intermediate antigen presenting cells, such as dendritic cells. 
Once activated in the lymphoid organs, tumour specific lymphocytes migrate to the 
site of the transformed cells (Schreiber et al., 2011). Despite this, tumours do develop, 
introducing the concept of immunoediting, during which the anti-tumour response 
fails to eliminate all the premalignant cells and under selective pressure new resistant 
tumour cell variants emerge, allowing tumour development (Ostrand-Rosenberg 
2008; Schreiber et al., 2011).  
1.1.4.3.2 Tumour infiltrating immune cells 
Tumour infiltrating immune cells include myeloid cells (macrophages, neutrophils, 
and dendritic cells) as well as lymphocytes. It is still not fully understood whether 
they constitute an immune response against tumour cells or whether they contribute 
to tumour progression. Cytotoxic T cells, T helper cells (Th1) and M1 macrophages 
are usually associated with anti-tumour effects, while M2 macrophages, T helper cells 
(Th2 and Th17) and regulatory T cells are characterised by pro-tumour activities 
(Fridman et al., 2011). Dendritic cells are often considered as anti-cancer cell types as 
they are the main players for antigen presentation and T cell activation. Dendritic cell 
activation is the main strategy for immunotherapies. However, it has recently been 
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shown that upon tyrosine kinase inhibitors (known to improve the treatment of some 
leukaemia), dendritic cells can upregulate immune inhibitory receptors, therefore 
preventing T cell activation (Schwarzbich et al., 2012). As illustrated with dendritic 
cells, these pro- and anti-tumour characteristics seem to be context-dependent due to 
the plasticity of immune cells and therefore vary between different tumour types.  
 
The infiltrated cytotoxic T cells express activation markers, which are induced by 
tumour antigens, suggesting the effective induction of an immune response. In 
addition, a correlation between patient survival and infiltrated cytotoxic T cells has 
been shown in various different cancers, such as colorectal cancer (Dunn et al., 2004).  
 
Among T helper cells, Th17 cells can infiltrate different tumour types such as ovarian 
and prostate tumours and have been associated with poor prognosis in patients with 
hepatocellular carcinoma (Maniati et al., 2010; Miyahara et al., 2008; Sfanos et al., 
2008; Zhang et al., 2009). Th2 cells are characterised by an IL-4 secretion, which 
despite the leukocyte recruitment this cytokine generates, it also polarises 
macrophages towards an M2 phenotype, known to have a tumour-promoting role 
(Ruffell et al., 2010). However, Th1 cells are polarised by and secrete IFN, which 
corroborates the predominant anti-tumour role of this immune population 
(Johansson et al., 2008).  
 
Regulatory T cells have also been observed in various different tumours, including 
hepatocellular carcinoma and pancreatic adenocarcinoma. In these cancers, their 
presence is associated with poor prognosis (Gao et al., 2007a; Hiraoka et al., 2006). 
These cells can inhibit anti-tumour immune responses usually induced by T cells and 
natural killer cells (Ghiringhelli et al., 2005; Shevach et al., 2001).  
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The leukocyte infiltrate is also composed of tumour associated macrophages (TAMs), 
which can contribute to tumour progression (Sica 2010). Clinical studies in many 
different malignancies have shown that high levels of TAMs within the tumour 
microenvironment correlates with poor prognosis and reduced survival (Lewis and 
Pollard 2006). TAMs are plastic cells and are usually polarised to a tumour-
promoting phenotype when recruited into the tumours, therefore facilitating tumour 
progression and metastasis (Hallam et al., 2009; Qian and Pollard 2010). It has also 
been shown that the macrophage phenotype in tumours is plastic and that tissue-
specific inhibition of the NF-κB signalling pathway in macrophages can restore their 
anti-tumour activity (Hagemann et al., 2008).  
 
Tumour cells secrete a variety of growth factors such as colony stimulating factor 1 
(CSF1), and chemokines, such as CCL2, to recruit TAMs (Qian and Pollard 2010). 
Macrophages can have different phenotypes in response to the variety of signals 
present in the environment: the “classical activated “ phenotype, also called M1, 
mainly induced in response to microbial infection and IFN-γ, and the “alternatively 
activated” or M2 phenotype, generated by cytokines such as IL-4 and IL-10 (Qian 
and Pollard 2010). This distinction between M1 and M2 phenotypes is a simplified 
view of the variety of phenotypes these cells can have. TAMs are often associated 
with an M2-like phenotype and pro-tumoural properties (Biswas and Mantovani 
2010; Mantovani et al., 2011). 
 
Considering the context-specific role of each immune cell population, a balance 
between pro- and anti-tumour immunity is required within the tumour 
microenvironment. Immunotherapy is a strategy that has been used to stimulate and 
reactivate the host immune system to effectively fight cancer cells (Couzin-Frankel 
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2010; Sharma et al., 2011b). As described in section 1.1.4.3.1, an anti-tumour 
response requires T cell activation and proliferation, which are induced after the 
presentation of tumour specific antigens by antigen presenting cells and the 
activation of costimulatory signals between the CD80 and CD86 receptors on the 
antigen presenting cells and the CD28 or CTLA4 ligands on the T cells (Foell et al., 
2007). Signalling through CTLA4 generates signals which are inhibitory to the         
T cells as opposed to CD28 (Krummel and Allison 1995). Ipilumimab is an anti-
CTLA4 antibody which has recently shown promising anti-tumour activity and 
activation of T cells in patients with advanced melanoma (Fong and Small 2008; 
Weber et al., 2011). In the context of pancreatic cancer, combination of a 
chemotherapeutic agent with an agonist antibody for CD40 induces tumour 
regression in human patients. This involves the activation of macrophages into an 
anti-tumour phenotype (see also section 1.2.7) (Beatty et al., 2011).  
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1.2 Pancreatic cancer  
1.2.1 Anatomy and development of the pancreas 
The pancreas is an organ of the digestive system and is a mixed gland with exocrine 
and endocrine functions. Figure 1.4 represents its anatomy and histological 
characteristics.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Anatomy and histology of the pancreas 
(A) Gross anatomy of the pancreas. (B) Histological aspect of the pancreas with an islet of 
Langerhans (arrowhead), ducts (solid arrow) and acinar cells within the exocrine pancreas (asterisk). 
(C) Schematic representation of an acinus. (D) Schematic representation of an islet of Langerhans 
surrounded by exocrine pancreas. Adapted from (Bardeesy and DePinho 2002).  
 
The exocrine pancreas, representing 80 % of the organ, is composed of acinar and 
duct cells that secrete a pancreatic juice containing enzymes into the small intestine 
for food digestion. Centroacinar cells are also present between the acinar and the 
duct cells. The endocrine pancreas secretes hormones into the bloodstream to 
regulate metabolism and glucose homeostasis (Hezel et al., 2006). Clusters of 
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endocrine cells, also called islets of Langerhans, are composed of five different cell 
types, individually characterised by their specific hormone secretion (Assmann et al., 
2009; Herrera 2002): 
- α-cells secrete glucagon to increase blood glucose levels  
- β-cells produce insulin to reduce blood glucose levels  
- δ-cells release somatostatin to regulate α- and β-cells 
- PP cells secrete pancreatic polypeptide 
- ε-cells produce ghrelin 
 
A tight regulation of insulin and glucagon secretion is required to regulate glycaemia, 
as well as the uptake and release of the glucose stored into the different tissues 
(Quesada et al., 2008).  
 
The pancreas is endodermal in origin and its development, as well as the 
differentiation of cell lineages, involve various signalling pathways and transcription 
factors. The main one required in these processes is the Notch signalling pathway 
(Apelqvist et al., 1999; Fujikura et al., 2006; Jensen et al., 2000; Lammert et al., 2000; 
Murtaugh et al., 2003).  
 
The earliest and most important transcription factor involved at different stages of 
the development of this organ is the pancreatic and duodenal homeobox 1 (Pdx1), 
which can give rise to the three different cell lineages within the pancreas (duct, 
acinar and islet cells) (Cano et al., 2007). It has been demonstrated that the 
expression of Pdx1 is required at the early stages of pancreatic development, as 
animals lacking this transcription factor are born without a pancreas and are not 
viable (Jonsson et al., 1994; Offield et al., 1996). Inactivation of Pdx1 at a specific time 
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during pancreatic development can block and prevent islet and acinar cell 
differentiation (Hale et al., 2005). Finally, animals heterozygote for this gene have an 
impaired regulation of insulin secretion, showing that it also plays a role in β-cell 
function in the adult mouse (Brissova et al., 2002). Pdx1 is expressed in pancreatic 
progenitor cells, whereas in the adult tissue it is mainly found in β- and PP-cells 
within the endocrine compartment (Cano et al., 2007). Another transcription factor, 
P48, has been described to be involved in pancreatic organogenesis (Kawaguchi et al., 
2002; Krapp et al., 1998). The transcription factor neurogenin 3 (Ngn3) has also been 
shown to be important for endocrine development (Cano et al., 2007). The 
development of the exocrine compartment of the pancreas depends on the expression 
of specific transcription factors such as Mist1 (Johnson et al., 2004; Pin et al., 2000) 
but also on the expression of genes such as Elastase (Hammer et al., 1987) and Nestin 
(Delacour et al., 2004; Esni et al., 2004).  
 
The table below summarises the main transcription factors and genes involved in the 
development of the pancreas (Table 1.3).  
 
 
 
 
Table 1.3: Transcription factors and genes expressed during pancreatic 
organogenesis 
Table describes the transcription factors and genes expressed during the embryonic development of 
the pancreas, the embryonic day (E) from which they are expressed and their cell lineage specificity.  
 
1.2.2 Incidence, mortality and survival of pancreatic cancer 
Pancreatic cancer is the tenth most common cancer and the fifth leading cause of 
cancer-related death in the UK; it has a five-year survival rate of approximately 3 %, 
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the lowest among the most common cancers (Rachet et al., 2009). This low survival 
rate is mainly due to the fact that symptoms and therefore diagnosis, occurs at a late 
and advanced stage, meaning that surgery is not feasible for a large majority of 
patients.  
1.2.3 Risk factors for pancreatic cancer 
The main risk factor involved in the development of pancreatic cancer is smoking, 
which is linked with up to 20 % of pancreatic cancers in the UK. Regular smokers 
have a 50 % increased risk to develop this cancer as opposed to non-smokers (Iodice 
et al., 2008). “Passive” smoking also enhances the possibility of developing pancreatic 
cancer by approximately 50 % (Vrieling et al., 2010).  
 
A patient’s medical history can impact upon pancreatic cancer risk. For example, 
patients presenting chronic pancreatitis, mainly caused by alcohol consumption 
(Tapia et al., 2010), are more susceptible to pancreatic cancer (Malka et al., 2002). 
However, the role of chronic pancreatitis in increasing the risk of developing 
pancreatic cancer is controversial and this inflammatory condition might instead be a 
consequence of early and non-detected pancreatic cancer (Sharma et al., 2011a). A 
true positive association between these two conditions has been demonstrated in 
patients with hereditary pancreatitis (Lowenfels et al., 1997; Whitcomb et al., 1999). 
Two studies have shown that patients with type II diabetes mellitus have an 
increased risk of developing pancreatic cancer (Huxley et al., 2005; Stolzenberg-
Solomon et al., 2005). This is also the case for people with type I diabetes mellitus 
(Stevens et al., 2007). Other diseases such as gastric ulcers, ulcerative colitis, Crohn’s 
disease, respiratory and skin allergies or other cancers were also linked to pancreatic 
cancer development (Bao et al., 2010; Gandini et al., 2005; Hemminki et al., 2008, 
2009; Shen et al., 2006).  
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Other risk factors include an advanced age (8 out of 10 pancreatic cancers are 
diagnosed after 60 years of age), gender (men have a higher incidence rate than 
women) and family history when a first-degree relative is affected by pancreatic or 
prostate cancer (correlated with a 50 and 45 % increased risk, respectively) (Jacobs 
et al., 2010; Permuth-Wey and Egan 2009).  
 
A synergy between these risk factors has been demonstrated in women, in particular 
an interaction between cigarette smoking and family history (approximately 13 % 
versus 3 % when considering the risk factors individually) and between cigarette 
smoking and diabetes mellitus (approximately 9 % versus 3.8 % when considering 
the risk factors individually) (Hassan et al., 2007). 
1.2.4  Symptoms and diagnosis of pancreatic cancer 
The symptoms for pancreatic cancer are not unique and usually appear at a late stage 
of the disease. The medical risk factors (acute pancreatitis or diabetes) described 
earlier could be considered symptoms if present at advanced stages. However, the 
most common symptoms are obstructive jaundice, weight loss and abdominal and/or 
back pain (Kalser et al., 1985; Okusaka et al., 2001).  
 
Early diagnosis remains a critical challenge. Trans-abdominal ultrasound is used to 
detect tumours larger than 2 cm (Minniti et al., 2003). Other imaging techniques can 
be used, such as multi-slice computed tomography (MSCT) or magnetic resonance 
imaging (MRI) to effectively identify pancreatic tumours (Catalano et al., 2003; 
Lopez Hanninen et al., 2002). Endoscopic retrograde cholangio-pancreatography 
(ERCP) is typically favoured over magnetic resonant cholangio-pancreatography 
(MRCP) as it offers the advantage of gaining tissue samples for diagnosis but also 
because inserting a biliary stent relieves obstructive jaundice (Adamek et al., 2000).  
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Levels of carbohydrate antigen 19-9 (CA 19-9) in the blood are increased in patients 
with pancreatic cancer as opposed to healthy individuals and thus its measurement is 
also assessed (Kim et al., 2004; Steinberg 1990). However, this marker is not specific 
for pancreatic cancer and some humans do not synthesise this protein at all (Cascinu 
et al., 2010). Despite the lack of specificity, its measurement influences treatment 
decisions and patient follow-up care (Cascinu et al., 2010). The identification of new 
potential markers in other physiological fluids such as urine or serum, which would 
allow earlier detection, prediction of recurrence and measurement of efficacy of 
treatments, is still under investigation (Brand et al., 2011; Weeks et al., 2008). A 
variety of potential serum biomarkers have been identified in patients with pancreatic 
cancer. Examples of these are invasion and adhesion mediators (matrix 
metalloproteinases MMP and tissue inhibitor of metalloproteinases TIMP), 
cytokines, chemokines and receptors, such as TNFRI and TNFRII, or 
apolipoproteins (Brand et al., 2011). However, their validation as useful “true” 
markers needs to be awaited.  
1.2.5 Treatments for pancreatic cancer 
1.2.5.1 Resectable tumours  
The only curative treatment for pancreatic cancer is surgical resection. If the cancer 
is already at an advanced stage with metastases to the peripheral organs (liver and 
peritoneal cavity) and/or to distant lymph nodes, the patient will not be eligible for 
surgical removal. Recurrence after surgery is high (90 %) and usually appears within 
1 or 2 years (Kayahara et al., 1993). Pancreatectomy, which could be considered as an 
alternative to partial surgical resection, is not recommended as unseen metastases at 
the time of surgery are sufficient to induce recurrence (Amikura et al., 1995; Karpoff 
et al., 2001).  
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1.2.5.2 Non resectable tumours 
Patients with advanced pancreatic cancer are usually not operable and are treated 
with chemotherapy. Therapies for these patients are aimed at increasing survival, 
improving quality of life and reducing the pain associated with the different 
symptoms.  
 
The nucleoside analogue gemcitabine is so far widely used for the treatment of 
pancreatic cancer, although with limited success. Once incorporated into the cells 
and phosphorylated, gemcitabine can have two different modes of action: inhibition 
of the synthesis of new deoxynucleosides and competition with existing 
deoxynucleosides for their incorporation into the newly synthesised DNA (Plunkett 
et al., 1995). Once incorporated into the DNA strand, the repair machinery of the cell 
is unable to remove this analogue, leading to cell death. Patients treated with 
gemcitabine achieved a clinical benefit over that of 5-FU/FA (Burris et al., 1997). 
Since then, gemcitabine is considered the “standard of care” for pancreatic cancer, 
even though the benefits remain minimal.  
 
Irinotecan, a cytotoxic agent, or specific inhibitors such as marimastat (an MMP 
inhibitor) or tipifarnib (which inhibits farnesyltransferase, an enzyme involved in 
post-translational modification of RAS) did not show a clinical advantage when used 
alone or in combination with gemcitabine (Berlin et al., 2002; Bramhall et al., 2002; 
Rocha Lima et al., 2004; Van Cutsem et al., 2004). Recently, the combination of 
gemcitabine with erlotinib, targeting the HER1/EGFR receptor often overexpressed 
in pancreatic cancers (Fjallskog et al., 2003; Tobita et al., 2003), has shown some 
modest effect in improving patient survival (Moore et al., 2007). The results of a 
phase III clinical trial showed that the overall survival of patients with pancreatic 
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cancer can be slightly improved (approximately 1 month) by treating them with the 
combination of gemcitabine and capecitabine (Xeloda® - Roche) as compared with 
gemcitabine alone (Cunningham et al., 2009). Combination of oxaliplatin, irinotecan, 
fluorouracil and leucovorin (FOLFIRINOX) was used in phase II expansion trial as 
a first-line therapy in metastatic pancreatic cancer and compared with single agent 
gemcitabine. The toxicity associated with FOLFIRINOX was significantly 
increased, but the FOLFIRINOX combination led to significant increase in tumour 
response and provided a survival advantage (Conroy et al., 2011).  
 
Using a genetically engineered mouse model of pancreatic cancer, Olive et al. have 
demonstrated that phosphorylated gemcitabine (active form) is not detectable in the 
core of pancreatic tumours, possibly explaining the chemoresistance observed in 
patients. However, they have shown an improvement in gemcitabine delivery by 
combining it with an inhibitor of the Hedgehog signalling pathway, which is known 
to be activated in pancreatic cancer and to contribute to desmoplasia (Bailey et al., 
2008). This was demonstrated by revascularisation of the pancreatic tumours and a 
better response to the chemotherapeutic agent (Olive et al., 2009). This inhibitor has 
been used in a phase I clinical trial and has proven to be safe and to provide some 
promising effects on patients with basal cell carcinoma or medulloblastoma (LoRusso 
et al., 2011). However, clinical trials in pancreatic cancer using the combination of 
gemcitabine with this Hedgehog inhibitor have shown to be unsatisfying thus far 
(Olson and Hanahan 2009). This suggests that, in human patients, drug resistance 
might not only be due to ineffective drug delivery, as illustrated above with the 
efficacy of FOLFIRINOX.  
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Other potential mechanisms of gemcitabine resistance have been described to try to 
identify combination therapies. Resistance to gemcitabine in pancreatic cancer cell 
lines but also in lymphoma cell lines has been associated with a deficiency in the 
deoxycytidine kinase, or a deficiency in some nucleoside transporters on tumour cells 
or an increased activity of the ERK kinase (Fryer et al., 2011; Galmarini et al., 2004).  
 
These pre-clinical data are encouraging for the potential development of new 
combinational therapies which would be able to increase the survival of pancreatic 
cancer patients.  
1.2.6 Initiation, progression and classification of pancreatic cancer 
The development of pancreatic cancer is a multifactorial and multistep process. The 
early stages of the disease are characterised by pancreatic intraepithelial neoplasia 
lesions (PanIN), which represent the main precursors of the invasive form. 
Morphological and genetic changes contribute to the progression from PanIN to 
pancreatic ductal adenocarcinoma (PDAC) (Feldmann et al., 2007). A detailed 
chronology is shown in Figure 1.5. 
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Figure 1.5: Chronology of pancreatic cancer development 
It is well accepted that pancreatic cancer follows a linear development, evolving from normal cells to 
PanIN lesions (PanIN-1A, PanIN-1B, PanIN-2 and PanIN-3) and invasive PDAC. Each stage is 
characterised by morphological and genetic changes within proto-oncogenes or tumour suppressor 
genes. Adapted from (Bardeesy and DePinho 2002; Maitra et al., 2003).  
 
The origin of PanIN lesions has not been identified and remains under investigation 
(Ijichi 2011; Morris et al., 2010b). Considering the characteristics of this organ, such 
lesions can arise from the duct cells, the acinar cells, the centroacinar cells or the 
endocrine cells. Using genetically engineered mouse models of pancreatic cancers, the 
involvement of each cell type has been tested, without providing a clear answer so far 
(see section 1.2.8.3).  
1.2.6.1 Classification of duct lesions - morphological characteristics 
PDAC can arise from three different lesions: mucinous cystic neoplasm (MCN), 
intraductal papillary mucinous neoplasm (IPMN) and pancreatic intraepithelial 
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neoplasia (PanIN) (Hezel et al., 2006). Only the progression from PanIN to PDAC, 
which is the most common, will be presented and discussed in this section. The 
nomenclature used to classify the pancreatic duct lesions is now well established and 
each stage is well characterised (Hruban et al., 2001). PanIN lesions are separated 
into four different stages: PanIN-1A, PanIN-1B, PanIN-2 and PanIN-3 and their 
morphological characteristics are summarised in Figure 1.5.  
 
PanIN-1A lesions are characterised by elongated cells that secrete mucin. The 
epithelium of these lesions remains flat whereas it becomes papillary in the PanIN-1B 
lesions. At these stages, nuclear atypia is minimal. Low-grade dysplasia is more 
characteristic of the PanIN-2 stage lesions, presenting more frequent nuclear 
abnormalities (enlarged nuclei, hyperchromatism - excess of chromatin - and 
degeneration of the nuclei, increasing its staining capacity) and loss of polarity with 
cells no longer correctly ordered within the basement membrane. PanIN-3 lesions 
have high-grade dysplasia, with emphasised nuclear atypia and they also present 
some “budding” into the lumen. Although these lesions resemble carcinoma, they 
remain within the basement membrane and are not invasive. PDAC is characterised 
by an invasive growth beyond the basement membrane and by an important 
desmoplastic reaction. The stroma, mainly composed of fibroblasts and immune cells, 
is very dense and plays an important role in cancer progression. PDAC presents a 
glandular structure and different levels of cellular atypia and/or differentiation (Hezel 
et al., 2006; Hruban et al., 2001; Ottenhof et al., 2009). PDAC is characterised and 
graded depending on the differentiation status of these glandular structures. 
Undifferentiated structures are more malignant and indicate a poor prognosis (Pan 
and Wang 2007). 
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1.2.6.2 Pancreatic cancer and genetics 
Pancreatic tumorigenesis requires several gene mutations (gain or loss of function), 
usually occurring within proto-oncogenes or tumour suppressor genes affecting 
different pathways. Genetic analyses of different PanIN lesions from human patients 
have been performed. Although the genetic changes identified did not seem to appear 
in a specific and repetitive order in all cases, a tendency regarding some mutations 
occurring at earlier stages than others was identified (Hruban et al., 2008). This 
simplified vision of a sequential order for genetic mutations is represented in Figure 
1.5 and is now well accepted as the standard progression model for pancreatic cancer 
development. The table below summarises the genes most commonly mutated in 
PDAC and the frequency of these mutations (Table 1.4).  
 
 
 
 
 
Table 1.4: Mutations during PDAC progression 
Table describes the most common genes mutated in PDAC and the frequency of mutation. Data 
adapted from (Yonezawa et al., 2008).  
 
According to this progression model, the main genetic changes observed in each 
PanIN grade lesions will be described and discussed.  
 
The first main genetic changes occurring at the PanIN-1 stage include telomere 
shortening (Hong et al., 2011; van Heek et al., 2002) and an activating mutation in the 
KRAS proto-oncogene (DiGiuseppe et al., 1994; Moskaluk et al., 1997). KRAS is a 
GTP-binding protein and its activation and deactivation regulates many cellular 
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processes, such as cell growth and survival via the RAS/RAF/MAPK and PI3K/AKT 
effector pathways (Castellano and Downward 2011). The most frequent point 
mutation in KRAS replaces a glycine with an aspartate at the twelfth codon 
(KRASG12D) which generates a constitutively active protein leading to constant cell 
proliferation. Expression of the KRASG12D mutant protein is associated with an 
upregulation of epidermal growth factor (EGF) (Watanabe et al., 1996) and 
overexpression of EGF receptor (EGFR) has been detected in early PanIN-1 
pancreatic lesions (Day et al., 1996). Activating mutations in this tyrosine kinase 
receptor have also been described and its expression is associated with enhanced 
tumour aggressiveness and poor survival (Friess et al., 1999; Kwak et al., 2006). 
Activation of this growth factor receptor controls, via various downstream signalling 
pathways, many cellular processes such as cell migration, adhesion and proliferation 
(Oliveira-Cunha et al., 2011).  
 
Inactivating mutations of the tumour suppressor CDKN2 (coding for the p16 protein) 
are detected in PanIN lesions in PanIN-2 stage disease (Moskaluk et al., 1997). This 
protein negatively regulates cell cycle and alteration of the gene encoding this protein 
leads to uncontrolled cell proliferation (Romagosa et al., 2011).  
 
In PanIN-3 lesions, two other tumour suppressor genes are inactivated: 
SMAD4/DCP4 and TP53 (Luttges et al., 2001; Wilentz et al., 2000). Inactivation or loss 
of expression of these proteins contributes further to PanIN progression. The main 
roles of the p53 transcription factor are to block cell cycle progression or to induce 
apoptosis in response to stress signals (Suzuki and Matsubara 2011). SMAD4 is also 
a transcription factor and is activated by the transforming growth factor beta    
(TGF-β) signalling pathway (Massague et al., 2005). Inactivation of the wild type 
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BRCA2 allele is also a late event in pancreatic cancer progression (Goggins et al., 
2000). BRCA2 is a tumour suppressor gene encoding for a protein mainly involved in 
the repair of DNA double strand breaks. Mutations in this gene were first associated 
with an increased risk of developing breast cancer but are now related to many 
different cancers (Yoshida and Miki 2004).  
1.2.7 The stroma in pancreatic cancer 
One of the characteristics of pancreatic adenocarcinoma is the presence of a rich and 
dense desmoplasia (stroma with fibrous and connective tissue), which can account 
for up to 90 % of the tumour mass (Neesse et al., 2010). As described in section 1.1.4, 
the tumour microenvironment contributes to cancer development and invasion in 
different types of cancer, and this also applies to pancreatic adenocarcinoma.  
 
In pancreatic adenocarcinoma, the stroma is mainly composed of fibroblasts, 
pancreatic stellate cells, endothelial cells and macrophages (Farrow et al., 2008). 
Pancreatic stellate cells are similar to myofibroblasts in that they express smooth 
muscle actin (α-SMA) when activated, but they also express additional specific 
markers such as desmin. Once activated by the pancreatic cancer cells, these cells 
secrete high levels of ECM components such as collagen, therefore playing a critical 
role in the development of the pancreatic tumour stroma (Apte et al., 2004; Farrow et 
al., 2008; Hwang et al., 2008). Pancreatic stellate cells can promote pancreatic cancer 
progression; their co-injection with pancreatic cancer cells in an orthotopic mouse 
model is associated with an increased tumour growth and metastasis, as well as a 
reduction in the efficacy of the chemotherapy treatment (Hwang et al., 2008). 
 
Gene expression profiling has been used to identify potential genes involved in 
tumour-stroma interactions by co-culturing pancreatic cancer cells with stromal 
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fibroblasts. Interestingly, the Cox-2 gene was overexpressed in both cell types and the 
pancreatic cancer cells had an increased invasive potential, which could be 
suppressed using a COX-2 inhibitor (Sato et al., 2004). As mentioned in section 1.1.3, 
this enzyme contributes to the generation of a more inflamed microenvironment.  
 
Clark et al. studied the immune response in the spontaneous krasG12D mouse model of 
pancreatic cancer (see section 1.2.8.2 for a detailed description of this mouse model) 
and showed that leukocyte infiltration in the stroma increased during pancreatic 
cancer progression from PanIN to PDAC stage. They further analysed the leukocyte 
populations and found that T cells did not have an activated phenotype, excluding 
the presence of an immune T cell response during pancreatic cancer progression in 
this model. Furthermore, macrophages were able to infiltrate the surrounding stroma 
from the early stages of the disease and were still present at the PDAC stage. These 
data indicate that the anti-tumour immune response, usually initiated by T cells, may 
not exist in this context. In addition, tumour-promoting and immunosuppressive 
cells, such as macrophages, were recruited from the early events of pancreatic 
carcinogenesis, demonstrating their important role in the stroma during cancer 
progression (Clark et al., 2007). Another study revealed that macrophages in the 
pancreatic stroma express angiogenic factors and can therefore contribute to tumour 
development-supporting angiogenesis (Esposito et al., 2004).  
 
More recently, in a spontaneous mouse model of pancreatic cancer (see section 1.2.8 
for a detailed description of in vivo models), Ijichi et al. showed that pancreatic cancer 
epithelial cells secrete high levels of CXC chemokines. These chemokines induce the 
secretion of connective tissue growth factor by the surrounding fibroblasts and 
accelerate tumour progression. They identified the CXCR2 receptor as being 
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important in this tumour-stroma interaction and its inhibition in vivo reduces tumour 
progression and angiogenesis (Ijichi et al., 2011).  
 
The density of the surrounding stroma has proven to be an obstacle for the efficient 
delivery of chemotherapeutic drugs, in particular due to the absence of an effective 
blood vessel network (Olive et al., 2009). Therefore, targeting the tumour 
microenvironment, at least in the context of pancreatic cancer, seems to be a novel 
approach to assist the current treatments.  
 
Paracrine Hedgehog signalling from neoplastic cells to stromal cells has been shown 
to promote desmoplasia in pancreatic carcinogenesis (Bailey et al., 2008). Olive et al. 
have demonstrated that treating pancreatic cancer bearing krasG12Dtrp53R172H mice 
with an inhibitor of the Hedgehog signalling pathway can deplete the desmoplastic 
stroma, and that this process was associated with revascularisation of the core of the 
tumour and thus improvement of drug delivery (Olive et al., 2009).  
 
The activation of the CD40 receptor has been shown to be critical for T cell-
dependent anti-tumour immune response (Vonderheide 2007). Moreover, it was 
suggested that such an anti-tumour immune response might be absent in the context 
of pancreatic cancer (Clark et al., 2007). Recently, a study combining gemcitabine 
and an agonist antibody for CD40 led to pancreatic tumour regression, both in mice 
and humans (Beatty et al., 2011). Surprisingly, when deciphering the mechanisms 
involved, they showed that macrophages, and not T cells, responded to CD40 
activation and that once activated, these macrophages had an anti-tumour phenotype 
and could not only infiltrate the tumour, but could also participate in a stromal 
depletion reaction (Beatty et al., 2011).  
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Several clinical trials for stromal depletion compounds (alone or in combination with 
chemotherapeutic agents) have been launched, especially with the Hedgehog 
inhibitor described earlier in section 1.2.5.2 (Garber 2010; LoRusso et al., 2011; 
Neesse et al., 2010). Combining existing treatments with molecules targeting the 
tumour microenvironment is a promising strategy for the treatment of pancreatic 
cancer. The current treatments available for patients with pancreatic cancer are 
discussed in section 1.2.5.  
1.2.8 In vivo models  
1.2.8.1 Cre-lox system 
The Cre-lox system is derived from the P1 bacteriophage and was rapidly identified as 
a very powerful tool to excise specific portions of DNA flanked by two loxP sites in 
both prokaryotic cells (Sauer 1987) and eukaryotic cells (Sauer and Henderson 
1988). This system has also been applied in vivo to specifically delete DNA sequences 
in selected cell types of transgenic animals (Gu et al., 1994; Orban et al., 1992). This 
technology is widely used throughout the world to help understand the function of 
genes in specific cell types and conditions, without facing the main problem 
encountered with loss-of-function animal models: lethal phenotypes. Once the 
experimental difficulties of inserting the loxP sites into the genome by homologous 
recombination and maintaining a functional gene have been overcome, conditional 
gene knockout animals are relatively straightforward to generate. However, in these 
models, due to the variability of the expression of CRE recombinase, genetic deletion 
is often incomplete and tissues contain cells expressing the wild type allele and cells 
deleted for the gene of interest (Schulz et al., 2007). This can be disadvantageous 
when gene and protein function analyses are performed. However, the mosaic 
therefore created in the tissue represents a positive aspect to study cancer 
development in mice as cancers arise from spontaneous and/or random genetic 
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alterations (see section 1.1.1). Another limitation with the Cre-lox system is the 
impossibility to control temporal gene expression as opposed to spatial expression. 
Genes can have multiple known and/or unknown functions in different tissues but 
also at different stages of the development process. The use of inducible systems has 
been presented as one possible tool to be able to control when and where 
recombination events will occur. The tamoxifen inducible system is one of them. In 
this model, a mutant of the ligand-binding domain of the human oestrogen receptor 
(ER) is fused with CRE recombinase (Danielian et al., 1993; Metzger et al., 1995). 
This protein fusion retains the recombinase in the cytosol complexed with Hsp90 
until tamoxifen administration (an antagonist of the ER) releases this inhibition, 
allowing its translocation to the nucleus, thus permitting inducible recombination of 
loxP sites (Mattioni et al., 1994). However, the main disadvantage observed with 
inducible promoters is the detection of CRE recombinase activity in absence of 
tamoxifen (leakage), which in mouse models of cancer for example allows disease 
initiation and slower progression (Strachan and Read 1999).  
 
The Cre-lox system is not only used to knockout gene expression but also to turn on 
the expression of a foreign or mutant gene, by removing an upstream STOP cassette 
(Figure 1.6).  
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Figure 1.6: Cre-lox system 
The Cre-lox technology allows the knockout of gene expression in a specific tissue when the 
recombinase CRE is expressed under the control of a tissue specific promoter. This constitutive model 
can become inducible following the expression of the CRE-ER protein fusion and its translocation to 
the nucleus upon tamoxifen administration.  
 
1.2.8.2 Modelling pancreatic cancer - krasG12D mouse model 
Considering the genetic changes involved and required during pancreatic cancer 
progression but also the morphological and histological characteristics of the different 
PanIN lesions (see section 1.2.6), a progression model for human pancreatic cancer 
has been suggested (Figure 1.5). To better understand the molecular processes 
operating during pancreatic cancer development and to overcome the limitations 
encountered with orthotopic mouse studies, genetic mouse models were developed. 
 
A wide range of genetically engineered mouse models modelling human pancreatic 
cancer have been generated. The first genetic mouse model that fully recapitulated 
human pancreatic cancer progression, from PanIN lesions to invasive carcinoma, was 
the krasG12D mouse model, created by Dr David Tuveson (Cancer Research UK 
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Cambridge Research Institute, Cambridge, UK) (Hingorani et al., 2003). This model 
harbours a kras mutation, which is the most frequent genetic alteration in this disease 
and is considered an early event in pancreatic carcinogenesis (as described in section 
1.2.6.2). This model, described below in Figure 1.7, has kindly been provided by Dr 
David Tuveson and used in the research detailed in this thesis. In this mouse model, 
two genetic modifications have been introduced (Hingorani et al., 2003): 
- expression of the mutated krasLSL-G12D gene, controlled by a STOP cassette 
flanked by two loxP sites (loxP-STOP-loxP cassette - LSL). 
- Cre expression, allowing recombination between the loxP sites and removal of 
the STOP cassette, under the control of the pancreas specific promoter: Pdx1.  
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Conditional expression of krasLSL-G12D allele 
A loxP-STOP-loxP cassette upstream of the krasLSL-G12D allele allows its expression upon CRE-
recombination only. 
 
As explained in section 1.2.1, Pdx1 is initially expressed in pancreatic progenitors and 
later in the adult pancreas. KRASG12D production therefore followed the same 
temporal pattern and can be modulated to induce duct-lesion formation in the murine 
pancreas. In these genetically engineered mice, PanIN development occurs in all 
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animals from 2 months of age onwards while progression towards the invasive 
carcinoma is observed in only 10 % of the mice and from 12 months of age onwards 
(Hingorani et al., 2003). Mutant kras has been shown to be sufficient to induce cell 
transformation, but additional genetic mutations are usually required to allow 
complete cancer progression (Grippo et al., 2003; Hingorani et al., 2005; Tuveson et 
al., 2004). This mouse model clearly confirms that mutated kras is sufficient to initiate 
PanIN development and is therefore a very useful tool to study pancreatic cancer 
initiation and progression in a molecular context similar to the human disease.  
 
Previous mouse models resulted in acinar cell carcinoma and did not recapitulate the 
stepwise progression observed in humans. This was mainly due to the fact that the 
oncogene was expressed consitutively and at higher levels in transgenic models 
(Brembeck et al., 2003; Grippo et al., 2003; Ornitz et al., 1987; Quaife et al., 1987). 
However, in the krasG12D model, mutated kras is expressed at endogenous levels using 
the native Pdx1 promoter, mimicking the spontaneous activation of this oncogene in 
humans. However, low penetrance was observed following the reduced frequency in 
the expression of the kras mutated gene (O'Hagan and Heyer 2011).  
 
To study and/or test inhibitors or new therapeutic strategies, mouse models 
harbouring additional mutations were introduced as PDAC development occurs 
faster and more frequently (Hingorani et al., 2005).  
1.2.8.3 Other mouse models of pancreatic cancer 
Since the creation of the mosaic krasG12D mouse model in 2003, similar genetic 
approaches have led to the development and creation of additional models. The 
variety of these existing models was recently reviewed and some are described below 
(Ijichi 2011; O'Hagan and Heyer 2011).  
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1.2.8.3.1 Modelling human PDAC 
Other models of PDAC, which are more invasive, have been developed by combining 
the expression of mutated oncogenic kras with another genetic alteration, such as the 
knockout of a tumour suppressor gene. In these mice, the expression of mutant kras 
and the knockout of a tumour suppressor gene were mediated by Cre expression, 
which was in turn controlled by the Pdx or P48 promoters.  
 
Cdkn2 knockout along with mutant kras expression in the mouse pancreas, leads to an 
accelerated development of PanIN and PDAC compared with the krasG12D mouse 
model (Aguirre et al., 2003). All animals develop invasive carcinoma and 100 % 
mortality occurs at 11 weeks. Concomitant expression of oncogene kras and mutant 
trp53 (trp53R172H) also generates metastatic PDAC, further imitating human disease 
development (Hingorani et al., 2005). In this model, 100 % mortality occurs by 12 
months.  
 
Mice harbouring expression of mutant kras and smad4 knockout have been 
simultaneously generated by different research groups (Bardeesy et al., 2006; 
Izeradjene et al., 2007; Kojima et al., 2007). These groups have shown that in this 
model, PanIN development is accelerated (100 % mortality at 24 weeks), but MCN 
and IPMN are also generated as additional precursors of PDAC.  
 
The effects of knocking out non-tumour suppressor genes on PanIN and PDAC 
development have also been investigated. Many other proteins are mutated or 
overexpressed in pancreatic cancer (see Table 1.4) and signalling pathways involving 
growth factors are involved in PDAC progression. Tgfbr2 knockout in cooperation 
with mutant kras expression promotes and accelerates PDAC progression, 
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recapitulating the human progression of the disease. All animals are moribund within 
six months (Ijichi et al., 2006). This observation has reinforced the role of the TGF-β 
signalling in pancreatic cancer. In this same model, inhibition of the CXCL-CXCR2 
axis inhibits tumour growth and angiogenesis in vivo, showing the importance of the 
tumour-stromal interactions (see section 1.2.7) (Ijichi et al., 2011).  
 
All the mouse models described in this section harbour an endogenous expression of 
the mutated oncogene kras, combined with a null allele within the pancreatic 
progenitor cells, as the recombinase CRE was under the control of Pdx or P48 
promoters only.  
1.2.8.3.2 Understanding the origin of PanIN lesions 
The exact origin of PanIN lesions is still a topic of extensive investigation, as the Pdx 
and P48 promoters used to model pancreatic carcinogenesis are expressed before the 
differentiation step between the three pancreatic cell lineages (Figure 1.8) (Ijichi 
2011; Morris et al., 2010b). To investigate the potential role of the different cell types 
of the adult pancreas in PanIN formation, cell lineage specific promoters have been 
used to control Cre expression and consequently KRASG12D production (Figure 1.8 
and Figure 1.9).  
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Figure 1.8: Schematic representation of cell differentiation during the 
development of the pancreas 
Pancreatic development is a well-orchestrated process, which involves the expression of different 
transcription factors and genes that regulate cell differentiation. The origin of PanIN lesions is still not 
understood. E: Embryonic day - Adapted from (Carriere et al., 2007; Ijichi 2011).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Cell types in the adult pancreas and their contribution to 
PanIN/PDAC formation 
The exocrine pancreas is composed of acinar cells, duct cells and centroacinar cells, while the 
endocrine compartment is composed of islet cells, mainly β-cells producing insulin (pink). Acinar cells 
and insulin-positive cells have been targeted to express mutant kras and to evaluate their implication in 
PanIN and PDAC formation and progression in the presence or absence of a formely inflamed 
pancreas. RIP: rat insulin promoter. Adapted from (Bardeesy and DePinho 2002; Morris and Hebrok 
2009). 
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The main hypothesis regarding the origin of PanIN lesions is that they arise from 
normal duct cells. However, this has yet to be proved, as mouse models with specific 
endogenous expression of mutant kras in these cells have not been generated (Ijichi 
2011).  
 
Several research groups have reported that using a specific acinar cell marker to 
target kras expression under the promoter of genes such as Elastase or Mist1, thus 
allowing endogenous expression of mutated kras in acinar cells during development, 
could lead to PanIN formation (Grippo et al., 2003; Shi et al., 2009; Tuveson et al., 
2006). Targeting endogenous expression of mutated kras in adult and mature acinar 
cells has also been effective in inducing PanIN formation (De La et al., 2008; Habbe 
et al., 2008; Shi et al., 2009). As opposed to the mouse models described so far, these 
animals are inducible models allowing the control of the expression of the transgene 
in the adult animals only. Not only is the expression of the mutated kras allele under 
the control of the CRE recombinase, whose expression is regulated by an acinar cell 
specific promoter (Elastase or Mist1), but the CRE recombinase is retained in an 
inactive state and its activity is induced upon tamoxifen administration (CRE-ER 
protein fusion described in section 1.2.8.1). The endogenous expression of mutated 
kras in P48 positive cells is not cell lineage specific, because this transcription factor is 
ubiquitous and is expressed in all pancreatic progenitor cells. However, one scientific 
group analysed early PanIN-1 lesions from these mice and suggested that they may 
arise from acinar cells (Zhu et al., 2007). 
 
Another scientific research group has tested the effects of endogenous expression of 
mutated kras in Nestin positive cells. Nestin is a specific marker for progenitors of the 
exocrine pancreas and the mutant mice develop PanIN lesions in a similar pattern to 
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the krasG12D model used (Carriere et al., 2007). Interestingly, Nestin is a neuronal 
progenitor cell marker and an increased expression has been identified in various 
cancer cells as well as a correlation with enhanced aggressiveness and metastasis in 
some tumours (Ishiwata et al., 2011).  
 
Although pancreatic carcinoma mostly arise from exocrine tumours, endocrine 
tumours are also detected in human patients, though at a lower incidence 
(Halfdanarson et al., 2008). Gidekel Friedlander et al. considered the insulin-
producing cells as a possible origin for PanIN formation, with Cre expression being 
controlled by the rat insulin promoter (RIP) (Gidekel Friedlander et al., 2009). They 
have shown that when mutant kras is expressed in endocrine cells, PanIN formation 
is induced if mice are previously treated with caerulein to induce chronic pancreatitis. 
The requirement of a formely injured or inflamed pancreas for PanIN formation has 
already been suggested (Guerra et al., 2007). 
 
Pancreatic cancer is linked to inflammation and two major signalling pathways are 
found to be “switched on” in this pathology: the NF-κB signalling pathway, which is 
a key regulator of inflammation and the Notch signalling pathway, which is 
associated with cell fate decisions and organ development. These two important 
signalling mechanisms will be described in the following two sections.  
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1.3 The TNF-α /NF-κB signalling pathway 
1.3.1 The NF-κB signalling pathway 
The NF-κB family of transcription factors is important and can be activated by many 
different stimuli. It can regulate the transcription of many different genes encoding 
for proteins, such as cytokines and chemokines (TNF-α and IL-6), immunoreceptors 
(TNFR and mouse histocompatibility antigene MHC), cell adhesion molecules 
(Tenascin-c), regulators of apoptosis (inhibitor of apoptosis protein IAP and Fas-
ligand), growth factors or other transcription factors (Pahl 1999). Originally 
described as a “central mediator of the human immune response”, it regulates many 
different cellular processes such as cell survival, cell proliferation, cell adhesion, 
migration and stress response (Oeckinghaus et al., 2011). 
 
This signalling pathway is represented in the figure below (Figure 1.10).  
 
 
 
 
 
 
 
 
 
Figure 1.10: The TNF-α/IKK2/NF-κB signalling pathway 
NF-κB dimers (p50/Rel A) are sequestred into the cytoplasm by binding to IκB proteins. Activation of 
the signalling pathway via TNF-α for example, activates the IKK complex which targets IκB to 
proteosomal degradation, releasing NF-κB for nuclear translocation and regulation of gene 
transcription.  
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1.3.1.1 Components of the pathway 
In vertebrates, the NF-κB transcription factor family is comprised of 5 different 
members: Rel A (also called p65), Rel B, c-Rel, p50 and p52 respectively processed 
from the precursors NF-κB1 (also called p105) and NF-κB2 (also called p100) 
(Hayden and Ghosh 2004). These proteins usually exist as homodimers or 
heterodimers and they are maintained in an inactive status by binding to an inhibitor 
of κB (IκB) in the cytosol. The presence of a Rel homology domain within their N-
terminus allows their dimerisation, but also their binding to the IκB proteins and 
DNA to regulate gene transcription (Hayden and Ghosh 2004). The dimers most 
frequently found in physiological conditions are the following: p50/Rel A (classically 
called NF-κB), p52/Rel B and p50/c-Rel (Shih et al., 2011). The presence of a 
transactivation domain is essential for the heterodimers to be able to promote 
transcription. This domain is only found in the Rel A, Rel B and c-Rel proteins 
(Gerondakis et al., 1999).  
 
The phosphorylation of the IκB proteins allows for ubiquitination and protosomal 
degradation, therefore releasing the NF-κB complexes and allowing their 
translocation to the nucleus for specific gene activation (Oeckinghaus et al., 2011). 
IκB phosphorylation is mediated by the inhibitor of κB kinase (IKK) complex, which 
consists of two catalytic subunits, IKK1 and IKK2 and the regulatory protein IKK3 
(or NEMO) (Hagemann et al., 2009) (Figure 1.10).  
1.3.1.2 Classical and alternative pathways 
There are two NF-κB activation pathways in cells: the classical (canonical) pathway 
and the alternative (non-canonical) pathway (Bonizzi and Karin 2004). The stimuli 
and the cell-receptors involved are different, but in both cases activation of the 
pathway will lead to NF-κB nuclear translocation and subsequent gene transcription.  
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The canonical pathway is dependent on IKK2, NEMO and Rel A. Their respective 
knockout has proved to be lethal and animals show similar phenotypes, with severe 
liver degeneration due to apoptosis (Beg et al., 1995; Li et al., 1999; Rudolph et al., 
2000). The canonical NF-κB activation pathway is mostly involved in the regulation 
of innate immunity (Alcamo et al., 2001; Senftleben et al., 2001). Following infections, 
its activation leads to the transcription of genes coding for cytokines and chemokines 
which are required for the inflammatory process.  
 
During canonical NF-κB signalling, signals mostly arise from cytokine receptors, 
such as TNF receptor or interleukin 1 receptor (IL-1R), but also from Toll-like 
receptors, which recognise pathogen-associated molecule patterns (PAMP). Pro-
inflammatory stimuli, including cytokines such as TNF-α or IL-1, will signal via 
these receptors leading to IKK2 activation by phophorylation on two serine residues 
(177 and 181) (Delhase et al., 1999). Once activated, IKK2 can phosphorylate IκB-α, 
allowing the recruitment of ubiquitin ligase, which will mark this protein for 
proteosomal degradation (Chen et al., 1996). NF-κB heterodimers (mostly containing 
p65) are then released and translocate to the nucleus to regulate the transcription of 
an important variety of genes involved in various cellular processes, such as 
inflammation and immune responses (Shih et al., 2011).  
 
The non-canonical pathway depends on the activation of the IKK1 subunit of the 
IKK complex. Once activated, IKK1 can process the p100 precursor into its active 
form (p52), allowing the formation of the p52/Rel B heterodimers. This pathway is 
induced by different ligands, including lymphotoxin-β, B cell activating factor BAFF 
and CD40 ligand and is implicated in lymphoid organ development and adaptive 
immunity (Bonizzi and Karin 2004).  
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Interestingly, the NF-κB signalling pathway is involved in the control of some of the 
hallmarks of cancer cells described in section 1.1.1 (Figure 1.1), such as cell 
proliferation, evasion of apoptosis, angiogenesis, invasion and metastasis. Links 
between this pathway and oncogenesis have also been shown, such as the ability of 
oncoproteins to activate the NF-κB signalling pathway (Basseres and Baldwin 2006) 
(further discussed in section 1.3.2.2).  
1.3.2 NF-κB: between inflammation and cancer 
As described in the previous section, the canonical NF-κB pathway is involved in 
inflammation. Upon its activation, a wide variety of genes are activated, mainly 
encoding for cytokines and chemokines such as TNF-α and IL-6 (Pahl 1999).    
TNF-α is also an effector of this pathway and the resulting positive feedback loop 
can rapidly induce a constitutive activation of the pathway. 
 
The role of canonical NF-κB signalling as a link between inflammation and cancer 
has been shown in a number of models. Constitutive activation of this pathway can 
act as a tumour promoter in different types of cancer (see section 1.3.2.2) (Ben-
Neriah and Karin 2011).  
 
Activation of NF-κB signalling has been associated with abnormal growth of cells in 
a variety of organisms, from Drosphila melanogaster to mammals (Ben-Neriah and 
Karin 2011). In the context of Scribble deficiency, a gene involved in cell polarity, 
and the expression of the oncoprotein RAS, hemocyte-derived TNF-α enhances 
tumour growth and migration in Drosphila melanogaster (immune responses in 
invertebrates are mediated by hemocytes) (Cordero et al., 2010). In human lung 
cancer, inhibition of the NF-κB axis enhances cell death, associating this signalling 
with tumour growth (Bivona et al., 2011).  
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IKK2 has been shown to be essential for tumour growth in a model of inflammation-
induced carcinogenesis (colitis-associated cancer). The deletion of this kinase in 
either intestinal epithelial cells or myeloid cells leads to a reduction in tumour 
incidence and tumour growth. This is due to an increase in apoptosis when the 
deletion occurs in the enterocytes. However, deletion in the myeloid cells leads to a 
reduction in the production of inflammatory mediators which usually contribute to 
tumour growth (Greten et al., 2004). 
 
Inactivation of the NF-κB signalling pathway does not always inhibit tumorigenesis; 
its role in tumour initiation has been shown in skin and hepatic mouse models (Dajee 
et al., 2003; Sakurai et al., 2006). Inhibition of the NF-κB signalling pathway 
concomitant with activation of the RAS signalling pathway (hras mutant) has been 
observed in patients with squamous cell carcinoma. Although RAS induces cell cycle 
arrest, this is counterbalanced by the inhibition of the NF-κB signalling pathway, 
which restores cell proliferation (Dajee et al., 2003). The second study involved 
genetic deletion of the IKK2 kinase in the liver, after which mice are more susceptible 
to chemically-induced hepatocarcinogenesis (Maeda et al., 2005; Sakurai et al., 2006). 
It has been shown that this enhanced formation of hepatocellular carcinoma is due to 
the absence of JNK inhibition, usually induced by TNF-α, therefore leading to an 
increase in hepatocyte proliferation (Deng et al., 2003; Kamata et al., 2005; Maeda et 
al., 2005; Sakurai et al., 2006) 
 
This project focuses on the autocrine role of TNF-α in pancreatic cancer and 
therefore the function of this cytokine in the context of the NF-κB signalling 
pathway will be the main topic of discussion.  
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1.3.2.1 TNF-α , IL-1β  and IL-6: the main cytokines involved 
TNF-α is a major inflammatory cytokine and a classical stimulus of the canonical 
NF-κB signalling pathway. It recognises two different receptors, TNFRI and 
TNFRII, expressed in most cell types or on haemopoietic cells, respectively (Balkwill 
2006). Its activation via TNFRI leads to NF-κB activation as described in the 
previous section.  
 
Originally described as a tumour necrosis factor, when TNF-α is administrated 
locally and at high doses in tumours, it induces necrosis (Balkwill et al., 1986; 
Talmadge et al., 1988). However, the tumour-promoting action of this cytokine came 
to light when mice deficient for tnfa were found to be protected from developing skin 
tumours following experimental induction of skin carcinogenesis with the classical 
DMBA/TPA protocol (Moore et al., 1999).  
 
TNF-α is expressed by many different tumours and a real balance between a tumour-
promoting or a tumour-necrotic role exists (Balkwill 2002). The reasons for such 
contrary effects still remain a major point of interest and investigation. The cell types 
involved in the secretion of this cytokine and its concentration in the milieu seem to 
be critical for this balance as high local doses of TNF-α are associated with tumour 
necrosis (Balkwill et al., 1986; Talmadge et al., 1988). This cytokine is involved in 
tumour progression and in some models, this is dependent on the NF-κB pathway 
(Balkwill 2006). TNF-α produced by tumour cells or by cells in the tumour 
microenvironment such as immune cells, contributes to oncogene activation, to DNA 
damage and consequently to tumour development. TNF-α can therefore be 
considered as a therapeutic target for cancer treatment (Balkwill 2009).  
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Immune and endothelial cell-derived TNF-α in the liver tumour microenvironement 
leads to the activation of the NF-κB signalling pathway and anti-TNF-α treatment 
can decrease tumour incidence (Pikarsky et al., 2004). Similar to the fact that tnfa 
deficient mice are resistant to chemically-induced skin carcinogenesis (Moore et al., 
1999), tnfr1 knockout mice are resistant to chemically-induced hepatocellular 
carcinoma (Knight et al., 2000). TNF-α-treatment of pancreatic cancer cell lines in 
vitro or of mice bearing orthotopic pancreatic tumours induces and enhances tumour 
growth and invasiveness. The use of anti-TNF-α antibodies in vivo, such as infliximab 
or etanercept, reduces tumour growth and metastasis, therefore suggesting this 
cytokine as a therapeutic target for pancreatic cancer (Egberts et al., 2008). 
 
Constitutive expression of TNF-α by epithelial ovarian cancer cells contributes to the 
maintenance of the production of other cytokines and chemokines within the tumour 
microenvironment, providing a network of inflammatory molecules and contributing 
to tumour development (Kulbe et al., 2007; Kulbe et al., 2011).  
 
IL-1β is another pro-inflammatory cytokine, which, as opposed to TNF-α, can 
activate the NF-κB pathway in an IKK2-independent manner (Solt et al., 2007). An 
enhanced production of this cytokine has been associated with an increased risk of 
gastric cancer (El-Omar et al., 2000). IL-1β is known to be upregulated in different 
types of cancer and to have a tumour-promoting role, favouring angiogenesis and 
increasing metastasis (Lewis et al., 2006). Tumours secreting high amounts of IL-1β 
are often associated with poor prognosis (Apte et al., 2006; Elaraj et al., 2006). This 
cytokine has also been shown to be responsible for the increased activity of the NF-
κB signalling pathway observed in pancreatic adenocarcinoma cell lines, also 
contributing to explain their chemoresistance (Arlt et al., 2002). This IL-1β secretion 
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by the pancreatic epithelial cells is induced by the production of nitric oxide by the 
fibroblasts surrounding the tumour cells (Muerkoster et al., 2004).  
 
IL-6 induction during inflammation is one of the consequences of the activation of 
the NF-κB signalling pathway by TNF-α and/or IL-1β. IL-6 activates another 
inflammatory signalling pathway, STAT3, which is also activated in cancer and 
which has been shown to cooperate with the NF-κB signalling pathway to promote 
tumorigenesis (Grivennikov and Karin 2010). IL-6 is upregulated in human ovarian 
cancer cells (Chou et al., 2005), in human lung adenocarcinoma (Gao et al., 2007b) 
and in human breast cancer (Sansone et al., 2007). IL-6 contributes to inflammation-
associated carcinogenesis and this has been demonstrated in a mouse model of colitis-
associated cancer and hepatocellular carcinoma (mostly induced by inflammatory 
conditions) (Naugler and Karin 2008). A research group has recently demonstrated 
that the activation of STAT3 signalling in pancreatic cancer cells is induced by 
paracrine IL-6 from myeloid cells in the krasG12D genetic mouse model of pancreatic 
cancer. Genetic inactivation of IL-6 trans-signalling or of the STAT3 signalling 
pathway in this model inhibits PanIN progression (Lesina et al., 2011). 
1.3.2.2 Constitutive activation of NF-κB in cancer 
The constitutive activation of the NF-κB signalling pathway observed in many 
different cancers has been shown to have several origins: genetic mutations or 
alterations in the different components of the pathway and exposure to inflammatory 
mediators or genetic mutations in other pathways (mainly affecting oncogenes and 
tumour suppressor genes) leading to an activation of the NF-κB signalling pathway 
(Ben-Neriah and Karin 2011).  
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1.3.2.2.1 Mutations in the components of the NF-κB pathway and exposure to inflammatory 
mediators  
A chromosomal translocation leading to a constitutive activation of a Rel 
transcription factor has been identified in B cell lymphoma (Neri et al., 1991). The 
constitutive activation of NF-κB signalling observed in diffuse large B cell lymphoma 
has recently been attributed to oncogenic mutations affecting MYD88, a protein 
required for TLR activation (Ngo et al., 2011). Overexpression of cytokines, 
chemokines and growth factors by the cancer cells themselves also leads to activation 
of this pathway (Lu and Stark 2004; Lu et al., 2004).  
 
In human PDAC, a constitutive activation of the transcription factor Rel A was 
shown (Wang et al., 1999). Blocking NF-κB activation in pancreatic cancer cell lines 
and tumours with a proteasome inhibitor leads to a reduction in cell proliferation and 
to induction of apoptosis (Shah et al., 2001). Pancreatic cancer cell lines expressing a 
mutant form of the IκB-α protein that blocks the activity of NF-κB cannot induce 
tumour formation in vivo (Fujioka et al., 2003b).  
 
Constitutive secretion of different cytokines, such as IL-1α and IL-8, in human 
pancreatic cancer cells have been identified as activators of the NF-κB pathway, 
contributing to increased growth and tumorigenesis (Le et al., 2000; Melisi et al., 2009; 
Niu et al., 2004). Many of these studies indicate that autocrine secretion of 
proinflammatory cytokines is one of the routes which leads to the activation of the 
NF-κB signalling pathway and contributes to tumour progression. Constitutive    
NF-κB signalling in epithelial lung cells increases the risk of lung carcinogenesis 
(Zaynagetdinov et al., 2011). Persistent activated NF-κB signalling in human breast 
cancer cells contributes to maintain abnormal cell proliferation (Biswas et al., 2004).  
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As described in section 1.1.4, a variety of cell types are present in the tumour 
microenvironment. The previous examples illustrated the role of autocrine signalling 
of epithelial cell-derived inflammatory mediators. However, the effects of paracrine 
signalling of these molecules on tumour cells is also very important and can originate 
from the stromal cells (Mantovani et al., 2008).  
 
In a genetic mouse model of prostate cancer, it has been demonstrated that immune 
infiltrating cells expressing the ligand for the receptor activator of NF-κB (RANK) 
could activate the respective receptor on prostate cancer cells, leading to IKK1 
activation and subsequently to an enhanced metastatic phenotype (Luo et al., 2007). 
In vitro studies have shown that the co-culture of macrophages with ovarian tumour 
cells can increase the invasive capacity of the tumour cells in a TNF-α and NF-κB-
dependent manner (Hagemann et al., 2005; Hagemann et al., 2006).  
 
Fibroblasts are also a main component of the tumour microenvironment. Activation 
of NF-κB signalling by IL-1α in this cell type in breast cancer stroma induces the 
secretion of IL-6 and promotes angiogenesis and metastasis (Bhat-Nakshatri et al., 
1998).  
 
The NF-κB pathway has also been shown to regulate apoptosis by controlling the 
expression of antiapoptotic proteins, such as IAP1, IAP2, TRAF1 (TNF receptor 
associated factor) and Bcl-2, therefore providing an additional route to enhance 
tumour cell growth. This has been shown in the context of pancreatic tumour 
progression (Holcomb et al., 2008).  
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Furthermore, NF-κB controls the production of angiogenic factors such as IL-8 and 
VEGF in human pancreatic cancer cells (Holcomb et al., 2008). Several studies have 
shown that inhibiting the NF-κB pathway in pancreatic cancer cells reduces and 
prevents tumour angiogenesis (Holcomb et al., 2008; Xiong et al., 2004). However, 
reducing angiogenesis in an originally poorly vascularised tumour might prevent 
efficient delivery of therapeutic drugs (Olive et al., 2009). Inhibition of NF-κB also 
significantly prevents pancreatic tumour metastasis into the liver and the peritoneal 
cavity (Fujioka et al., 2003a; Xiong et al., 2004).  
 
Finally, NF-κB activity is associated with chemoresistance in pancreatic cancer and 
the combination of a chemotherapeutic agent with a specific inhibitor of the pathway 
has been shown to improve the responsiveness of the cancer cells and reduce tumour 
growth (Arlt et al., 2001; Arlt et al., 2003; Muerkoster et al., 2003).  
 
1.3.2.2.2 Oncogenes and NF-κB in cancer: kras, myc and tp53 
Oncogenes can drive the activation of inflammatory signalling pathways such as the 
NF-κB axis. The main oncogenes involved in human cancers belong to the RAS 
family and 25 % of human tumours have a mutated form of these small GTPases 
(Castellano and Downward 2011). More than 90 % of human pancreatic cancers are 
associated with a KRAS mutation (see section 1.2.6.2) (Yonezawa et al., 2008). 
Constitutive activation of the main downstream pathway (RAF/MEK/ERK) results 
in the production of inflammatory cytokines and chemokines controlling cell 
proliferation and survival (Montagut and Settleman 2009). Mutant RAS proteins are 
known to be able to activate the canonical pathway of NF-κB signalling. This has 
been shown in lung epithelial cells and in prostate epithelial cells following kras 
overexpression (Basseres et al., 2010; Kim et al., 2002), but also in fibroblasts with 
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overexpression of mutant hras (Finco et al., 1997). Overexpression of oncogenic kras 
can induce lung adenocarcinoma and is associated with activation of the NF-κB 
signalling pathway (Basseres et al., 2010; Meylan et al., 2009). Overexpression of 
mutant hras in melanocytes deficient for a specific tumour suppressor gene (cdkn2) 
can induce melanoma. In this spontaneous model, additional genetic deletion of ikk2 
in melanocytes impairs the development of melanoma, confirming the importance of 
the NF-κB signalling pathway in cancer initiation (Yang et al., 2010). In all these 
models, activation of the NF-κB signalling pathway was due to overexpression of 
oncogenic kras rather than endogenous expression, allowing physiological levels like 
in the krasG12D mouse model used.  
 
The cooperation between oncogene activation and inflammatory conditions for 
tumour development is well described and in the context of pancreatic carcinogenesis 
is associated with pancreatitis and kras activation (see section 1.2). This has been 
shown in a mouse model of pancreatic cancer associated with caerulein-induced 
pancreatitis (Guerra et al., 2007).  
 
The RAS signalling pathway can activate inflammatory cytokines such as IL-8, 
therefore increasing tumour growth and angiogenesis in mouse xenograft models 
(Sparmann and Bar-Sagi 2004). It has also been demonstrated that in melanoma, 
RAF mutations contribute to the maintenance of a constitutively active ERK and 
STAT3 signalling, enhancing the secretion of inflammatory mediators such as VEGF 
and IL-6 (Sumimoto et al., 2006).  
 
The MYC transcription factor controls various cellular processes such as cell 
proliferation and apoptosis. Mutations in this oncogene contribute to tumour 
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development and its overexpression has been shown to control and modulate the 
tumour microenvironment, favouring tumour angiogenesis and stimulating 
inflammation (Whitfield and Soucek 2011). In a mouse model of B cell lymphoma 
(driven by myc), constitutive activation of two main inflammatory signalling 
pathways was observed: NF-κB and STAT3 (Han et al., 2010). In addition, the 
transcription factor NF-κB controls the expression of myc, demonstrating a 
bidirectional cooperation in tumour development (Kanda et al., 2000). 
 
Inactivating mutations in the tumour suppressor gene tp53, which codes for p53, are 
also frequently found in human cancers (at least 50 % of the tumours) (Soussi and 
Wiman 2007). This protein is a transcription factor, which plays a critical role in the 
control of the cell cycle by activating the expression of genes involved in cell cycle 
arrest or apoptotic signals in response to DNA damage. Crosstalk between the p53 
and the NF-κB signalling pathways has been demonstrated in lung and pancreatic 
cancer cells, showing that p53 mutants can activate the NF-κB promoter and 
enhance some tumour-promoting responses such as anti-apoptotic signals (Schneider 
et al., 2010; Scian et al., 2005). In mouse embryonic fibroblasts, kras activation 
associated with loss of trp53 (mouse gene homologue for tp53) activates the NF-κB 
signalling pathway (Meylan et al., 2009). Lung tumour cell lines derived from animals 
with mutant kras and trp53 loss also present with enhanced NF-κB activity, 
suggesting the cooperation between the two oncogenes and the activation of an 
inflammatory signalling pathway (Meylan et al., 2009). Interestingly, mycoplasma 
infection has been shown to be associated with an activated NF-κB signalling and a 
reduced p53 signalling, increasing the sensibility of mouse embryonic fibroblasts to 
hras-induced transformation (Logunov et al., 2008).  
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Along with NF-κB, a number of other signalling pathways are deregulated in 
pancreatic cancer such as Notch, Wnt and Hedgehog (De La et al., 2008; Pasca di 
Magliano et al., 2006; Pasca di Magliano et al., 2007; Thayer et al., 2003). The present 
work focuses on the interplay between the NF-κB and the Notch pathways. The 
Notch signalling cascade and the evidence of its implication in pancreatic cancer are 
described in the following section.  
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1.4 The Notch signalling pathway 
1.4.1 Components of the pathway 
Notch receptors and ligands are transmembrane proteins, allowing communication 
between a signal-sending cell and a signal-receiving cell (Figure 1.11). In mammals, 
four different Notch receptors have been identified (Notch1 to Notch4) and five 
different ligands belonging to two distinct families: the Jagged family (Jagged1 and 
Jagged2) and the delta-like family (Dll1, Dll3 and Dll4) (Lobry et al., 2011).   
 
Following Notch ligand-receptor interaction, the Notch protein is cleaved by a 
metalloprotease TACE (TNF-α converting enzyme), releasing the extracellular part 
of the Notch receptor, which is endocytosed by the signal-sending cell (Kopan and 
Ilagan 2009). The mechanisms triggered after this endocytosis are still unclear and 
under investigation. In the signal-receiving cell, proteolytic cleavage of the Notch 
receptor results in the release of the Notch intracellular domain (NICD), which can 
translocate to the nucleus and regulate the transcription of different genes via the 
canonical or the non-canonical Notch signalling mechanisms (Lobry et al., 2011).  
1.4.2 The canonical and non-canonical Notch signalling pathways 
When NICD translocates to the nucleus, it cannot directly bind to the DNA. In the 
context of the canonical signalling pathway, it associates and forms a complex with 
RBPjκ, which is already present at the promoter of the Notch target genes. In the 
absence of NICD, RBPjκ forms a complex with corepressor proteins, to repress the 
transcription of Notch target genes. NICD binding with RBPjκ switches this 
repressed state to an activated state, associated with the recruitment of coactivator 
proteins to allow gene transcription (Borggrefe and Oswald 2009; Kopan and Ilagan 
2009) (Figure 1.11).  
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The main Notch target genes regulated by the canonical pathway are proteins 
belonging to bHLH families (basic helix-loop-helix) such as HES and HEY (Fischer 
and Gessler 2007; Iso et al., 2003). HES and HEY proteins are transcriptional 
repressors, mainly thought to bind to the promoter region of their target genes on N-
box and/or E-box sequences (Fischer and Gessler 2007).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: The canonical Notch signalling pathway 
A signal-sending cell expressing a Notch ligand (Jagged1, Jagged2, Dll1, Dll3 or Dll4) interacts with 
a signal-receiving cell expressing a Notch receptor (Notch1 to Notch4). Upon receptor-ligand 
recognition, two successive proteolytic cleavages occur in the signal receiving cells and are mediated 
by TACE and γ-secretase complex cleavage. The intracellular domain of Notch (NICD) is therefore 
released and translocates to the nucleus to regulate gene transcription. In the context of canonical 
Notch signalling, NICD binds to RBPjκ, releasing the corepressor proteins (CoR) and recruiting 
coactivator proteins (CoA) to allow the transcription of Notch target genes, such as hes1 and hey1.  
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The non-canonical Notch signalling pathway is RBPjκ independent and still not well 
described and understood (Martinez Arias et al., 2002). NICD can bind to other 
signalling molecules including the transcription factor Deltex (Matsuno et al., 1995; 
Ordentlich et al., 1998; Ramain et al., 2001; Yamamoto et al., 2001). Binding of NICD 
to IKK complex contributes to the maintenance of the NF-κB signalling pathway in 
an active state (Vacca et al., 2006; Vilimas et al., 2007) and NICD has also been 
shown to interact with SMAD proteins (Blokzijl et al., 2003; Dahlqvist et al., 2003; 
Itoh et al., 2004). These interactions highlight that the Notch signalling pathway can 
cooperate and interact with many other signalling pathways such as NF-κB, TGF-β 
and bone morphogenic protein signalling (via SMAD).  
 
Notch ligands can activate or inhibit the Notch signalling pathway. The activity of 
these ligands can be regulated by post-translational modifications, such as 
glycosylation or ubiquitination, but also via cellular mechanisms such as endocytosis 
or proteolysis. All these regulation processes add to the complexity and diversity of 
this pathway as they also involve cross-signalling with other signalling pathways 
(D'Souza et al., 2008). 
1.4.3 Notch functions - links between development and cancer 
1.4.3.1 Context- and tissue-dependent  
The Notch signalling pathway is involved in the embryonic development of many 
organs and tissues in all multicellular organisms, showing high genetic conservation 
(Artavanis-Tsakonas et al., 1999; Gridley 1997). Notch not only regulates tissue 
homeostasis but also cell fate, and was originally identified as involved in 
neurogenesis in flies and vertebrates. It is now established that the Notch pathway is 
implicated in the development of a variety of organs, such as the organs of the central 
nervous system or of the cardiovascular system, but also the pancreas, the gut and 
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bones (Bolos et al., 2007). Controlling various cellular processes, deregulation of this 
pathway has been identified in a number of pathological conditions, including cancer.  
 
The Notch signalling pathway has been shown to be involved in the regulation of 
lymphocyte development and in particular of B and T cell lineages (Tanigaki and 
Honjo 2007). Chromosomal translocations or genetic mutations in components of the 
Notch signalling pathway leading to its constitutive activation have been associated 
with the development of chronic lymphocytic leukaemia and T lymphoblastic 
neoplasms (Allenspach et al., 2002; Ellisen et al., 1991; Puente et al., 2011).  
 
Appropriate kidney development requires Notch signalling and its reactivation in the 
adult organ contributes to the development of inflamed renal pathologies (Bielesz et 
al., 2010; Cheng and Kopan 2005). Notch is involved in the regulation of 
differentiation of the human epidermis and a downregulation has been observed and 
associated with basal cell carcinoma (Thelu et al., 2002). Cervix development is also 
regulated by Notch signalling and both an upregulation or a downregulation of the 
pathway have been associated with cervical cancer, the latest occurring when 
carcinogenesis is induced by human papillomavirus infection (Maliekal et al., 2008; 
Talora et al., 2002; Zagouras et al., 1995). 
 
For the purpose of this thesis, the effects of the Notch signalling pathway on 
pancreas development and the status of this pathway in the context of pancreatitis 
and pancreatic cancer are described in more detail in section 1.4.4.  
 
Notch signalling has also been implicated in the induction of the epithelial-
mesenchymal transition process, which is usually associated with solid tumour 
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development and aggressiveness. Activation of this pathway in epithelial cells leads to 
the expression of specific mesenchymal markers such as α-SMA. This contribution is 
in agreement with the reactivation of the Notch signalling pathway observed in many 
epithelial cancers and inhibiting this pathway may represent a therapeutic strategy to 
prevent this mesenchymal transformation (Wang et al., 2010). 
 
Targeting the Notch signalling pathway is now considered as a new strategy for 
cancer treatment, as its inappropriate reactivation has been observed in various 
cancers and it is also associated with cancer progression (Sethi and Kang 2011). 
Several inhibitors, such as γ-secretase inhibitors or antibodies against Notch ligands, 
are being investigated (Garber 2007). A Cancer Research UK sponsored phase I/II 
clinical trial is currently evaluating the efficacy of a γ-secretase inhibitor in 
combination with gemcitabine in patients with metastatic pancreatic carcinoma 
(EudraCT number 2008-004829-42).  
1.4.3.2 Notch: oncogene or tumour suppressor gene? 
Due to its tissue- and context-dependent implications, it is difficult to classify the 
Notch protein as an oncogene or a tumour suppressor (Lobry et al., 2011; 
Ranganathan et al., 2011). Notch was for a long time considered an oncogene in 
different cancers and was first identified in T cell acute lymphoblastic leukaemia 
(Ellisen et al., 1991). Activating mutations in the Notch1 receptor have been 
identified in human cases of chronic lymphocytic leukaemia (Fabbri et al., 2011; 
Puente et al., 2011). Increased expression of Notch or Jagged1 have also been shown 
to correlate with poor prognosis in human breast cancer (Reedijk et al., 2005).  
 
A tumour suppressor role has been shown in the skin where loss of Notch function 
can lead to spontaneous skin carcinoma (Nicolas et al., 2003). In a genetic mouse 
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model of hepatocellular carcinoma, cancer development is associated with an 
upregulation of the genes coding for the components of the Notch pathway, therefore 
suggesting an oncogenic role. However, inhibition of the Notch pathway with a γ-
secretase inhibitor accelerates the development of hepatocellular carcinoma in this 
mouse model, therefore suggesting a tumour suppressor role. This observation has 
been corroborated by the detection of an increased expression of HES1 in patients 
with hepatocellular carcinoma and presenting a better survival (Viatour et al., 2011). 
Finally, constitutive activation of Notch in fibroblasts in the microenvironment of 
melanoma can reduce tumour growth and angiogenesis (Shao et al., 2011).  
1.4.3.3 Notch and oncogenes in cancer  
In section 1.3.2.2, the ability of oncogenes such as kras, myc or tp53 to activate 
inflammatory signalling pathways was discussed. However, the same oncogenes do 
not appear to be able to activate Notch signalling directly, but a cooperation between 
these different signalling pathways is suggested, especially in pancreatic cancer and 
in leukaemia.  
 
Expression of oncogenic kras cooperates with the activation of Notch signalling to 
promote tumour progression (De La and Murtaugh 2009). This cooperation has only 
been shown in the context of pancreatic carcinogenesis (see also section 1.4.4.3) and 
the exact mechanisms involved are still unknown.  
 
The MYC oncogene is activated in acute lymphoblastic T cell leukaemia and its 
expression, associated with Notch signalling, induces tumour progression. A recent 
study qualified Notch as a dominant oncogene in acute lymphoblastic T cell 
leukaemia (Demarest et al., 2011). Notch activation has also been shown to be 
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upstream of MYC and that Notch directly regulates MYC expression, contributing to 
the growth of leukemic cells (Palomero et al., 2006).  
 
The TP53 oncogene is often mutated or lost in the setting of chronic lymphocytic 
leukaemia (Zenz et al., 2008). In these cells, a cooperation between p53 and Notch 
pathways has been demonstrated: leukemic cell lines expressing the wild type TP53 
gene have an upregulated expression of Notch, which is absent upon loss of 
functional TP53 (Secchiero et al., 2009). Notch therefore appears to be an 
antiapoptotic target of p53 and inhibiting the induction of Notch in chronic 
lymphocytic leukaemia can represent a new treatment approach (Wickremasinghe et 
al., 2011).  
1.4.4 Implications of the Notch pathway in pancreatic development, pancreatitis 
and pancreatic cancer 
1.4.4.1 The Notch pathway in the developing and adult pancreas 
The components of the Notch pathway (receptors, ligands and target genes) are 
expressed during pancreatic organogenesis which reveals that this pathway is 
activated in this process (Apelqvist et al., 1999; Jensen et al., 2000; Lammert et al., 
2000). Notch signalling is important for the development of the endocrine cells of the 
pancreas as inactivation of some components of the pathway leads to an accelerated 
differentiation of the endocrine compartment (Apelqvist et al., 1999; Jensen et al., 
2000). However, inappropriate and constitutive activation of the Notch signalling 
pathway in pancreatic precursor cells prevents the development of both exocrine and 
endocrine lineages (Hald et al., 2003; Murtaugh et al., 2003). The Notch signalling 
pathway has also been shown to be active in adult mouse pancreatic islets and its 
inhibition can induce apoptosis in the endocrine β-cells (Dror et al., 2007).  
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1.4.4.2 Notch in acute pancreatitis 
Following experimentally induced pancreatic injury, pancreatic regeneration involves 
acinar cell dedifferentiation, with the re-expression of the components of the Notch 
pathway, normally expressed in undifferentiated pancreatic progenitor cells during 
the development stage (Jensen et al., 2005; Rooman et al., 2006). Simultaneous 
inhibition of the Notch signalling pathway and induction of acute pancreatitis in a 
mouse model impairs the regeneration of the exocrine compartment of the pancreas 
(Siveke et al., 2008). Genes coding for different components of the Notch signalling 
pathway are rapidly expressed after experimental induction of acute pancreatitis 
(Gomez et al., 2004).  
1.4.4.3 Notch in pancreatic cancer 
The Notch pathway, normally quiescent in the adult pancreas, is reactivated in 
pancreatic cancer from PanIN to PDAC progression (Mazur et al., 2010a; Miyamoto 
et al., 2003; Plentz et al., 2009). An active Notch signalling pathway is identified by 
the expression of classic target genes such as hes1 and hey1. These genes are also 
found to be upregulated in early PanIN lesions and throughout PDAC, but not in 
normal pancreatic epithelium (Hingorani et al., 2003; Miyamoto et al., 2003). 
However, Notch-independent HES1 production has been shown in other cell types, 
such as endothelial cells or neuroblastoma cells, involving the RAS/RAF/MAPK 
and/or the JNK signalling pathways (Curry et al., 2006; Katoh 2007; Stockhausen et 
al., 2005). 
 
Transgenic overexpression of TGF-α in the acinar cells of the pancreas is 
accompanied by activation of the Notch signalling pathway in PanIN lesions 
(Miyamoto et al., 2003). The presence of TGF-α is therefore shown to be an initiating 
event in neoplasia and an increase of acetylated-histone H3 at the hes1 promoter is 
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associated with this process (Miyamoto et al., 2003). However, adenovirus-mediated 
overexpression of Notch target gene hes1 in normal pancreatic epithelial cells does 
not induce metaplasia, as opposed to NICD overexpression (Miyamoto et al., 2003). 
Moreover, in response to TGF-α, the matrix metalloproteinase MMP7 is expressed 
and contributes to Notch activation during pancreas metaplasia (Sawey et al., 2007).  
 
Experiments inhibiting or downregulating Notch signalling in pancreatic cancer cell 
lines have shown that this pathway is required to maintain the transformed status of 
these cells, rather than to initiate transformation. This has been observed using either 
a γ-secretase inhibitor leading to a reduction in tumour growth and PDAC 
progression (Plentz et al., 2009) or siRNAs against Notch, leading to increased 
apoptotic events and a reduction in cell proliferation in human pancreatic cell lines 
(Wang et al., 2006).  
 
In pancreatic cancer, the Notch pathway has been shown to cooperate with other 
signalling pathways, in particular with oncogenic KRAS. PanIN lesions induced by 
the expression of mutated kras express Notch target genes, suggesting the presence of 
an activated Notch pathway in this context (Guerra et al., 2007). In the context of 
mutant kras, the Notch pathway activation has been shown to have a tumour-
promoting role and was implicated in mediating metaplasia of acinar to ductal 
epithelium, a critical process in pancreatic carcinogenesis (De La et al., 2008; Mazur 
et al., 2010a; Morris et al., 2010a).  
 
A clinical trial is currently evaluating the efficacy of a γ-secretase inhibitor in 
combination with gemcitabine on patients with metastatic pancreatic cancer (see 
section 1.4.3.1). Even though currently used γ-secretase inhibitors present some side 
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effects, such as diarrhoea, they can be safely tolerated (Mysliwiec and Boucher 
2009). Moreover, an additional study has shown that Notch activation is mostly due 
to an overexpression of Notch ligand in pancreatic cancer cells, reinforcing the idea 
of inhibiting this pathway with small molecule inhibitors (Mullendore et al., 2009).  
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1.5 Focus of thesis  
Most pancreatic tumours express an activating mutation in the KRAS proto-oncogene 
(Yonezawa et al., 2008) and activation of NF-κB signalling upon expression of this 
oncogene has been established in other cancers (Basseres et al., 2010; Meylan et al., 
2009).  
 
The aim of this thesis is to study the role of TNF-α produced by pre-malignant 
epithelial cells in the early stages of pancreatic tumour progression, hypothesising 
that autocrine effects of this cytokine can promote pancreatic carcinogenesis.  
 
The krasG12D genetic mouse model of pancreatic carcinogenesis was used as this model 
recapitulates PanIN progression with a low penetrance of the invasive form. To 
study the role of the TNF-α/IKK2 signalling pathway on pancreatic carcinogenesis, 
new genetic mouse models were generated combining mutant kras expression with 
ikk2 or tnfa genetic deletion in pancreatic epithelial cells. In vitro studies using cell 
lines generated from PanIN bearing animals were performed to investigate the 
molecular mechanisms downstream of the TNF-α/IKK2 pathway that may 
contribute to the carcinogenic process. This work focused on the cooperation 
between the TNF-α/IKK2 and the Notch signalling pathways, which suppresses the 
expression of anti-inflammatory proteins and promotes pancreatic carcinogenesis in 
mice.  
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Buffer recipes can be found in Appendix A: Solutions. 
2.1 Transgenic animals 
Mice were maintained in the Biological Services Unit of Barts Cancer Institute, 
Queen Mary, University of London, in a specific pathogen-free environment and 
used according to established institutional welfare guidelines under the authority of a 
UK Home Office project licence (PL 70/6578) (Guidance on Operation of Animals 
Scientific Procedures - Act 1986). Experimental protocols and procedures were also 
approved by the UK Home Office and performed under the following personal 
licence number: PIL 70/21874.  
2.1.1 Mouse models and breeding 
kras+/LSL-G12D, pdx1-cre, tnfaflox/flox and ikk2flox/flox strains were interbred to obtain krasG12D, 
krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx triple mutant mice on a mixed 
C57BL/6/129/SvJae background (See Figure 3.1 for breeding plan). Dr Eleni 
Maniati developed the krasG12D/tnfa∆Pdx mice (Barts Cancer Institute, Queen Mary, 
University of London, London, UK). The ikk2flox/flox mice were kindly provided by Dr 
Toby Lawrence (Inflammation Biology Group, Centre d'Immunologie Marseille - 
Luminy, Parc Scientifique de Luminy Case 906, 13288 Marseille, France) (Fong et 
al., 2008). The tnfaflox/flox mice were a kind gift from Dr Sergei Nedospasov 
(Laboratory of Molecular Immunology, Engelhardt Institute of Molecular Biology, 
119991, Moscow, Russia) (Grivennikov et al., 2005). The kras+/LSL-G12D and pdx1-cre 
strains were generated and provided by Dr David Tuveson (Cancer Research UK 
Cambridge Research Institute, Robinson Way, Cambridge CB2 0RE, UK) 
(Hingorani et al., 2003; Johnson et al., 2001). The Mx-cre mice (The Jackson 
Laboratory - stock number 005673 - BALB/cJ background) were interbred with the 
tnfaf/f (Grivennikov et al., 2005) to generate tnfaf/f/Mx-cre mice on a mixed 
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C57BL/6/BALB/cJ background. The ROSA26-LSL-EYFP mice (The Jackson 
Laboratory - stock number 006148 - C57BL/6 background) were crossed with the 
krasG12D mice to obtain the composant mutant strain on a mixed C57BL/6/129/SvJae 
background. All mice were genotyped at weaning by a commercial vendor 
(Transnetyx, Tennessee, USA). 
2.1.2 Chimeras 
To delete tnfa expression in the bone marrow-derived cells, tnfaf/f/Mx-cre mice were 
injected intravenously once a day, for 3 days with poly(I:C) at 5 µg/g body weight 
(Invivogen - tlrl-picw). tnfaf/f/Mx-cre mice treated with poly(I:C) are abbreviated as 
tnfa∆Mx mice. Bone marrow-derived cells were isolated from the bones of tnfaf/f and 
tnfa∆Mx mice (described in section 2.2.3.1). Six weeks old krasG12D and krasG12D/tnfa∆Pdx 
female mice (n=10 per strain) were irradiated with a single dose of 10 Gy using a 
linear accelerator with 15 MV nominal photon energy and set to deliver a dose rate of 
3.6 Gy/min. The irradiated mice were left to rest for 6 hours and were then 
reconstituted with 5x106 bone marrow-derived cells from tnfaf/f or tnfa∆Mx mice 
injected intravenously. To reduce the risk of infection following irradiation, mice 
were treated with a fluoroquinolone antibiotic (enrofloxacin - Baytril) for 4 weeks 
(0.56 mg/ml in drinking water). To allow complete reconstitution of the immune 
system and repopulation of the organs with immune cells, mice were maintained for 8 
weeks in individually ventilated microisolator cages and were given sterilised food 
and acidified sterile water. Peripheral leukocytes from transplanted mice were 
collected and cultured in vitro to measure TNF-α secretion upon LPS stimulation by 
ELISA (see sections 2.2.3.2 and 2.5.4). Chimera mice were generated with the help 
of Dr Thorsten Hagemann, Barts Cancer Institute, Queen Mary, University of 
London, London, UK.  
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2.1.3 In vivo cell proliferation 
To detect proliferating cells in the pancreas, kras, krasG12D and krasG12D/ikk2∆Pdx mice 
were injected intraperitoneally with 250 µl of 5-bromo-2'-deoxyuridine (BrdU - 
Sigma-Aldrich - B9285) at 50 µg/g of total body weight. 90 minutes after BrdU 
injection, mice were sacrificed and each pancreas was processed and stained as 
described in sections 2.8.1 and 2.8.4.2. BrdU is a synthetic nucleoside which is an 
analogue of thymidine and which can therefore be incorporated into the newly 
synthesised DNA of live replicating cells. 
2.1.4 In vivo experiments with small inhibitors 
In the in vivo experiments described, mice were treated with the following 
compounds: 
- Rosiglitazone (Cayman Chemical - 71740) was incorporated into standard 
rodent chow at 3 mg/kg/day. 
- Notch antagonist N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT/γ secretase inhibitor IX) (Cayman Chemical - 13197) was 
injected intraperitoneally at 100 mg/kg/day. 
- Bay11-7082 (Alexis Biochemicals Corporation) was injected intraperitoneally 
at 10 mg/kg/day. 
- Anti-murine-TNF-α (R&D Systems - AB-410-NA) was injected 
intraperitoneally at 10 mg/kg/day. 
- IgG control antibody (R&D Systems - AB-105-C) was injected 
intraperitoneally at 10 mg/kg/day. 
The age of the mice and the duration of treatment varied and are specified in the 
figure legend of each individual experiment.  
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2.2 Tissue culture 
2.2.1 PanIN and PDAC cell lines 
2.2.1.1 Collection and generation 
PanIN and PDAC cell lines derived from the different mouse strains were generated 
by Dr David Tuveson’s laboratory as previously described (Schreiber et al., 2004). 
PanIN cell lines were derived from PanIN lesions with no invasive cancer present 
within the pancreas of the mouse.  
 
Pancreases from the required mice genotype and age were harvested, minced and 
digested by incubation in Hank's buffered salt solution (HBSS) with glucose (1 g/l), 
calcium chloride (0.185 g/l) (Sigma Aldrich - H8264) and complemented with           
2 mg/ml of collagenase V (Sigma Aldrich - C9263) for 30 minutes at 37ºC. The cell 
suspension obtained (mainly containing immune cells) was filtered through a 100 µm 
cell strainer and tissue fragments left in the cell strainer were further digested in   
0.05 % w/v Trypsin-EDTA for 2 minutes at 37ºC to obtain epithelial cells. Trypsin 
was inhibited by adding fresh complete Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10 % v/v foetal calf serum (FCS). The tissue was 
washed three times with HBSS buffer and the fragments were plated in plastic 
dishes, previously precoated with rat tail collagen type I at 2.3 mg/ml (BD 
Biosciences - 354236) in fresh complete medium (DMEM supplemented with 10 % 
v/v FCS). Monolayers of cells were rapidly obtained and cells were expanded and 
frozen as described in the next section.  
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2.2.1.2 Culture conditions 
PDAC and PanIN cell lines were maintained in culture with DMEM (PAA - E15-
810), 10 % v/v FCS (PAA - A15-102), 1 % v/v penicillin/streptomycin (PAA - P11-
010) under sterile conditions at 37°C and in a 5 % v/v CO2 atmosphere. The cells 
were passaged and divided twice weekly or when 80 % confluency was reached. All 
cell-lines were adherent and were detached from the culture flask using Trypsin-
EDTA (0.1 % w/v and 0.05 % w/v in PBS respectively) (PAA - L11-003). The cells 
were washed with phosphate buffered saline (PBS) (PAA - H15-002) to remove any 
excess FCS. Trypsin-EDTA was added and cells were incubated at 37°C until they 
were completely detached. The action of Trypsin was stopped by adding fresh 
complete medium. Cells were centrifuged at 450 x g for 5 minutes. Following 
centrifugation, the supernatant was removed and cells were resuspended in the 
appropriate culture medium. 
 
To freeze the cells down, cell numbers and viability were determined by counting live 
cells using a Vi-CELLTM image analyzer (Beckman Coulter). Cells were stained with 
trypan blue to distinguish the live population from the non-viable cells. Cells were 
resuspended in fresh complete medium at 4x106 cells/ml. In parallel, a solution of     
10 % v/v DMSO (Sigma Aldrich - D2650) in FCS was prepared. This freezing 
medium was added to the cells (1:1 v/v) and 1 ml of solution was aliquoted into 
cryovials. Cells were slowly frozen down by incubating them in a freezing container 
(Mr Frosty - Nalgene®) containing isopropanol, overnight at -80ºC. Isopropanol 
allows an optimal cooling rate of -1ºC per minute. Vials can be stored in liquid 
nitrogen (-196ºC), thus retarding the growth of ice crystals. When thawing, the cells 
should be warmed very quickly in a 37ºC water bath to maximize the recovery rate. 
Once completely melted, cells were diluted into prewarmed to 37ºC fresh complete 
CHAPTER TWO MATERIALS AND METHODS 
 
101 
medium and pelleted by centrifugation at 450 x g for 5 minutes in order to remove 
DMSO, which is toxic to cells. The cells were resuspended in the appropriate culture 
medium and placed in culture under sterile conditions at 37°C and in a 5 % v/v CO2 
atmosphere. 
2.2.2 OP9-DL1 cells 
OP9 cells stably transfected with the Notch ligand Delta-like 1 (OP9-DL1) were 
obtained from Dr Juan-Carlos Zuniga-Pflucker (Schmitt and Zuniga-Pflucker 
2002). This mouse bone marrow-derived stromal cell line was co-cultured with cells 
derived from PanIN bearing krasG12D/tnfa∆Pdx mice. OP9-DL1 stromal cells were 
cultured in Minimum Essential Medium Alpha (Invitrogen - 12561056), 
supplemented with 20 % v/v FCS and 1 % v/v penicillin/streptomycin.  
2.2.3 Immune cells 
2.2.3.1 Collection of bone marrow-derived cells 
Donor mice (tnfaf/f or tnfa∆Mx) were sacrificed by cervical dislocation and their femurs 
and tibias were collected in ice-cold PBS. Bones were scraped clean with a scalpel 
under sterile conditions and the ends of the bones were removed at the epiphyses, 
also with a scalpel. Holding the shaft of the bone with forceps, PBS was used to flush 
the bone marrow with a 27G needle. The suspension obtained was washed with PBS 
and after centrifugation at 450 x g for 5 minutes, the cells were resuspended in 5 ml of 
1X red blood cell lysis buffer (BD Biosciences - 555899). The action of the lysis 
buffer was stopped by adding 30 ml of PBS and cells were pelleted by centrifugation 
at 450 x g for 5 minutes. Cells were resuspended in 1 ml of PBS, passed through a 70 
µm cell strainer, centrifuged at 450 x g for 5 minutes and resuspended at 25x106 
cells/ml, to be injected into irradiated mice for adoptive transfer (see section 2.1.2).  
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2.2.3.2 Collection of peripheral blood leukocytes 
Mice were anaesthetised with isoflurane (Baxter Healthcare - FDG9623) delivered 
at 3 % v/v for induction and 1.5 % v/v for maintenance in oxygen. Blood was 
collected by cardiac puncture using a 27G needle in heparin-loaded syringes (5,000 
units/ml) and collection tubes (a drop of this anti-coagulant was sufficient). Mice 
were sacrificed by cervical dislocation. Under sterile conditions, red blood cells were 
lysed as described above and peripheral blood leukocytes (PBL) and other immune 
cells were placed in culture in Petri dishes in complete DMEM. Immune cells were 
simultaneously treated with LPS (Sigma Aldrich - L2630) at 10 ng/ml for 16 hours to 
activate them and to induce TNF-α secretion. Supernatants were collected and cell 
debris, membranes and dead cells were removed by centrifugation at 450 x g for 15 
minutes at 4°C. Supernatants were stored at - 80ºC until TNF-α measurement by 
ELISA.  
2.2.4 Cell culture treatment 
Cells derived from PanIN bearing krasG12D, krasG12D/ikk2∆Pdx or krasG12D/tnfa∆Pdx mice 
were plated in complete medium in 6-well plates and left to adhere overnight at 37°C 
in a 5 % v/v CO2 atmosphere (0.3x10
6 cells per well). The following day, cells were 
treated with the following compounds: 
- Recombinant mouse TNF-α (Peprotech - AF-300-01A) at a final 
concentration of 1 ng/ml. 
- Cycloheximide (Sigma Aldrich - C7698) at a final concentration of 15 µM. 
- Recombinant Jagged 2 (R&D Systems - 4748-JG-050) at a final 
concentration of 20 µg/ml. 
- L685458 (γ-secretase inhibitor) (5S)-(tert-Butoxycarbonylamino)-6-phenyl-
(4R)-hydroxy-(2R)-benzylhexanoyl)-L-leucy-L-phenylalaninamide (Shearman 
et al., 2000) (Sigma Aldrich - L1790) at a final concentration of 5 µM. 
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- Bay11-7082 (NF-κB inhibitor) ((E)-3-[4-methylphenylsulfonyl]-2-
propenenitrile) (Pierce et al., 1997) (Sigma Aldrich - B5556) at a final 
concentration of 1 µM. 
 
The origin of the cells used and the duration of treatment varied and are specified in 
the figure legend of each individual experiment.  
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2.3 Cloning and transfection of cells 
2.3.1 Plasmid constructs  
The plasmids used are described in Table 2.1 below and their map can be found in 
Appendix B: Plasmid Maps.  
 
pCR-FLAG-IKK2 (Addgene plasmid 15465) and pCR-FLAG-IKK2-KM (Addgene 
plasmid 15466) were received as a stab culture from Addgene (Nakano et al., 1998). 
pDEST40-NICD-V5 plasmid was kindly provided by Dr Michael Potente, Goethe 
University, Frankfurt, Germany. 
 
 
 
Table 2.1: Plasmid constructs used and their characteristics 
Table describes the plasmids used, the insert, the protein fusion, the gene of selection and the 
transfection reagent used.  
 
2.3.2 Transformation of bacteria 
JM109 competent E. coli cells (Promega - L2001) were transformed by a standard 
heat shock protocol. 100 µl of competent cells were used per transformation reaction. 
pDEST40-NICD-V5 plasmid was received on Whatman paper and was 
reconstituted by incubation in 50 µl of 10 mM Tris, pH 7.6 for 15 minutes at room 
temperature. 10 µl of this supernatant was added to the competent bacteria (or 10 µl 
of water as negative control) and incubated on ice for 30 minutes. A brief heat shock 
at 42°C was performed for 45 seconds and samples were incubated on ice for 5 
minutes. 400 µl of lysogeny broth (L. broth) was added and samples were incubated 
for 1 hour at 37°C with shaking (225 rpm). Samples were spread on L. agar plates 
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containing ampicillin at a final concentration of 60 µg/ml. Plates were incubated 
overnight at 37°C to allow individual clones to develop. The following day, colonies 
were picked with sterile pipette tips and grown in 5 ml of L. broth, containing 
ampicillin at a final concentration of 60 µg/ml for 16 hours at 37°C with shaking at 
225 rpm. 750 µl of bacterial culture was added to 150 µl of autoclaved 70 % v/v 
glycerol for long-term storage at -80°C (glycerol stock). The remaining bacterial 
culture was pelleted by centrifugation for 10 minutes at 4,500 x g and plasmid DNA 
was isolated using a mini-prep kit as described in section 2.3.4.   
 
The plasmids pCR-FLAG-IKK2 and pCR-FLAG-IKK2-KM were received as a stab 
culture. Samples were streaked on L. agar plates containing ampicillin at a final 
concentration of 60 µg/ml, allowing isolation of a single colony, and the same steps as 
above were followed. 
2.3.3 Recovery of bacteria from frozen glycerol stocks 
Using a sterile pipette tip, a small amount of frozen stock was added to 5 ml of L. 
broth medium with ampicillin (60 µg/ml) and cultured for 16 hours at 37°C with 
shaking at 225 rpm. Plasmid DNA was extracted with a miniprep kit (Qiagen - 
27106) (see section 2.3.4.1) or further expanded into 150 ml of L. broth with 
ampicillin (60 µg/ml). In the latter case, bacteria were cultured for a further 16 hours 
at 37°C with shaking at 225 rpm and plasmid DNA was extracted with a maxiprep 
kit (Qiagen - 12262) (see section 2.3.4.2).  
2.3.4 Plasmid DNA extraction 
2.3.4.1 Miniprep 
Plasmid DNA from E. coli bacteria was extracted using the QIAprep® Spin 
Miniprep Kit (Qiagen - 27106). Bacterial cultures were pelleted by centrifugation for 
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10 minutes at 4,500 x g and after removing the L. broth supernatant, the bacteria 
pellet was resuspended in 250 µl buffer P1. Bacteria were lysed in alkaline solution 
with 250 µl buffer P2. Buffer N3 was added to neutralise the samples and therefore 
stop the lysis process but also allow plasmid DNA renaturation. Tubes were 
thoroughly mixed by inversion until a white precipitate containing bacteria and 
genomic DNA formed. This precipitate was removed by centrifugation for 10 
minutes at 16,100 x g and the supernatant, containing the plasmid DNA, was applied 
to a column containing a DNA binding matrix. Columns were then washed with two 
different buffers: PB (500 µl, isopropanol solution) and PE (750 µl, ethanol based 
solution). Each buffer was applied to the column and eliminated via a centrifugation 
step (1 minute at 16,100 x g). Plasmid DNA was finally eluted by adding 50 µl of 
deionised water to the spin column and centrifuging for 1 minute at 16,100 x g into a 
clean 1.5 ml centrifuge tube. Plasmid DNA concentration was determined using the 
ND-100 spectrophotometer (Nanodrop Technologies). 
2.3.4.2 Maxiprep 
The QIAfilterTM Plasmid Maxi Kit (Qiagen - 12262) was used to prepare high 
amounts of plasmid DNA (up to 500 µg for high-copy plasmids). Bacterial cultures 
were pelleted by centrifugation for 15 minutes at 6,000 x g. The bacterial pellet was 
resuspended in 10 ml of buffer P1. Once fully resuspended, bacteria were lysed with 
10 ml of buffer P2 for no more than 5 minutes at room temperature. To neutralise the 
cells, 10 ml of pre-chilled buffer P3 was added. Tubes were thoroughly mixed by 
inversion until a white material had formed and the lysate was no longer viscous. To 
prevent later disruption of the precipitate layer, lysates were immediately transferred 
into a closed QIAfilter cartridge and incubated for up to 10 minutes at room 
temperature, allowing the precipitate to form a layer on top of the solution. The cap 
from the QIAfilter cartridge was removed and with a plunger, the cell lysate was 
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filtered into a QIAGEN-tip, which was previously equilibrated with 10 ml of buffer 
QBT. Once the lysate entered the resin by gravity flow, the QIAGEN-tip was 
washed twice with 30 ml of buffer QC. Plasmid DNA was eluted from the resin with 
15 ml of buffer QF and precipitated with 0.7 volumes (10.5 ml) of isopropanol. DNA 
was pelleted by centrifugation at ≥ 15,000 x g for 30 minutes at 4ºC. After carefully 
decanting the supernatant, DNA pellets were washed with 70 % v/v ethanol, air-
dried and redissolved in a suitable volume of slightly alkaline TE buffer. Plasmid 
DNA concentration was determined using the ND-100 spectrophotometer 
(Nanodrop Technologies). 
2.3.5 Integrity of the plasmid constructs 
The integrity of the plasmid constructs pCR-FLAG-IKK2 and pCR-FLAG-IKK2-
KM was assessed by digesting the DNA with the appropriate restriction enzymes 
and buffers (New England BioLabs - NEB) to cut out bands which depending in the 
size would indicate the presence of the insert. The following were incubated for 2 
hours at 37ºC and 15 minutes at 65°C (for heat inactivation) and for 5 minutes on ice. 
 
200 ng plasmid DNA  
2 µl NEBuffer 4 (NEB - B7004) 
1 µl EcoR1 (NEB - R0101) 
1 µl Xho1 (NEB - R0146) 
0.5 µl BSA (100X) (NEB - B9001) 
deionised water up to 20 µl final volume  
 
Plasmid DNA fragments were separated on an agarose gel as described in section 
2.4.2.  
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2.3.6 Transcient transfection of target cells with FuGENEHD 
The pCR-FLAG-IKK2 and pCR-FLAG-IKK2-KM vectors were transfected into target 
cells derived from PDAC bearing krasG12D mice using the transfection reagent 
FuGENE HD (Promega - E2311).  
 
Cells were plated in penicillin/streptomycin-free medium in 6-well plates and left to 
adhere overnight at 37°C in a 5 % v/v CO2 atmosphere (0.5x10
6 cells per well). When 
cells reached 80 % confluency, transfection complexes were prepared by diluting 5 
µg of DNA into 135 µl of OptiMEM reduced serum medium (Invitrogen - 
31985.047) and 15 µl of FuGENE HD (3:1 ratio µl FuGENE HD:µg DNA) and 
incubated for 20 minutes at room temperature. Complexes were added drop-wise 
onto the cells and the preparations were gently mixed by rocking the plates. Cells 
were incubated for 24 to 36 hours at 37°C in a 5 % v/v CO2 atmosphere. Proteins 
were extracted as described in section 2.5.1. 
2.3.7 Silencing genes in vitro - small interference RNA (siRNA) 
RNA interference (RNAi) is a gene-silencing pathway active in most eukaryotes cells 
(Fire et al., 1998), which uses short interference RNA (siRNA) to target specific 
mRNA degradation.  
 
Commercially validated rbpj-, ikk1-, ikk2-, nemo- and hes1-specific individual siRNAs 
and non-targeting control individual siRNAs were purchased from Dharmacon (3 
individual siGENOME siRNAs per target gene). These were resuspended in sterile, 
nuclease-free water at a final concentration of 20 µM.  
 
The siRNAs were transfected into target cells derived from PDAC bearing krasG12D 
mice using the transfection reagent LipofectamineTM RNAiMAX (Invitrogen - 13778-
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075), according to the manufacturer’s instructions. Cells (0.1x106 cells in 5 ml) were 
plated in penicillin/streptomycin-free medium in small Petri dishes (60 mm ∅) and 
left to adhere overnight. When the cells had reached 50-70 % confluency, 
transfection complexes were prepared by adding 150 pmol of siRNA to 500 µl of 
OptiMEM reduced serum medium (Invitrogen - 31985-047) and incubating this 
solution for 5 minutes at room temperature. In parallel, 10 µl of LipofectamineTM 
RNAiMAX were also diluted in 500 µl of OptiMEM reduced serum medium and 
incubated for 5 minutes at room temperature. The siRNA/OptiMEM mix was 
slowly added to the centre of the diluted LipofectamineTM RNAiMAX and incubated 
for 20 minutes at room temperature. Complexes were added drop-wise onto the cells 
and the preparations were gently mixed by rocking the plates. This gave a final 
volume of 6 ml and a final siRNA concentration of 25 nM. Cells were incubated for 
24 to 36 hours at 37°C in a 5 % v/v CO2 atmosphere. RNA extraction was performed 
as described in section 2.4.3.  
2.3.8 Luciferase reporter assay 
For hes1 reporter gene assays, primary krasG12D/tnfaΔPdx and krasG12D/ikk2ΔPdx cells were 
transfected in duplicate in 24-well plates. A hes1 luciferase reporter construct 
containing the -194 to +160 promoter fragment of the hes1 gene inserted upstream of 
the luciferase gene in pGL2 (gift from Prof Sangram Sisodia, Department of 
Neurobiology, The University of Chicago, Chicago, USA) (Berechid et al., 1999; 
Jarriault et al., 1995) and an internal control plasmid encoding renilla luciferase pRL-
CMV (Promega - E2261) were used. These reporters were transfected using 
LipofectamineTM LTX (Invitrogen - 15338-100). On the next day, cells were 
stimulated with rTNF-α for 6 h, and cell lysates were prepared and analysed for 
firefly and renilla luciferase activity with the Dual-Luciferase Reporter Assay System 
(Promega - E1910).  
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The reporter construct allows the expression of the firefly luciferase from the firefly 
Photinus pyralis while the internal control allows the expression of the renilla luciferase 
from the anthozoan coelenterate Renilla reniformis. These enzymes do not catalyse the 
same substrate: with the firefly luciferase, the light is produced by oxidation of 
luciferine and this reaction involves ATP and Mg2+. The renilla luciferase produces 
light after oxydising coelenterazine, in an ATP and Mg2+ independent manner 
(Nieuwenhuijsen et al., 2003). As these enzymes catalyse two different substrates, 
their activity can be measured in a single reaction. The activity of the reporter is 
correlated with the effect associated with the experimental conditions while the 
activity associated with the control provides a baseline response. Results are shown 
as firefly luciferase activity normalised to renilla luciferase activity, to minimise 
experimental variability due to cell viability and/or transfection efficiency.  
 
For cell lysate preparation from adherent cells, the medium was aspirated and the 
cells washed twice with ice-cold PBS. Cells were treated with lysis buffer for 15 
minutes at room temperature on a rocking platform. Cells were harvested using a cell 
scraper and membranes, debris and DNA were eliminated by centrifugation at 
16,100 x g for 15 minutes at 4°C. Cleared lysates (20 µl) were transferred into tubes 
containing 100 µl of Luciferase Assay Substrate and firefly luciferase activity was 
measured using a luminometer (Tecan - Infinite® F200). The reaction was then 
quenched and the renilla luciferase activity was simultaneously initiated by adding 
100 µl Stop & Glo® reagent. Renilla luciferase activity was measured using the same 
luminometer.  
 
The pparg luciferase reporter gene and hes1 plasmid (gifted by Prof Marc Montminy 
Salk Institute for Biological Studies, La Jolla, USA) were previously described 
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(Herzig et al., 2003). Cells were transfected with the pparg luciferase reporter plasmid 
and an expression plasmid encoding hes1 or a control vector (as described for hes1 
reporter gene assays). Luciferase activity was measured in presence of luciferin at    
150 µg/ml final concentration (Caliper Life Science - 122796) using a luminometer 
(Tecan - Infinite® F200) and was proportional to the activity of the promoter.  
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2.4 Nucleic acids 
2.4.1 Nucleic acid quantification 
DNA and RNA concentrations were determined using the ND-100 
spectrophotometer (Nanodrop Technologies). To assess the purity of DNA and 
RNA, two ratios of absorbance were considered: 
• A ratio of sample absorbance at 260 and 280 nm (260/280). A value of ~ 1.8 
for DNA or ~ 2.0 for RNA are generally accepted as “pure”. A lower value may 
indicate the presence of protein, phenol or other contaminants absorbing close to 
the 280 nm region.  
• A ratio of sample absorbance at 260 and 230 nm (260/230). The 260/230 
values for “pure” nucleic acid are often higher than the respective 260/280 values. 
They are usually between 1.8 and 2.2. A lower ratio may indicate the presence of 
co-purified contaminants.  
2.4.2 Agarose gel electrophoresis 
In order to visualise DNA fragments, agarose gel electrophoresis was used. 
Typically, 1.2 % w/v agarose gels were prepared by melting the agarose (Invitrogen - 
16500-500) in 1X TAE buffer, adding GelRedTM Nucleic Acid Gel Stain (Cambridge 
Bioscience - BT41003) at a final concentration of 4 % v/v and cooling the mix to 55ºC 
in a water bath. The gel was allowed to solidify in a tray with combs inserted for 
sample loading and equilibrated in 1X TAE buffer. 6X loading buffer was added to 
the samples to a final concentration of 1X and the samples were loaded into the gel 
and allowed to run at 90 V for 30 minutes (6 V/cm). DNA samples and a DNA 
ladder (Invitrogen - 15615-016) were visualised using a UV lamp and photographed 
(Alpha Innotech - RedTM Imaging System).  
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2.4.3 Total RNA isolation - Trizol 
For RNA isolation from adherent cells, medium was first removed and cells were 
washed once with PBS. Cells were detached with Trypsin-EDTA (PAA - L1-003) 
for 3 minutes at 37ºC and the action of Trypsin was stopped by adding fresh 
complete medium. Cells were then centrifuged at 300 x g for 5 minutes. Following 
centrifugation, the supernatant was removed leaving only approximately 100 µl (by 
eye) of medium, in the tube, to which 900 µl of Trizol (Sigma Aldrich - T9424) was 
added. Once in Trizol, cell suspensions were mixed well and incubated at 4ºC for 10 
minutes or stored at - 80ºC for long term storage. After this incubation, 200 µl of 
chloroform (CHCl3) was added. The sample was mixed well and incubated at 4ºC for 
another 10 minutes and centrifuged at 16,100 x g for 15 minutes at 4ºC to separate 
the RNA, in the aqueous phase, from the chloroform, which remained in the bottom 
organic phase. The supernatant (~ 500 µl) was transferred to a fresh tube containing 
1.2 µl of RNAse-free glycogen at 5 mg/ml (Ambion - AM9510) to facilitate its 
pelleting and mixed well. An equal volume (500 µl) of isopropanol was added to 
precipitate the RNA and incubated at 4ºC for 5 minutes, centrifuged at 16,100 x g for 
15 minutes at 4ºC. The RNA pellet was washed with 70 % v/v ethanol and either 
stored at - 80ºC as a pellet or resuspended in 40 µl RNAse-free water.  
2.4.4 DNase treatment of RNA 
In order to remove contaminating DNA, all RNA samples used for cDNA 
preparation were treated with RQ1 DNAse (Promega - M6101), according to the 
manufacturer’s instructions. DNAse was added to the RNA preparation (at least one 
unit of enzyme/µg of RNA) and incubated in a total volume of at least 50 µl for 30 
minutes at 37ºC, in the presence of the appropriate enzyme buffer. Following this 
treatment, the RNA was purified by adding an equal volume of 
Phenol:Chloroform:Iso-amyl alcohol (pH 5.2, Sigma Aldrich - P1944), mixing well 
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and centrifuging at 16,100 x g for 5 minutes to separate the aqueous and organic 
phases, respectively containing RNA and proteins. The upper phase was transferred 
to a fresh microfuge tube. RNA precipitation was performed by adding sodium 
acetate (3 M, pH 5.2 - 10 % of total volume of sample) and mixing well, followed by 
the addition of 2x volumes of ice-cold 100 % v/v ethanol. The sample was well mixed 
and RNA was allowed to precipitate at 4ºC for 15 to 30 minutes. The RNA pellet was 
recovered by centrifugation at 16,100 x g for 15 minutes at 4ºC and resuspended in     
40 µl RNase-free water.  
2.4.5 Total RNA isolation - RNeasy technology 
2.4.5.1 From adherent mammalian cells 
To obtain high-quality RNA, the RNeasy technology was used to purify RNA from 
adherent mammalian cells, according to the manufacturer’s instructions (Qiagen - 
74104). 
 
Cells were harvested as described in section 2.4.3 and the pelleted cells were 
detached thoroughly by flicking the tube and finally disrupted by adding 600 µl of 
buffer RLT. After mixing well and to ensure a good homogenisation, the lysate was 
directly pipetted into a QIAshredder spin column (Qiagen - 79654), placed in a 2 ml 
collection tube and centrifuged at 16,100 x g for 2 minutes. To provide appropriate 
binding conditions, 600 µl of 70 % v/v ethanol was added to the homogenised lysate 
and mixed well by pipetting. The sample was applied to an RNeasy spin column, 
where the total RNA binds to the membrane of the column and contaminants are 
efficiently washed away after centrifugation at 11,200 x g for 30 seconds (discarded 
in the flow-through). Membrane-bound RNA was then washed with 350 µl of buffer 
RW1 after centrifugation at 11,200 x g for 30 seconds (flow-through discarded). To 
digest contaminating DNA, the RNase-free DNase Set (Qiagen - 79254) was used, 
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applying 70 µl of buffer RDD and 10 µl of DNase onto the membrane for 15 minutes 
at room temperature. The spin column membrane was washed a second time with 
350 µl of buffer RW1 after centrifugation at 11,200 x g for 30 seconds (flow-through 
discarded). The spin column membrane was again washed twice with 500 µl of buffer 
RPE after centrifugation at 11,200 x g for 30 seconds (flow-through discarded). To 
eliminate any possible carryover of buffer RPE or any residual flow-through, the 
RNeasy spin column was placed into a new 2 ml collection tube and centrifuged at 
16,100 x g for 1 minute. High-quality RNA was eluted in 30 µl of RNase-free water 
by centrifugation at 11,200 x g for 1 minute. RNA was stored at - 80ºC. 
2.4.5.2 From animal tissues 
Pancreases from age-matched mice were harvested in a cryovial and snap frozen by 
immersion in liquid nitrogen. Fractions of these pancreases were disrupted and 
homogenised by placing them into gentleMACTM M tubes (Miltenyi Biotec - 130-
093-236) with 1 ml of buffer RLT (Qiagen - 74104) supplemented with 4 % v/v       
β-mercaptoethanol. Samples were processed using the gentleMACS dissociator 
(Miltenyi Biotec) set to the RNA-02 program. The lysate was centrifuged at 1,200 x g 
for 1 minute and 350 µl of the supernatant was directly pipetted into a QIAshredder 
spin column (Qiagen - 79654) and placed in a 2 ml collection tube. The rest of the 
lysate was stored at - 80ºC. After one centrifugation at 16,100 x g for 2 minutes and 
another one for 3 minutes to remove tissue debris, the supernatant was transferred 
into a new 1.5 ml microfuge tube. The same volume of 70 % v/v ethanol was added to 
the homogenised lysate and mixed well by pipetting. The sample was applied to an 
RNeasy spin column and the RNA was extracted following the same steps described 
above in the section 2.4.5.1. 
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2.4.6 cDNA synthesis 
To perform cDNA synthesis, all RNA samples were treated with M-MLV Reverse 
Transcriptase (Promega - M1705), according to the manufacturer’s instructions.    
1.2 µg of DNAse treated RNA was added to 1 µg of random primers (Invitrogen - 
48190-011) in a final volume of 14 µl. Samples were incubated at 75°C for 5 minutes 
to allow primer annealing and to remove any secondary structures, and then cooled 
on ice for 5 minutes to prevent the reformation of these structures. 200 units of       
M-MLV RT were then added to the RNA along with 5 µl of the appropriate buffer 
(Promega - M5313), 5 mM dNTPs (Applied Biosystems - N8080007) and 0.6 µl of 
RNAsin Ribonuclease inhibitor (Promega - N2111). Samples were incubated at 
room temperature for 10 minutes followed by 50 minutes at 40°C for cDNA 
synthesis. The final sample volume was adjusted to 100 µl with deionised water and 
stored at - 80°C. 
2.4.7 Quantitative Real-Time PCR (qRT-PCR) 
The references of the assays used for each gene of interest are described in Appendix 
C: Quantitative RT-PCR assays. Each assay contains one gene specific fluorogenic 
probe, two primers and the AmpliTaq Gold® DNA polymerase and were purchased 
from Applied Biosystems. The first two letters in the assay ID represent the species 
(Mm for Mus musculus) and the suffix designates the assay placement: “_m” indicates 
that the probe crosses over an exon junction and will therefore not detect genomic 
DNA; “_s” indicates that the probe and primers will bind specific sequences within a 
single exon, allowing genomic DNA detection ; “_g” indicates that the probe and the 
primers of this assay may bind specific sequences within a single exon.  
2.4.7.1 TaqMan® qRT-PCR - Principle of the method 
qRT-PCR was developed to allow the quantitation of different mRNA expression 
levels but also to increase the sensitivity of detection when small amounts of RNA are 
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used. Various fluorescent chemistries exist to detect PCR products, the most well-
known of which are TaqMan® and SYBR®-Green.  
 
TaqMan® chemistry uses a fluorogenic probe coupled to a reporter fluorescent dye 
on the 5’ end (usually FAM or VIC) and a quencher fluorescent dye on the 3’ end 
(usually TAMRA). When the probe is intact, fluorescence resonance energy transfer 
(FRET) occurs, and the quencher reduces the fluorescence emitted by the reporter. 
However, when annealed to its target, the probe is cleaved by the 5’ nuclease activity 
of the DNA polymerase, separating the dyes and increasing the reporter dye signal. 
The fluorescent intensity measured is therefore proportional to the amount of 
amplicon produced.  
2.4.7.2 TaqMan® qRT-PCR - Protocol 
qRT-PCR reactions were prepared by adding 500 ng of cDNA (2 µl at 250 ng/µl),   
10 µl master mix (Applied Biosystems - 4364340), 1 µl assay for the gene of interest 
and 1 µl assay for the eukaryote 18S gene (Applied Biosystems - 4310893E) and 
deionised water to a final volume of 25 µl. The reaction was set up in a MicroAmp 
optical 96-well reaction plate (Applied Biosystems - 4306737) and amplified in an 
ABI Prism 7700 sequence detection system (Applied Biosystems). Data were 
collected and analysed using the SDS software, version 1.9.1, (Applied Biosystems) 
in order to determine Ct (threshold cycle) values for each sample. Induction values 
were calculated using the formula 2-∆∆Ct. ∆Ct represents the difference between the Ct 
values of the target genes and Ct values of the reference gene 18S. ∆∆Ct represents 
the difference between the ∆Ct values of each sample and the ∆Ct of the reference 
sample (i.e. non-stimulated cells). The following thermal cycling conditions were 
used: 
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Step 1:  50ºC for 2 minutes 
Step 2:  95ºC for 10 minutes 
Step 3:  95ºC for 15 seconds 
Step 4:  60ºC for 1 minute 
Step 5:  Repeat steps 3 and 4 for 39 cycles  
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2.5 Protein analysis 
2.5.1 Protein extraction 
Procedures were carried out on ice, with ice-cold buffers and materials.  
2.5.1.1 From adherent mammalian cells 
For total protein extraction from adherent cells, medium was aspirated and cells were 
washed twice with ice-cold PBS. Cells were treated with 80 µl of complete lysis 
buffer per well for 30 minutes at 4°C. Cells were harvested using a cell scraper and 
the membranes, debris and DNA were eliminated by centrifugation at 16,100 x g for 
15 minutes at 4°C. Supernatants were transferred into new tubes and stored at           
- 80°C. Protein concentration was measured as described in section 2.5.2. 
2.5.1.2 From animal tissues 
Pancreases from age-matched mice were harvested in a cryovial and snap frozen by 
immersion in liquid nitrogen. Fractions of these pancreases were disrupted and 
homogenised by placing them into gentleMACTM M tubes (Miltenyi Biotec - 130-
093-236) with complete lysis buffer (up to 15 mg of tissue was used per ml of lysis 
buffer). Samples were processed using the gentleMACS dissociator (Miltenyi Biotec) 
set to the Protein-01 program. The lysate was centrifuged at 4,000 x g for 5 minutes 
at 4°C. Supernatants were transferred into new tubes and stored at - 80°C. Protein 
concentration was measured as described in section 2.5.2.  
2.5.2 Protein quantification 
For each sample, the concentration of protein was determined using the bicinchoninic 
acid (BCA) protein assay. This method combines the reduction of Cu2+ to Cu+ by 
proteins in an alkaline medium (the biuret reaction) with the highly sensitive and 
selective colorimetric detection of the cuprous cation (Cu+) using bicinchoninic acid. 
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A purple-coloured reaction product is formed by the chelation of two molecules of 
BCA with one cuprous cation. This water-soluble complex exhibits a strong 
absorbance at 562 nm that is nearly linear with increasing protein concentrations. 
Bovine Serum Albumin (BSA) standard stock solution was diluted in PBS to final 
concentrations ranging from 0 to 10 mg/ml to create a standard curve. In a 96-well 
plate, 10 µl of BSA standard, sample or control were pipetted. Working reagent was 
prepared by combining 50 parts BCA solution (Sigma Aldrich - B9643-L) with one 
part of Copper (II) sulfate solution (Sigma Aldrich - C2284). This working reagent 
was dispensed into each well (200 µl) and samples were incubated at 37°C for 30 
minutes. The optical density (OD) was read by spectrophotometry at 595 nm and the 
protein concentration (mg/ml) of each sample was calculated by comparison with the 
BSA standard curve. 
2.5.3 Western blot 
To analyse and identify several proteins within a sample, they first need to be 
denatured chemically and by heating, and then separated according to their 
molecular weight in a Bis-Tris buffered sodium dodecyl sulfate (SDS) 
polyacrylamide gel under an electric field. Higher concentrations of acrylamide in 
these gels will lead to better separation of small proteins. Proteins are then 
transferred onto a polyvinylidine fluoride (PVDF) membrane to enable detection 
using antibodies.  
 
Resolving and stacking gels were prepared to the desired specification using 40 % 
w/v 19:1 acrylamide:bis-acrylamide (Fisher Scientific - ELR/138/010H), Tris HCl 
and SDS. Gels were polymerised by the addition of ammonium persulphate (APS - 
Sigma-Aldrich - A3678) and tetramethylethylenediamine (TEMED - Sigma-Aldrich 
- T8133). Gel formulations are summarised below in Table 2.2 and Table 2.3.  
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Table 2.2: Formulation of resolving gels  
Table describes the formulation for 8 %, 10 % and 12 % w/v acrylamide resolving gels.  
 
 
 
 
 
 
Table 2.3: Formulation of stacking gels 
Table describes the formulation for 4 % and 6 % w/v acrylamide stacking gels.  
 
Cell lysates were diluted in cell lysis buffer to a final concentration of 1 µg/µl. 4X 
lithium dodecyl sulfate (LDS) sample buffer was added to the sample to a final 
concentration of 1X. Samples were then heated to 95°C for 10 minutes followed by 
brief centrifugation at 12,000 x g for 30 seconds. After cooling on ice, denatured 
samples were loaded into the gel. Prestained molecular weight standards (SeeBlue 
Plus2 Pre-Stained Standards - Invitrogen - LC5925) were also run on every gel to 
monitor electrophoresis, and were used to calibrate the mobility and hence apparent 
mass (kDa) of proteins of interest. Gels were run by electrophoresis in 1X running 
buffer for 15 minutes at a constant voltage of 90 V, and then for 1 hour and 30 
minutes at a constant voltage of 120 V (Mini-PROTEAN Tetra Electrophoresis 
System - BioRad - 165-8029).  
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Resolved proteins were transferred to PVDF membranes (PerkinElmer - 
NEF1002001PK) by tank transfer (Mini Trans-Blot Cell - BioRad - 165-8029). 
PVDF membranes are hydrophobic and need to be hydrated in methanol for             
1 minute followed by a rinse in 1X transfer buffer. The transfer cassette, comprising 
pre-equilibrated gel and PVDF membrane, was sandwiched between 
chromatography paper (Grade 3MM Chr - Whatman - 30306189) and Scotch-Brite 
pads. The cassette was placed in a transfer tank, immersed in transfer buffer, and 
electrotransfer was performed at a constant voltage of 75 V for 1 hour and 30 
minutes.  
 
To prevent non-specific antibody binding, the membranes were blocked with 5 % 
w/v milk powder in 1X tris buffered saline (TBS) with 0.1 % v/v Tween-20 (TBS/T) 
for 45 minutes at room temperature on a rocking platform. Primary antibodies were 
diluted in antibody dilution buffer and applied to the membrane overnight at 4°C or 
for 1 hour at room temperature. Membranes were washed three times for 5 minutes 
each wash in TBS/T and then incubated for 45 minutes in horseradish peroxidase 
(HRP)-conjugated secondary antibodies (Amersham ECL™-HRP Linked 
Secondary Antibodies - GE Healthcare) in TBS/T (Table 2.5). After again washing 
the membrane as described earlier, immunodetection was carried out by adding a 
substrate for the HRP (Amersham ECL™ Western Blotting Detection Reagents - 
GE Healthcare - RPN2106) followed by an exposure onto Super RX 
autoradiography films (Fujifilm - P10M000266A) to detect the light emitted. The 
HRP enzyme catalyses the oxidation of luminol to 3-aminophthalate and this reaction 
is accompanied by emission of low intensity light. However, in the presence of certain 
chemicals (p-iodophenol), the light emitted can be enhanced to increase the 
sensitivity of the reaction. This enhancement of light emission is called enhanced 
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chemiluminescence (ECL). The intensity of light emitted is a measure of the number 
of enzyme molecules reacting and thus of the amount of protein.  
 
Once the proteins of interest were revealed, membranes could be stripped to remove 
previous antibodies and could be re-incubated with a different primary antibody. 
This was done by briefly washing the membranes in water to eliminate the excess of 
reagent, and then incubating them in Reblot solution (Millipore - 2504) diluted 1:10 
in water for 10 minutes at room temperature, followed by a 5 minutes incubation in 
TBS/T 5 % w/v milk powder. Membranes were blocked in fresh TBS/T 5 % w/v milk 
powder for 45 minutes and primary and secondary antibodies were then applied as 
described earlier and proteins were revealed using ECL™ reagent, again as above.  
 
All primary and secondary antibodies used are listed below in Table 2.4 and Table 
2.5 respectively. 
 
 
 
 
 
 
 
Table 2.4: Primary antibodies used for Western blot 
Table describes the primary antibodies used for Western blot listing the supplier, catalogue reference 
(Cat. Ref.) and antibody isotype. Appropriate dilutions and concentrations are shown for each 
antibody.  
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Table 2.5: Secondary antibodies used for Western blot 
Table describes the secondary antibodies used for Western blot listing the supplier, catalogue 
reference (Cat. Ref.) and appropriate dilutions.  
 
2.5.4 Enzyme-linked immunosorbent assay (ELISA) 
Mouse pancreatic cancer cell lines derived from PanIN or PDAC bearing mice were 
cultured for 24 hours and their supernatants were collected. Cell debris, membranes 
and dead cells were removed by centrifugation at 450 x g for 15 minutes at 4°C. 
Supernatants were stored at - 80ºC until analysis by ELISA.  
 
ELISA kits from BD Biosciences (catalogue numbers in brackets) were used to 
measure mouse IL-1β (559603), IL-6 (555240), IL-10 (555252), IL-12p40 (55165), 
IL-12p70 (555256) and TNF-α (558534) protein levels, according to manufacturer’s 
instructions. Mouse IL-23p19/p40 protein levels were detected with an eBiosience 
ELISA kit (88-7234). ELISA tests were performed in half area 96-well microplates 
(Fisher - DPS150030Q).  
 
Plates were coated by overnight incubation at 4ºC with a capture antibody (50 µl) 
diluted 1:250 in PBS. The following day, wells were washed three times with 150 µl 
PBS with 0.05 % v/v Tween-20 (PBS/T). To prevent non-specific binding, blocking 
was performed by adding 50 µl per well of PBS with 10 % v/v FCS for 1 hour at 
room temperature. Meanwhile, standards were diluted in blocking solution according 
to the manufacturer’s instruction (usually to final concentrations ranging from 15.6 to 
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1,000 pg/ml, 31.3 to 2,000 pg/ml or 62.5 to 4,000 pg/ml, depending on the protein 
measured) to create a standard curve. If necessary, samples were also diluted 1:2 in 
blocking solution. Wells were washed three times with 150 µl PBS/T and samples, 
controls and standards were plated in duplicate (50 µl) and incubated for 2 hours at 
room temperature. Wells were once again washed three times with 150 µl of PBS/T 
and diluted detection antibody (1:250, 1:500 or 1:1,000 in blocking solution 
depending on the kit used) was added and incubated for 1 hour at room temperature. 
Detection antibodies used were biotinylated. The streptavidin-horseradish peroxidase 
(SAv-HRP) system was used as the detection method. Streptavidin and biotin have a 
high affinity, allowing the HRP enzyme to be nearby the detection antibody and 
therefore nearby the protein of interest. Again, depending on the kit used, the SAv-
HRP reagent was incubated pre-mixed with the detection antibody or separately for 
30 minutes at room temperature. After washing the wells with 150 µl of PBS/T, 50 µl 
of the HRP substrate was added (Kirkegaard & Perry Laboratories - 507600). Equal 
volumes of 3,3',5,5'-tetramethylbenzidine (TMB) at 0.4 g/l in organic base and      
0.02 % v/v hydrogen peroxide (H2O2) in citric acid buffer were mixed and added to 
the wells for 30 minutes at room temperature in the dark. In this case, the HRP 
enzyme will catalyse the oxidation of the chromogenic substrate (TMB) in the 
presence of hydrogen peroxide as an oxidising agent, converting it into a coloured 
molecule detectable by spectrophotometry. The developing reaction was stopped by 
addition of 50 µl of 1 M phosphoric acid (H3PO4). Optical densities were measured 
at 450 nm within 30 minutes on a spectrophotometer. Protein concentrations (pg/ml) 
in each sample were calculated by comparison with the corresponding standard 
curve. 
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2.5.5 Kinase assay 
In vitro IKK2 kinase activity assays were performed by Dr Toby Lawrence and his 
group (Inflammation Biology Group, Centre d'Immunologie Marseille - Luminy, 
Marseille, France). Pancreatic cell lysates from the different mouse models were 
obtained as described in sections 2.2.1 and 2.5.1. The IKK complex containing the 
kinase of interest (IKK2) was immunoprecipitated using 20 µl of Protein A/G PLUS-
Agarose (Santa Cruz - Sc-2003) and 2 µg of antibody against NEMO (Cell Signaling 
- 2685) for 1 hour at 4ºC on a rotating device (for a more detailed protocol on 
immunoprecipitation, see section 2.7.1). The purified protein was incubated with   
200 µM ATP (Cell Signaling - 9804) and 1.5 µM of the biotinylated IκB-α peptide 
(Cell Signaling - 1146) in kinase buffer. The reaction was incubated for 30 minutes at 
30ºC and stopped with 50 mM EDTA, pH 8.0. The samples were transferred into a 
96-well plate precoated with an anti-phospho-IκB-α (Ser32/36) antibody (Cell 
Signaling - 9246), overnight at 4ºC. Samples were incubated for 2 hours at room 
temperature and direct detection was carried out as described in the previous section 
2.5.4 using SAv-HRP. Optical densities were measured by spectrophotometry and 
IKK2 kinase activity was calculated by setting the expression of the control sample 
(without substrate) as 100 %.  
2.5.6 Cytokine and chemokine arrays 
ChemiArrayTM Mouse Cytokine Antibody Arrays III (Chemicon International - 
AA1003M) were used to measure cytokine and chemokine levels (62 proteins) in the 
pancreases of wild type mice and krasG12D mice either untreated or treated with a γ-
secretase inhibitor (DAPT). 
 
Mice were sacrificed by cervical dislocation and the pancreases were collected in ice-
cold PBS. Protein extraction was performed as described in section 2.5.1.2. 
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ChemiArrays were used according to the manufacturer’s instructions. Membranes 
were blocked with blocking buffer for 30 minutes at room temperature. Pancreatic 
protein extracts from untreated or treated mice (n=5) were pooled and diluted 1:10 
with blocking buffer and incubated with the membranes for 2 hours at room 
temperature. Membranes were washed three times with wash buffer I for 5 minutes 
with gentle shaking. After an additional two washes with wash buffer II in the same 
conditions, diluted biotin-conjugated anti-cytokines primary antibody was applied for 
2 hours at room temperature. The washing step was repeated and membranes were 
incubated with HRP-conjugated streptavidin for 2 hours at room temperature. After 
washing the membrane as described before, immunodetection was carried out by 
adding a substrate for the HRP, followed by an exposure to Super RX 
autoradiography films to detect the light emitted. Relative levels of cytokine were 
evaluated by performing image densitometry analysis with the Image J software 
(public domain) and data were represented graphically as normalised to the signal 
intensity obtained for the wild type mice.  
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2.6 Protein-DNA interactions 
Chromatin immunoprecipitation assays (EZ-ChIPTM Assay Kit) were performed 
according to the manufacturer’s instruction (Millipore - 17-371). Adherent cells were 
treated with 1 % v/v formaldehyde for 10 minutes at room temperature. This 
treatment leads to covalent cross-linking of proteins to DNA. The excess of 
formaldehyde was quenched by adding glycine at 1.25 M and incubating the cells for 
5 minutes on ice. Medium was removed and cells were washed twice with ice-cold 
PBS. Cells were incubated with ChIP lysis buffer and harvested using a cell scraper. 
Cells were pelleted by centrifugation at 700 x g for 5 minutes at 4°C. Cells were 
resuspended in 1 ml ChIP SDS lysis buffer containing 1X protease inhibitor cocktail 
(Millipore - 20-283) to break cell membranes and remove the nuclei. Lysates were 
sonicated or stored at - 80°C. 
 
Sonication was performed on wet ice, to shear DNA into appropriately sized 
fragments (around 300 bp). 5 sets of 10 second pulses using a Sanyo - Soniprep 150 
sonicator were sufficient to obtain DNA fragments of the required length (verified on 
a 1.2 % w/v agarose gel - see section 2.4.2). Insoluble material was removed by 
centrifugation at 10,000 x g for 10 minutes at 4°C. Supernatants were transferred into 
new tubes and stored at - 80°C. 
 
Cross-linked Protein/DNA were immunoprecipitated with protein G agarose. To 
firstly remove proteins or DNA that would unspecifically bind to the protein G 
agarose, 100 µl of sheared chromatin was incubated with 900 µl of ChIP dilution 
buffer containing 1X protease inhibitor cocktail (Millipore - 20-283) and 60 µl of 
protein G agarose. Samples were incubated for 1 hour at 4ºC on a rotating device and 
the agarose was pelleted by centrifugation at 4,000 x g for 1 minute. 10 µl of the 
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supernatant were saved and stored at 4ºC as the input. The remaining supernatant 
was dispensed into new tubes and 1 µg of the immunoprecipitating antibody or 
isotype control was added (Table 2.6). Samples were incubated for 10 hours at 4ºC 
on a rotating device. 60 µl of Protein G Agarose was added and samples were once 
again incubated overnight at 4ºC on a rotating device. Immunoprecipitates were 
collected by centrifugation at 4,000 x g for 1 minute at 4ºC. Supernatants were 
carefully aspirated and discarded and the pellets were successively washed once with 
low salt immune complex wash buffer (Millipore - 20-154), once with high salt 
immune complex wash buffer (Millipore - 20-155), once with LiCl immune complex 
wash buffer (Millipore - 20-156) and twice with TE buffer (Millipore - 20-157). 
Protein/DNA complexes were eluted by incubating the samples and the input for 15 
minutes at room temperature with 100 µl of elution buffer (Millipore - 20294).  
 
Cross-link reversal was performed by incubating the samples and the input with    
200 mM of NaCl overnight at 65ºC. Samples were treated with RNase A (Millipore - 
20297) for 30 minutes at 37ºC and with Proteinase K in 40 mM EDTA, 40 mM Tris-
HCl for 2 hours at 45ºC for protein digestion. DNA was purified using the spin 
columns provided (Millipore - 17-371). qRT-PCR was performed on the samples and 
the input as described in section 2.4.7.2 with hes1 or pparg promoter-specific primers.  
 
 
 
 
Table 2.6: Antibodies used for chromatin immunoprecipitation 
Table describes the antibodies and the isotype control used for chromatin immunoprecipitation listing 
the supplier, catalogue reference (Cat. Ref.), isotype and quantity. 
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2.7 Protein-Protein interactions 
2.7.1 Immunoprecipitation 
Cells derived from PDAC bearing krasG12D mice were transiently transfected with 
either pCR-FLAG-IKK2, pCR-FLAG-IKK2-KM or pDEST40-NICD-V5 as 
described in section 2.3.6. Cells were stimulated with recombinant TNF-α for 12 
hours before performing protein extraction and quantification as described in 
sections 2.5.1 and 2.5.2.  
 
500 µg of total cellular protein were diluted in 1 ml PBS and incubated with 2 µg of 
antibody against the fusion protein (FLAG or V5) for 10 hours at 4ºC on a rotating 
device. 20 µl of Protein A/G PLUS-Agarose (Santa Cruz - Sc-2003) were added. 
Samples were incubated overnight at 4ºC on a rotating device. Immunoprecipitates 
were collected by centrifugation at 1,000 x g for 5 minutes at 4ºC. Supernatants were 
carefully aspirated and discarded and the pellets were washed four times with 1 ml 
PBS, each time repeating the centrifugation step described. After the final wash, 
samples were resuspended in a small volume (15 µl) of PBS with LDS sample buffer 
to a final concentration of 1X. Samples were heated at 95°C for 10 minutes, cooled on 
ice and centrifuged to pellet the agarose beads before loading them into an SDS-
NuPAGE® pre-cast 4-12 % w/v gradient bis tris gel (Invitrogen - NP0336BOX). 
Prestained molecular weight standards (Precision Plus Protein Dual Color Standards 
- BioRad - 161-0374) were also run on every gel to monitor electrophoresis, and were 
used to calibrate the mobility and hence apparent mass (kDa) of proteins of interest. 
Gels were subjected to electrophoresis in 1X 3-(N-morpholino)propanesulfonic acid 
(MOPS) SDS running buffer for 15 minutes at a constant voltage of 110 V, and then 
for 1 hour at a constant voltage of 150 V (NuPAGE® System - Invitrogen).  
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2.7.2 Coomassie brilliant blue stain  
To estimate the complexity of the samples after immunoprecipitation, resolved 
proteins were stained with EZBlueTM gel staining reagent (Sigma Aldrich - G1041). 
In a clean container, the gel was rinsed three times for 5 minutes with an excess of 
deionised water to remove the SDS from the gel, which causes background staining. 
The proteins were fixed by incubating the gel for 15 minutes in 50 % v/v methanol, 
10 % v/v acetic acid and the gel was then rinsed again for 15 minutes with an excess 
of deionised water. The gel was stained by adding 40 ml of EZBlueTM gel staining 
reagent and mixing with gentle shaking for 45 minutes to 1 hour. The protein band 
development was periodically checked and the staining process was usually stopped 
after approximately 1 hour. Because the pre-cast gels used were quite thick (1.5 mm) 
and had a high percentage of SDS especially at the bottom, the background was 
slightly blue. For full background destaining, the gel was washed three times for 15 
minutes with deionised water and left overnight in fresh deionised water.  
2.7.3 Mass Spectrometry 
After performing immunoprecipitation as described in section 2.7.1, 
immunocomplexes were once again resolved by electrophoresis on an SDS-
NuPAGE® pre-cast 4-12 % w/v gradient bis tris gel (Invitrogen - NP0336BOX). 
Gels were subjected to electrophoresis in 1X MOPS SDS running buffer for 15 
minutes at a constant voltage of 110 V (NuPAGE® System - Invitrogen). The 
electrophoresis was stopped when the leading edge of the electrophoretic front had 
approximately run 2 cm. Lanes were cut into 1 to 2 mm3 cubes and sent for analysis 
to Central Proteomics Facility, Oxford University, Oxford, UK. Gel bands were 
excised on a clean surface with a clean scalpel blade to avoid any keratin 
contamination. The use of detergents such as Triton®-X-100 and Tween was avoided 
during the experiments and when washing the glassware used as they contain 
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polyoxyethylene which is a source of contaminants and which can bind to the 
proteins and slow down their migration. 
  
Gel bands were washed twice for 30 minutes with 25 mM ammonium bicarbonate 
dissolved in v/v ratio of water/acetonitrile, followed by one wash in pure acetonitrile 
for 10 minutes to completely dehydrate the bands. Once dried, gel bands were 
incubated with 10 mM DTT for 30 minutes at 37ºC and then washed twice with      
25 mM ammonium bicarbonate and once in pure acetonitrile. They were then 
incubated in 55 mM iodoacetamide for 60 minutes in the dark and once again washed 
twice for 10 minutes with 25 mM ammonium bicarbonate dissolved in v/v ratio of 
water/acetonitrile, then once in pure acetonitrile and finally dried. Trypsin (Promega 
- V5111) digestion was performed overnight at 37ºC, to hydrolyse the proteins at the 
lysine and arginine residues and to release them from the gel. The digestion was 
stopped with formic acid and the supernatants were collected. Complete extraction of 
the proteins from the gel was performed adding 0.1 % v/v formic acid in 
water/acetonitrile (1:1 v/v) for 30 minutes. The supernatant obtained was pooled with 
the previous one. Samples were dried and reconstituted in 0.1 % v/v formic acid in 
HPLC grade water.  
 
Samples were desalted on a C18 packed pipette tip and injected onto an Ultimate 
3000 RSLC nano high-performance liquid chromatography (HPLC - Dionex) 
system coupled to LTQ XL Orbitrap mass spectrometer (Thermo Electron). They 
were resolved on a 12 cm by 75 µm inner diameter picotip column (New Objective) 
which was packed in-house with Reprosil-Pur C18-AQ phase (Dr. Maisch). A 120 
minutes gradient was used to separate the peptides and each sample was injected 
three times and data merged in order to increase sample coverage. In these columns, 
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the stationary phase is composed of hydrophobic alkyl chains to capture peptides and 
small molecules. The peptides were eluted with 0.1 % v/v formic acid in HPLC grade 
acetonitrile. The mass spectrometer was operated in a data dependent acquisition 
mode. Precursor scans were performed in the Orbitrap instrument at a resolving 
power of 60,000, from which five precursor ions were selected and fragmented in the 
linear ion trap. Charge state +1 ions were rejected. Peak lists were generated using 
DTAsupercharge and searched using Mascot (Matrixscience). Data were searched 
against international protein index (IPI) database, restricting the taxonomy to mouse. 
Variable modifications were set as carbamidomethyl cysteine and oxidised 
methionine and deamidation of asparagine and glutamine. Precursor mass accuracy 
tolerance was set at 10 ppm and MS/MS at 0.5 Da.  
 
Mass Spectrometry analyses were performed by Dr Benjamin Thomas and Dr 
Fernando Martinez-Estrada (Central Proteomics Facility, Oxford University, 
Oxford, UK). 
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2.8 Histology, staining and immunohistochemistry 
All sections were visualised and images were taken using AxioVision 4.8 with an 
AxioCam HRc camera (Zeiss) coupled to an Axiophot microscope (Zeiss).  
2.8.1 Histology 
Histological analysis of pancreases was carried out by standard procedures. 
Specimens were harvested from time-matched animals and fixed in 4 % v/v buffered 
formalin overnight at 4°C. The following day, the organs were progressively 
dehydrated in gradient alcohols (30 minutes at room temperature in 30, 50 and 70 % 
v/v ethanol). Tissues were embedded in paraffin and sections were cut with a 
microtome (5 µm thickness) and prepared by the Barts Cancer Institute pathology 
department. Tumour incidence and histology grades of PanIN lesions and PDAC 
were assessed as previously described (Hruban et al., 2001) and with the help of 
Anne Schultheis (University Medical Center Hamburg-Eppendorf, Pathology 
department, Hamburg, Germany).  
2.8.2 Haematoxylin and eosin staining 
Systematically, one section of each embedded-tissue was stained with haematoxylin 
and eosin (H&E) by the Barts Cancer Institute pathology department to assess the 
general histopathology. Sections were deparaffinised in xylene (Fisher Scientific - 
X020017) for 5 minutes and again in fresh xylene for another 5 minutes. Sections 
were progressively rehydrated in gradient alcohols (twice for 2 minutes each in 100, 
95, 70 and 50 % v/v ethanol and water). Sections were stained with Harris 
haematoxylin solution for 8 minutes and washed in running deionised water for 5 
minutes. Haematin (the oxidation product of haematoxylin) binds to lysine residues 
of nuclear histones in the presence of aluminium ions. Such a long incubation time 
allows saturation of all binding sites and overstaining of the tissue. 1 % v/v acid 
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alcohol was applied onto the sections to differentiate the tissue, followed by addition 
of alkaline solution (0.2 % v/v ammonia water) to stop the differentiation, turning the 
haematin into a blue colour for identification of cell nuclei. This process is also 
known as “blueing”. Finally, tissue sections were counterstained with a mix of eosin 
and phloxine to enhance the colouration. Sections were dehydrated by incubating 
them twice for 5 minutes each in 95, 100 % v/v ethanol and xylene sequentially. 
Slides were air-dried and mounted with DPX mounting medium (Fisher Scientific - 
D/5319/05). This staining resulted in the following colours: pale pink for collagen, 
red for acidophilic cytoplasm, purple for basophilic cytoplasm, blue for nuclei and 
cherry red for erythrocytes.  
2.8.3 Masson’s trichrome 
Sections were deparaffinised and rehydrated as described previously in section 2.8.2. 
To re-fix and intensify the final colouration of the tissues, sections were incubated in 
Bouin’s solution (Sigma Aldrich - HT10132) overnight at room temperature. After 
several washes with tap water, sections were incubated in Weigert’s Iron 
Haematoxylin solution (Sigma Aldrich - HT1079) for 5 minutes, to allow nuclei to be 
stained in blue/black. Sections were washed for 5 minutes with tap water and rinsed 
with deionised water before incubating them in Biebrich Scarlet-Acid Fuchsin 
(Sigma Aldrich - HT151) for 5 minutes, to stain cytoplasm and muscle in red. 
Sections were rinsed with deionised water and incubated in phosphotungstic acid 
solution (Sigma Aldrich - HT152) for 10 minutes to allow the uptake of the aniline 
blue (Sigma Aldrich - HT154) stain in which the sections were directly incubated for 
10 minutes, to stain the collagen in blue. Slides were incubated for 2 minutes in 1 % 
v/v acetic acid, rinsed with deionised water and finally dehydrated by dipping them 
in 95 % v/v ethanol for 3 minutes, twice in 100 % v/v ethanol for 3 minutes and three 
times in xylene for 5 minutes. Slides were then air-dried and mounted with DPX 
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mounting medium (Fisher Scientific - D/5319/05). Masson’s trichrome staining was 
performed by Juliana Candido, Barts Cancer Institute, Queen Mary, University of 
London, London, UK.  
2.8.4 Immunohistochemistry 
All primary and secondary antibodies used for immunohistochemistry are listed 
below in Table 2.7 and Table 2.8 respectively.  
 
 
 
 
Table 2.7: Primary antibodies used for immunohistochemistry 
Table describes the primary antibodies and isotype controls used for immunohistochemistry listing the 
supplier, catalogue reference (Cat. Ref.) and antibody isotype. Appropriate dilutions and 
concentrations are shown for each antibody.  
 
 
 
 
Table 2.8: Secondary antibodies used for immunohistochemistry 
Table describes the secondary antibodies used for immunohistochemistry listing the supplier, 
catalogue reference (Cat. Ref.) and appropriate dilutions.  
 
2.8.4.1 Specific markers 
Sections were stained using a standard streptavidin-peroxidase complex technique 
and the following steps were carried out at room temperature using immunoboxes for 
washes. Sections were deparaffinised and rehydrated as described previously in 
section 2.8.2. Following fixation in formalin, methylene bridges are formed, which 
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cross-link proteins and therefore mask antigenic sites. To improve the exposure of 
antigen sites on the sections, an antigen retrieval step is usually necessary, which is 
specific for each primary antibody used. The heat-mediated method was used, which 
involves immersing the sections in antigen citric acid based unmasking solution 
(Vector Labs - H-3300) and heating for 9 minutes in a microwave. Sections were 
allowed to cool down at room temperature for at least 20 minutes and washed three 
times for 3 minutes each wash in PBS. Sections were circled with ImmEdgeTM 
hydrophobic barrier pen (Vector Labs - H4000) and blocked for non-specific binding 
with PBS/BSA/Goat serum for 1 hour at room temperature in a humidified chamber. 
Sections were incubated in primary antibody or isotype control diluted in blocking 
solution, as described in Table 2.7, overnight at 4°C in a humidified chamber. The 
following day, the sections were again washed three times for 3 minutes each wash in 
PBS and subsequently the biotinylated secondary antibody was applied (Table 2.8) 
and the sections were incubated for 45 minutes at room temperature in a humidified 
chamber. Sections were again washed three times for 3 minutes each wash in PBS 
and the endogenous peroxidase activity was quenched by incubating the sections in 
0.3 % v/v H2O2 diluted in 100 % v/v methanol for 20 minutes at room temperature.  
 
The sections were then washed three times for 3 minutes each wash in PBS and 
avidin biotinylated peroxidase complex (Vector Labs - Vectastain Elite ABC Kit - 
PK-6100) was added onto the sections and incubated for 30 minutes at room 
temperature in a humidified chamber. The sections were once again washed three 
times for 3 minutes each wash in PBS and the peroxidase activity was visualised by 
using SIGMAFastTM 3,3’-diaminobenzidine (DAB) at a final concentration of 0.7 
mg/ml DAB, 0.67 mg/ml urea hydrogen peroxide and 0.06 M Tris buffer (Sigma-
Aldrich - D4418). DAB solution was applied on each section for at least 3 minutes or 
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until a brown colour developed. Subsequently, sections were briefly washed in water 
to stop DAB development and counterstained by dipping in haematoxylin solution 
(Sigma-Aldrich - GSH316) for 30 seconds, washed in water and dipped 10 times in 
ammonium hydroxide (44.4 mM in water) for acid differentiation. Sections were 
dehydrated by dipping them 20 times in isobutanol (Fisher Scientific - B/5100/PB17) 
and incubated again in fresh isobutanol for 4 minutes and then twice in xylene for 5 
minutes. Slides were air-dried and mounted with DPX mounting medium (Fisher 
Scientific - D/5319/05).   
2.8.4.2 BrdU staining 
To detect proliferating cells in the pancreas, mice were injected intraperitoneally with 
BrdU (see section 2.1.3). 90 minutes after BrdU injection, mice were sacrificed and 
each pancreas was processed as described in section 2.8.1. The protocol described in 
section 2.8.4.1 was followed using the BrdU antibody from the BrdU labelling and 
detection kit (Roche - 11299964001) and the peroxidase activity was visualised using 
SIGMAFastTM 3,3’-diaminobenzidine (DAB) with metal enhancer at a final 
concentration of 0.5 mg/ml DAB, 0.2 mg/ml cobalt chloride, 0.3 mg/ml urea 
hydrogen peroxide, 0.05 M Tris buffer and 0.15 M sodium chloride (Sigma-Aldrich - 
D0426). 
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2.9 Confocal Microscopy - Immunofluorescence 
All confocal microscopy images were acquired with a laser scanning-microscope 
LSM 510 (Zeiss) with a digital signal processor using the LSM software.  
 
The day previous to immunofluorescence imaging, glass cover slips (13 mm Ø VWR 
- 631-0150) were washed in 70 % v/v ethanol, air-dried and transferred to a 24-well 
plate. Cell lines derived from PanIN bearing krasG12D mice were plated (30,000 
cells/well) and grown overnight at 37°C in a 5 % v/v CO2 atmosphere. 
 
Cells were first rinsed twice with cold PBS and fixed with 4 % v/v paraformaldehyde 
(Ecolab - 416479) at room temperature for 15 minutes. Cells were rinsed twice with 
PBS and permeabilised with 0.1 % v/v Triton®-X-100 (Sigma Aldrich - X100) in 
PBS at room temperature for 5 minutes. Cells were again rinsed twice with PBS and 
quenched with 50 mM ammonium chloride (NH4Cl) in PBS at room temperature for 
15 minutes. They were then washed once with PBS and blocked with 
PBS/BSA/Goat serum at room temperature for 45 minutes. Cells were incubated 
with primary antibody or isotype control diluted in blocking solution or with 
rhodamine-labelled phalloidin (which binds F-Actin) at room temperature for 1 hour 
(Table 2.9). Cells were rinsed three times with PBS and incubated with secondary 
antibody diluted 1:500 in blocking solution at room temperature for 1 hour in the 
dark (Table 2.10). After this, cells were rinsed three times in PBS and once in water 
and the cover slips were mounted on clean slides using Prolong Gold antifade reagent 
with DAPI (Invitrogen - P36931).  
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Table 2.9: Primary antibodies used for immunofluorescence 
Table describes the primary antibodies or probe and isotype controls used for immunofluorescence 
listing the supplier, catalogue reference (Cat. Ref.) and antibody isotype. Appropriate dilutions and 
concentrations are shown for each antibody. n/a: not applicable. 
 
 
 
 
Table 2.10: Secondary antibodies used for immunofluorescence 
Table describes the secondary antibodies used for immunofluorescence listing the supplier, catalogue 
reference (Cat. Ref.) and appropriate dilutions.  
 
A modified protocol combining immunohistochemistry and immunofluorescence was 
used to stain pancreatic paraffin sections from krasG12D, krasG12D/tnfa∆Pdx and 
krasG12D/ikk2∆Pdx mice. The protocol described in section 2.8.4.1 was followed but 
before blocking, cells were permeabilised with 0.1 % v/v Triton®-X-100 and 
quenched with ammonium chloride as described above. The method described for 
immunofluorescence was subsequently followed but before mounting the slides, 
sections were dehydrated by immersion in isobutanol followed by xylene as described 
in section 2.8.4.1.  
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2.10 Flow cytometry 
2.10.1 Analysis of immune populations from the pancreas 
Pancreases were harvested from time-matched PanIN bearing krasG12D,     
krasG12D/ikk2∆Pdx or krasG12D/tnfa∆Pdx mice and minced. Tissue samples were digested by 
incubation in Hank's buffered salt solution (HBSS) without calcium and without 
magnesium (Sigma Aldrich - H6648) complemented with 2 mg/ml of collagenase V 
(Sigma Aldrich - C9263) for 30 minutes at 37ºC. The cell suspension obtained 
(mainly containing immune cells) was filtered through a 100 µm cell strainer and the 
cells in the flowthrough were washed three times with HBSS buffer. After each 
wash, the cells were pelleted by centrifugation at 450 x g for 5 minutes and the 
supernatants were discarded. The cells were finally resupsended in HBSS buffer and 
counted using a Vi-CELLTM image analyzer (Beckman Coulter). 
 
The cells were then plated in a 96-well plate (5x105 cells/well) and cell surface 
markers were stained for flow cytometry analysis. To do this, the plates were 
centrifuged at 515 x g for 5 minutes at 4ºC and the pelleted cells were washed once in 
FACS buffer. After another centrifugation at 515 x g for 5 minutes at 4ºC, cells were 
resuspended and incubated for 15 minutes at 4ºC in 50 µl of anti-mouse CD16/CD32 
(eBioscience - 14-0161-81) diluted 1:200 in FACS buffer to block unspecific binding 
sites (CD16 and CD32 receptors are expressed by most immune cells and recognise 
the mouse IgG Fc portion). Primary antibodies and isotype controls (Table 2.11) 
diluted in 50 µl FACS buffer were added to each well and the cells were incubated 
for 30 minutes at 4ºC. The cells were pelleted by centrifugation at 515 x g for 5 
minutes at 4ºC and washed twice with FACS buffer. They were finally resuspended 
and fixed in 100 µl of 2 % v/v formaldehyde (Ecolab - 3036850) in PBS and the cells 
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were stored at 4ºC in the dark until analysis by flow cytometry (usually within 48 
hours).  
 
 
 
 
 
Table 2.11: Antibodies used for flow cytometry analysis 
Table describes the antibodies used for flow cytometry listing the clone, supplier, catalogue reference 
(Cat. Ref.) and appropriate dilutions. PE: Phycoerythrin and PE-Cy5: Phycoerythrin-cyanine dye 5. 
n/a: not applicable. 
 
Individual cells are passed through a beam of light and will scatter the ray. 
Depending on the fluorophore used to label them, they will be excited and will emit a 
light at a longer wavelength than the light source (Table 2.12). The light emitted is 
picked up by detectors, converted into electric signals and each event (each cell being 
analysed) is shown on a graphical scale. 
 
Three-colour flow cytometry was performed using an LSRFortessa cell analyser (BD 
Biosciences) and FACSDiva software Version 6.2. The fluorescence of 50,000 events 
was acquired for each sample. Data were transferred and analysed using the FlowJo 
software (Tree Star, Oregon, USA). 
 
 
 
Table 2.12: Flow cytometry spectrum guide 
Table describes the different dyes used for flow cytometry and their respective excitation and emission 
wavelengths in nanometers (nm). PE: Phycoerythrin and PE-Cy5: Phycoerythrin-cyanine dye 5.  
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2.10.2 Fluorescence-activated cell sorting (FACS) 
Pancreases from krasG12D mice carrying the ROSA26-LSL-EYFP allele were first 
minced and digested with collagenase V as described in section 2.10.1. However, the 
flowthrough was discarded and the tissue fragments left in the cell strainer were 
further digested in 0.05 % w/v Trypsin-EDTA for 2 minutes at 37ºC to obtain 
epithelial cells. Trypsin was inhibited by adding fresh complete medium (DMEM 
supplemented with 10 % v/v FCS). The cell suspension obtained was filtered through 
a 100 µm cell strainer and cells in the flowthrough were washed three times with 
HBSS buffer. After each wash, the cells were pelleted by centrifugation at 450 x g for 
5 minutes and the supernatants were discarded. Once resuspended in HBSS buffer, 
EYFP positive cells were sorted using the FACSAriaTMII sorter (BD Biosciences) 
and FACSDiva software Version 6.2. These cells were used for RNA extraction and 
qRT-PCR (see sections 2.4.5 and 2.4.7). FACS analyses were performed by Dr 
Guglielmo Rosignoli, Barts Cancer Institute, Queen Mary, University of London, 
London, UK. 
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2.11 Statistical analysis 
All data were expressed as the mean of the individual experiments + the standard 
deviation of the mean (SD), represented as an error bar, unless otherwise stated in 
the figure legend.  
 
The statistical method used to determine significant differences between two 
populations was the unpaired Student’s t test (Figure 3.4 B, Figure 3.4 C, Figure 6.5 
and Figure 6.10). For multiple comparisons, results were tested for statistical 
significance using one-way or two-way ANOVA and Bonferroni’s multiple 
comparisons tests. Tumour incidence and liver metastasis were analysed by Fisher’s 
exact test. All statistical analyses were performed on the GraphPad Prism software 
Version 4.0c.  
 
All p values of 0.05 or less were considered statistically significant and the level of 
statistical significance was indicated by asterisks as follows: * p<0.05, ** p<0.01 and 
*** p<0.001.  
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The work presented in this chapter was performed in collaboration with a postdoc in 
the research group, Dr Eleni Maniati, Barts Cancer Institute, Queen Mary, 
University of London, London, UK.  
3.1 Introduction 
As described in Chapter 1, oncogenic KRAS mutations are found in almost all PDAC 
cases and play an important role in pancreatic tumour induction (see section 1.2.6). It 
is also known that the expression of mutant kras activates NF-κB, a major 
transcription factor in the inflammatory response (Basseres et al., 2010; Meylan et al., 
2009). Various studies indicate that IKK2 and the p65 subunit of NF-κB are required 
in both murine and human kras-induced transformation of lung epithelial cells and in 
models of inflammation-induced carcinogenesis (Basseres et al., 2010; Greten et al., 
2004; Meylan et al., 2009; Yang et al., 2010).  
 
kras+/LSL-G12D; pdx1-cre mice (abbreviated as krasG12D) express an endogenous oncogenic 
kras allele, initially in pancreatic progenitors and later in the adult pancreas 
(Hingorani et al., 2003). In this model, PanIN formation usually occurs from 2 
months of age and evolves towards a PDAC phenotype from 12 months of age. In 
order to understand the mechanisms and to decipher the signalling pathways 
involved in kras-induced pancreatic cancer, cell lines derived from PanIN and PDAC 
bearing krasG12D mice were generated (Schreiber et al., 2004).  
 
In these cell lines, constitutive secretion of the TNF-α cytokine was identified by 
ELISA. This has already been shown in other cell types such as ovarian cancer cells 
(Kulbe et al., 2007). Further experiments were carried out to determine and 
understand the role of the TNF-α/IKK2 signalling pathway in the formation and 
progression of PanIN lesions and also to assess the autocrine role of malignant cell-
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derived TNF-α. The starting point was to genetically delete ikk2 or tnfa in krasG12D 
mice in order to generate krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice, respectively.  
 
This chapter describes the preliminary data that instigated the study of the role of the 
TNF-α/IKK2 signalling pathway in pancreatic cancer, how the triple mutant mice 
were generated and their characterisation. These new mutant mice were used to 
obtain pancreatic epithelial cell lines from early cancerous lesions and to delineate in 
vitro molecular mechanisms involved in the carcinogenic process.  
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3.2 Generation of krasG12D mouse models with conditional 
deletion of ikk2 or tnfa in the pancreas 
The triple mutant mouse strains were generated by interbreeding C57BL/6 mice 
carrying “floxed” ikk2 or tnfa alleles with the kras+/LSL-G12D and pdx1-cre strains. The 
intermediate mouse strains were generated and kindly provided by various 
collaborators (detailed in the Materials and Methods chapter).  
 
The ikk2flox/flox mice (Li et al., 2003) were first crossed with kras+/LSL-G12D mice or     
pdx1-cre mice (Hingorani et al., 2003; Johnson et al., 2001) to generate double 
heterozygote transgenic kras+/LSL-G12D/ikk2+/flox mice or ikk2+/flox/pdx1-cre mice 
respectively. These mice were interbred to generate triple mutants on a mixed 
C57BL/6/129/SvJae background, abbreviated to krasG12D/ikk2∆Pdx. The strategy 
described is illustrated in Figure 3.1 and the different mouse strains used in this 
thesis are summarised in Table 3.1. krasG12D/tnfa∆Pdx were developed using a similar 
strategy by Dr Eleni Maniati, Barts Cancer Institute, Queen Mary, University of 
London, London, UK. 
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Figure 3.1: Generation of krasG12D mice with targeted deletion of ikk2 
kras+/LSL-G12D and pdx1-cre mice were crossed with the ikk2flox/flox strain. Progenies were intercrossed to 
generate krasG12D/ikk2∆Pdx triple mutant mice. A similar strategy was used to develop the 
krasG12D/tnfa∆Pdx triple mutant mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Characteristics of the mouse strains used 
Table describes the mouse strains used, their genotype for each allele (″+″ for wild type; ″f″ for floxed 
and ″-″for floxed out) and their genetic background.  
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3.3 Assessment of tnfa and ikk2 genetic deletion in pancreatic 
epithelial cells in vitro 
To confirm CRE-mediated recombination and therefore ikk2 or tnfa genetic deletion 
in the mouse strains, PanIN cell lines were generated by collaborators using 
pancreases from 3-, 6- and 9-month old krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx 
mice as described in section 2.2.1. Cell lines from age-matched kras and kras/tnfa Cre 
negative mice were similarly generated. PDAC cell lines were generated from 1-year 
old krasG12D mice. No significant difference of in vitro proliferation was observed 
between the PanIN cell lines or the PDAC cell lines from the different mouse strains 
(personal communication Dr Eleni Maniati, Barts Cancer Institute, Queen Mary, 
University of London, London, UK). 
3.3.1 PanIN and PDAC cell lines secrete TNF-α  
PanIN and PDAC cell lines grew in clusters and had morphological characteristics 
typical of epithelial cells (Figure 3.2).  
 
 
 
 
 
 
 
 
 
Figure 3.2: Morphological characteristics of the cell lines generated  
Cell lines derived from PanIN and PDAC bearing krasG12D mice were generated and cultured in vitro. 
Cells grew in clusters, with little or no intercellular space, which is characteristic of epithelial cells.  
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These cells were positive for intermediate filament proteins from the cytokeratin 
group, which further confirmed their epithelial nature (personal communication Dr 
David Tuveson’s laboratory, Cancer Research UK Cambridge Research Institute, 
Cambridge, UK). 
 
The profile of cytokines released after 24 hours in culture was examined, showing 
that these cells secrete IL-6 and IL-1β but not IL-10, IL-12 and IL-23 (Figure 3.4 
and unpublished data from Dr Thorsten Hagemann’s group, Barts Cancer Institute, 
Queen Mary, University of London, London, UK). High levels of TNF-α were also 
produced (Figure 3.3). 
 
 
 
 
 
 
 
 
 
Figure 3.3: TNF-α  secretion from PanIN and PDAC cell lines 
TNF-α secretion by cell lines derived from PanIN or PDAC bearing krasG12D mice measured by 
ELISA. Control cells were generated from the pancreases of kras and kras/tnfa Cre negative mice. Data 
are shown as mean + SD of triplicate experiments and are representative of three independent 
experiments. ***p<0.001, detection limit 10 pg/ml.  
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3.3.2 Genetic deletion of tnfa 
Levels of TNF-α secreted by PanIN and PDAC cell lines derived from     
krasG12D/tnfa∆Pdx mice in vitro after 24 hours in culture were evaluated by ELISA. As 
shown in Figure 3.4 A, cells secreted minimal levels of TNF-α (around 10 pg/ml, the 
detection limit of the assay) confirming tnfa genetic deletion following CRE 
recombination.  
3.3.3 Genetic deletion of ikk2 
The absence of IKK2 in the pancreas was verified by performing kinase activity 
assays on cells derived from krasG12D and krasG12D/ikk2∆Pdx mice. IKK complexes were 
purified and incubated in vitro with ATP and the phosphorylation of the IκB-α 
substrate was measured by colorimetric reaction (see section 2.5.5).  
 
The activity of the IKK complex was abolished in cells derived from PanIN bearing 
krasG12D/ikk2∆Pdx mice (Figure 3.4 B), therefore confirming excision of the ikk2 locus. 
Their capacity to secrete TNF-α and IL-6, whose expression is regulated by NF-κB, 
was also significantly decreased (Figure 3.4 C), further confirming the genetic 
inactivation of the ikk2 gene.  
 
Due to the IKK complex being purified via NEMO to preserve the integrity of the 
IKK2 kinase, the phosphorylation of the IκB-α substrate could have been due to the 
IKK1 or the IKK2 kinase. However, IKK2 was identified as the main kinase 
responsible for the IκB-α phosphorylation, implying that the absence of the kinase 
activity from the IKK complex was due to the genetic deletion of ikk2 (Yamamoto et 
al., 2000). The kinase assays were performed by Dr Toby Lawrence and his group 
(CIML, Marseille, France). 
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Figure 3.4: Genetic deletion of ikk2 and tnfa in pancreatic cell lines  
Cell lines were derived from PanIN bearing krasG12D, krasG12D/ikk2∆Pdx or krasG12D/tnfa∆Pdx mice. (A) 
TNF-α secretion measured by ELISA. Control cells were generated from kras and kras/tnfa Cre 
negative pancreases. (B) Cellular IKK2 kinase activity. (C) TNF-α and IL-6 secretion measured by 
ELISA (n=6). Data are shown as mean + SD of triplicate experiments and are representative of three 
independent experiments, **p<0.01, ***p<0.001. (A) and (C) detection limit 10 pg/ml.  
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3.4 Effects on PanIN formation and progression 
To establish whether ikk2 or tnfa genetic deletion has an impact on PanIN formation 
and PDAC progression in the krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice compared 
with the krasG12D mice, tumour incidence and histology grade were evaluated. General 
histopathology analyses were also performed with support from Anne Schultheis 
(University Medical Center Hamburg-Eppendorf, Pathology department, Hamburg, 
Germany).  
3.4.1 Incidence of pancreatic tumours 
To evaluate the long-term impact of ikk2 genetic deletion, cohorts of 40 krasG12D mice 
and 50 krasG12D/ikk2∆Pdx mice were monitored for nearly two years (Appendices D and 
E). Mice were sacrificed when they developed any signs of distress or reached the 
UK Home Office limits. For each mouse, tumour incidence and histology grade were 
evaluated and the sites of metastasis (liver or lung), the presence of peritoneal 
disease, ascites, skin lesions (such as papilloma), biliary obstruction and atrophy were 
also recorded. Significant differences were identified regarding tumour incidence 
only (Figure 3.5). 
 
 
 
Figure 3.5: Tumour incidence and histology grade 
Tumour incidence and histology grade in krasG12D (n=40) and krasG12D/ikk2∆Pdx (n=50) mice, *p<0.05. 
Respectively, 50 % and 20 % of krasG12D and of krasG12D/ikk2∆Pdx mice developed PDAC. The number 
of mice presenting undifferentiated tumours was more important in the krasG12D group.  
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Figure 3.5 shows that only 20 % of krasG12D/ikk2∆Pdx mice succumbed to PDAC, while 
there was a 50 % tumour incidence in krasG12D mice. Tumours, including pancreatic 
adenocarcinoma, are characterised and graded depending on the differentiation 
status of their glandular structures. Undifferentiated structures are more malignant 
and suggest a poorer prognosis (Pan and Wang 2007). Interestingly, three-quarters 
of the krasG12D mice which developed PDAC presented with undifferentiated 
tumours. However, even though this ratio was reduced by almost half in 
krasG12D/ikk2∆Pdx mice (Figure 3.5), this difference was not significant. Genetic 
deletion of ikk2 appears to be sufficient to induce changes in histopathological 
features and to delay PDAC development in the genetic krasG12D mouse model. 
Moreover, the frequency of liver metastasis was reduced in krasG12D/ikk2∆Pdx mice   
(60 % compared with 75 % for the krasG12D mice) (Figure 3.6), but this difference was 
again not significant. This observation confirms that the pancreatic cancer in these 
mice is at a less advanced stage.  
 
 
 
 
 
 
 
Figure 3.6: Liver metastasis  
Liver metastasis was reduced in krasG12D/ikk2∆Pdx (n=50) mice compared with the krasG12D (n=40) mice. 
Respectively, 75 % and 60 % of krasG12D and of krasG12D/ikk2∆Pdx mice presented liver metastasis. 
 
In genetically modified mouse models, monitoring the weight of the mice ensures that 
the genetic modifications introduced do not affect the well-being of the animal. Body 
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weight also indicates the health status of the animal and cancer development can be 
accompanied by a significant loss of weight (Tian et al., 2010). Moreover, The 
Animals (Scientific Procedures) Act 1986 established that if a mouse looses 20 % of 
its initial body weight, it should be culled using an appropriate and humane method.  
 
The body weight of the main mouse strains used was monitored weekly (Figure 3.7) 
and no significant loss of weight was observed over a period of 20 weeks. Weight 
recording was stopped as over this time period ikk2 genetic deletion did not affect the 
general health status of the animal. However, as the mice aged, they developed 
cancer and they had to be culled as mentioned above.  
 
 
 
 
 
 
Figure 3.7: Body weight monitoring of the main mouse strains used 
The percentage of the initial body weight was assessed weekly for kras, kras/ikk2, krasG12D and 
krasG12D/ikk2∆Pdx mice. Data are shown as mean ± SD, n = 10.  
 
3.4.2 General histopathology  
The haematoxylin and eosin (H&E) stain is the most widely used staining technique 
to access the general histopathology of any tissue. This classical method detects any 
obvious and major abnormality in the tissue structure. Staining was carried out by 
the Barts Cancer Institute pathology department. A magnification from the 
pancreases of 5-month old mice is shown in Figure 3.8, indicating no gross pathology 
in all intermediate strains.  
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Figure 3.8: Haematoxylin and eosin staining of pancreas sections from 
intermediate strains 
Histological aspect of the pancreas from the indicated strains at 5 months of age. Normal epithelium is 
shown with islets of Langerhans (arrowhead), ducts (solid arrow) and acinar cells within the exocrine 
pancreas (asterisk). Each picture is representative of three mice examined for each genotype. blue = 
nuclei and pink to red = cytoplasm.  
 
In Figure 3.9, the pancreases from the pancreatic cancer mouse models were 
analysed and compared with the intermediate strains. As shown previously in Figure 
3.8, kras and kras/ikk2 strains did not present any PanIN lesions. As expected, the 
presence of PanIN lesions in the pancreases of 4-month old krasG12D mice was clearly 
visible (Hingorani et al., 2003). Conversely, those PanIN structures were less 
frequent in the pancreases of age-matched krasG12D/ikk2∆Pdx mice. This was an 
interesting observation, suggesting that the genetic deletion of ikk2 can delay PanIN 
formation and that signalling pathways leading to IKK2 activation seem to be 
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involved in pancreatic carcinogenesis. The IKK complex can be activated by Toll-like 
receptors or by the classical receptors involved in NF-κB activation (see section 
1.3.1.2). Additional experiments were carried out to further investigate the 
underlying mechanisms.  
 
 
 
 
 
 
 
 
Figure 3.9: Haematoxylin and eosin staining of pancreas sections from mouse 
models  
Histological aspect of the pancreas from the indicated strains at 4 months of age. kras: normal 
epithelium with an islet of Langerhans (arrowhead) and acinar cells within the exocrine pancreas 
(asterisk). kras/ikk2: normal epithelium with an islet of Langerhans (arrowhead), ducts (solid arrow) 
and acinar cells within the exocrine pancreas (asterisk). krasG12D: high-grade PanIN-3 lesions with loss 
of cell polarity, “budding” into the lumen (solid arrow) and surrounding stroma (asterisk). 
krasG12D/ikk2∆Pdx: PanIN-1B lesion with papillary epithelium (solid arrow) surrounded by normal 
exocrine tissue (asterisk). Each picture is representative of three mice examined for each genotype. 
blue = nuclei and pink to red = cytoplasm.  
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3.4.3 Histological quantification 
To quantify and evaluate the effect of ikk2 and tnfa genetic deletion on PanIN 
formation, the proportion of the pancreas occupied by PanIN lesions and their stage 
were histologically assessed in krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice. 
This was performed according to the universal classification system for pancreatic 
duct lesions (Hruban et al., 2001). Cohorts of 12 mice for each strain at 2, 5 or 8 
months of age were analysed and the results are presented in Figure 3.10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Proportion of the pancreas occupied by PanIN lesions  
Quantification of the proportion of the pancreas occupied by normal tissue (nl, no lesion) and PanIN 
lesions. Frequency and grade of the lesions were assessed at 2, 5 and 8 months of age. Ikk2 deletion 
reduces the frequency of PanIN lesions while tnfa deletion has an impact only on 2-month old mice. 
Data are shown as mean + SD, **p<0.01, n=12. 
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Ikk2 deletion in krasG12D/ikk2∆Pdx mice resulted in a profound decrease in the 
frequency of high-grade PanIN-3 lesions compared with krasG12D mice. At 5 and 8 
months of age, almost 80 % and 60 %, respectively, of the pancreatic parenchyma 
retained normal exocrine tissue. Even at 8 months of age, the formation of PanIN-2 
and PanIN-3 lesions was minimal and the frequency of PanIN-1 was lower compared 
with both krasG12D and krasG12D/tnfa∆Pdx mice. 
 
However, tnfa deletion in krasG12D/tnfa∆Pdx mice had an impact only in young mice. 
More specifically, 2-month old krasG12D/tnfa∆Pdx mice exhibited a significant reduction 
in early PanIN lesions, but by 5 months of age, PanIN lesions had formed and 
progressed in a pattern similar to the one observed in krasG12D mice. 
 
In the context of mutant kras, these results suggest that IKK2 signalling is important 
for the development and progression of PanIN lesions. However, deletion of tnfa in 
pancreatic progenitors affects only the early stages of carcinogenesis.  
3.4.4 Analysis of pancreatic tissue sections  
3.4.4.1 Pancreatic progenitor marker SOX9 
As reviewed by Morris et al., kras mutations are very common in pancreatic cancer 
and can be sufficient to drive PanIN and PDAC development (Morris et al., 2010b). 
In the krasG12D model, mutant KRASG12D was produced in Pdx1 positive cells (making 
up most cells in the developing pancreas), but it was not clear whether PanIN lesions 
were arising from the exocrine or the endocrine pancreas (see section 1.2.1 for 
pancreas biology and section 1.2.8.3 for possible origins of PanIN lesions).  
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SOX9 is a transcription factor that has been discovered to be involved primarily in 
many development processes such as chondrogenesis and osteogenesis (skeletogenic 
processes corresponding to cartilage and bone development respectively) (Akiyama et 
al., 2005; Lefebvre et al., 1997; Wright et al., 1995) but also gonadogenesis (Kent et al., 
1996; Morais da Silva et al., 1996). More recently, SOX9 has been shown to be a 
critical transcription factor for the development of many tissues and organs, in 
particular for the pancreas (Lioubinski et al., 2003; Piper et al., 2002). SOX9 is not 
only a marker of early pancreatic progenitor cells, but it can also drive pancreatic 
cells to differentiate into endocrine cells (Seymour et al., 2007; Seymour et al., 2008).  
 
Using SOX9 as a marker for islets of Langerhans, immunohistochemistry on 
pancreas sections was performed on the mouse strains (Figure 3.11) to identify 
whether the PanIN lesions could arise from the endocrine compartment.  
 
Figure 3.11: Immunohistochemistry staining for SOX9 in tissue sections 
Pancreas sections of 4-month old kras, krasG12D and krasG12D/ikk2∆Pdx mice stained with anti-SOX9. 
Islets of Langerhans and PanIN lesions are both positive for this transcription factor in each mouse 
strain (dark brown and asterisk). Each picture is representative of three mice examined for each 
genotype. 
 
Figure 3.11 confirms that SOX9 is a marker for islets of Langerhans but also 
demonstrates that PanIN lesions in the pancreases of krasG12D and krasG12D/ikk2∆Pdx 
mice express SOX9. This suggests that PanIN lesions can have an endocrine origin 
or that this protein is abnormally overexpressed during pancreatic carcinogenesis, 
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similarly to the Notch signalling pathway. SOX9 staining was weaker in the 
pancreases of krasG12D/ikk2∆Pdx mice and normal islets structures were still visible.  
3.4.4.2 Desmoplasia 
One of the features of PDAC is an abundant fibrosis, also called desmoplastic 
reaction. This dense stroma, absent in normal pancreases, surrounds the malignant 
cells and is mainly composed of collagen (Hezel et al., 2006; Mahadevan and Von 
Hoff 2007). 
 
Masson’s trichrome staining distinguishes cells from their neighbouring connective 
tissue (Goldner 1938). This method was used to evaluate the desmoplastic reaction in 
the pancreases of the different mouse models. To better visualise the more advanced 
stage of the PanIN lesions in the pancreases of krasG12D mice compared with the ones 
observed in the pancreases of krasG12D/ikk2∆Pdx mice, Masson’s trichrome staining was 
performed (Figure 3.12). Staining was carried out by Juliana Candido, Barts Cancer 
Institute, Queen Mary, University of London, London, UK. 
 
Figure 3.12: Masson’s Trichrome staining for collagen in tissue sections 
Pancreas sections of 4-month old kras, krasG12D and krasG12D/ikk2∆Pdx mice stained with Masson’s 
trichrome. Stroma is absent in kras and krasG12D/ikk2∆Pdx mice, while krasG12D present a dense stromal 
reaction (blue). Each picture is representative of three mice examined for each genotype. blue = 
collagen, red = cytoplasm and black = nuclei.  
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Histological analysis after Masson’s trichrome staining showed no desmoplastic 
reaction in the pancreases of kras mice. However, in the pancreases of krasG12D mice, a 
very dense stroma was visible (blue stain) around the PanIN structures characterised 
earlier. Furthermore, stromal reaction was profoundly delayed in the pancreases of 
krasG12D/ikk2∆Pdx mice, demonstrating a less advanced stage in PanIN formation. 
3.4.4.3 Cell proliferation  
In order to detect proliferating cells in tissue sections, two differents strategies were 
used: the measurement of 5-bromo-2'-deoxyuridine (BrdU) uptake and the detection 
of PCNA by immunohistochemistry on tissue sections (see the Materials and 
Methods chapter). 
3.4.4.3.1 BrdU uptake 
In vivo cell proliferation analyses evolved from the early days of using [3H]thymidine 
to using BrdU and from high doses and frequent injections to a single BrdU injection 
(Kempermann et al., 1997b, 1997a; Nowakowski et al., 1989). Sacrificing the animal 
as soon as 90 minutes after the injection allows sufficient time to visualise BrdU 
uptake and therefore measurement of cell proliferation. To evaluate cell proliferation 
in the pancreases of the different mouse models, BrdU was injected intraperitoneally 
into each mouse and their pancreases were harvested 90 minutes afterwards. BrdU 
immunohistochemistry staining was performed and data are shown in Figure 3.13.  
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Figure 3.13: Immunohistochemistry staining of BrdU in tissue sections 
Pancreas sections of 4-month old kras, krasG12D and krasG12D/ikk2∆Pdx mice stained with anti-BrdU. 
Proliferating cells are stained in dark blue (arrowhead) and no significant difference between the 
mouse strains is observed. Each picture is representative of three mice examined for each genotype.  
 
No major differences were visible between the three mouse strains analysed (Figure 
3.13). Only a few number of positive cells were detected in the endocrine part of the 
pancreases of kras mice and in PanIN structures of krasG12D and krasG12D/ikk2∆Pdx mice.  
 
Pancreas regeneration after chemically-induced damage is known to be very slow in 
healthy mice (Fendrich et al., 2008), but recent studies have shown that following 
tissue damage, pancreatic regeneration can occur, involving the islets of Langerhans 
(Georgia and Bhushan 2004, 2006; Kushner et al., 2005; Teta et al., 2005) or the 
acinar cells (Desai et al., 2007; Jensen et al., 2005). Malignant cells and PanIN 
development are characterised by enhanced proliferation (Klein et al., 2002). 
However, an increase in the number of BrdU positive cells was not detected in the 
pancreas of the different mouse strains, suggesting that at that stage either the cells 
were not hyperproliferating, or that the assay was not sensitive enough to detect the 
differences from the surrounding normal tissue. 
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3.4.4.3.2 Proliferating cell nuclear antigen staining 
Proliferating cell nuclear antigen (PCNA) is a nuclear protein and acts as a 
chaperone protein, assisting DNA polymerase δ during DNA replication. PCNA is 
therefore mainly expressed during the S-phase of the cell cycle and is used as a 
specific marker for cell proliferation (Kubben et al., 1994; Miyachi et al., 1978; Prives 
and Gottifredi 2008). Immunohistochemistry staining for PCNA in the pancreases of 
kras, krasG12D and krasG12D/ikk2∆Pdx mice was performed and data are shown in Figure 
3.14.  
 
Figure 3.14: Immunohistochemistry staining for PCNA in tissue sections 
Pancreas sections of 4-month old kras, krasG12D and krasG12D/ikk2∆Pdx mice stained with anti-PCNA. 
PCNA positive cells are stained in dark brown (arrowhead) and an increase in the number of PCNA 
positive cells is observed in krasG12D mice compared with kras mice. However, this number is reduced 
in the pancreases of krasG12D/ikk2∆Pdx mice. Each picture is representative of three mice examined for 
each genotype. 
 
Very little PCNA protein was observed in the pancreases of kras mice. PCNA 
positive cells were clearly visible and abundant in the pancreases of krasG12D mice, 
especially in PanIN areas (arrowheads). There was, however, a reduction in the 
number of proliferating cells in the pancreases of krasG12D/ikk2∆Pdx mice compared 
with krasG12D mice. As it was previously shown that krasG12D/ikk2∆Pdx mice presented 
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less PanIN lesions, a reduction in the number of PCNA positive cells was therefore 
not surprising. However, it should be noted that PCNA protein has been shown to 
play a role in DNA repair processes and that its detection may not be totally specific 
for cell proliferation (Muskhelishvili et al., 2003). 
 
The reduction in the number of PCNA positive cells observed in the pancreases of 
krasG12D/ikk2∆Pdx mice does not correlate with the results obtained from BrdU staining 
(Figure 3.13).  
 
Overall and despite the divergence of the results obtained with BrdU and PCNA 
staining, it seems that on ikk2 genetic deletion, malignant cell proliferation is reduced 
in vivo, even though no effect was shown in the PanIN cell lines generated from the 
different mouse models and cultured in vitro (see section 3.3).  
3.4.4.4 Apoptosis  
Caspase activation is a hallmark of apoptosis (Mazumder et al., 2008), and caspase-3 
is activated when cleaved by an initiator caspase following an apoptotic signal.  
 
To determine whether ikk2 genetic deletion results in higher levels of apoptosis as 
opposed to a reduction in proliferation, pancreas sections from different mouse 
strains were stained for cleaved caspase-3 by immunohistochemistry (Figure 3.15).  
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Figure 3.15: Immunohistochemistry staining for cleaved caspase-3 in tissue 
sections 
Pancreas sections of 4-month old kras, krasG12D and krasG12D/ikk2∆Pdx mice stained with anti-cleaved 
caspase-3. Apoptotic cells are stained in dark brown (arrowhead) and no significant difference 
between the mouse strains is observed. Each picture is representative of three mice examined for each 
genotype. 
 
Low amounts of cleaved caspase-3 protein was identified in the pancreases of kras, 
krasG12D and krasG12D/ikk2∆Pdx mice, revealing no differences between the genotypes, 
but also showing a very low level of apoptosis in general (Figure 3.15). This is in 
agreement with other published data, showing that apoptotic events are quite rare in 
any grade of PanIN lesion (Hamacher et al., 2008; Luttges et al., 2003).  
3.4.5 Inflammatory infiltrate in the pancreas 
As described in section 1.2.7, pancreatic cancer is characterised by a very dense 
stroma. The dynamics of the infiltration of immune cells in the pancreases of mice 
spontaneously developing pancreatic cancer (krasG12D mouse model) has been studied 
by Clark et al. and correlates with the progression of the disease (Clark et al., 2007). 
 
The formation of PanIN lesions is affected following ikk2 genetic deletion in the 
pancreas, therefore the impact of this genetic modification on the infiltration of the 
immune cells was evaluated. In addition, many cytokines and chemokines are 
secreted by immune cells and their potential effect in this context was also explored.  
CHAPTER THREE CHARACTERISATION OF PANCREATIC MURINE MODELS 
168 
3.4.5.1 Characterisation of the inflammatory infiltrate 
A major source of inflammatory cytokines at tumour sites is the infiltrating immune 
cells. To measure and identify which immune cells infiltrate the pancreases of 
krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice, the relative mRNA expression of 
different markers in whole organs was measured by qRT-PCR and the percentage of 
CD11b+Gr1-F4/80+ and CD11b+Gr1+F4/80- cells was analysed by flow cytometry, 
both at 2 and 5 months of age (Figure 3.16).  
 
Immune cells can be identified by the expression of specific markers (Joyce and 
Pollard 2009). Table 3.2 summarises the markers used to identify different immune 
cell populations.  
 
 
 
 
 
 
Table 3.2: Surface markers used for the identification of immune cells 
Table describes cell markers and the immune cell types they can be found on. The presence or absence 
of these markers can be assessed by measuring mRNA levels with qRT-PCR or protein levels by flow 
cytometry.  
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Figure 3.16: Profile of the infiltrated inflammatory cells 
Relative mRNA expression of immune cells markers in whole pancreases of (A) 2- and (B) 5-month 
old mice. cd2r for T cells (T), cd8a for cytotoxic T cells (CTL), b220 for B cells (B), nk1.1 for natural 
killers (NK), cd208 for dendritic cells (DC), f4/80 for macrophages (Mf) and cxcr1 for neutrophils (Nf). 
Gene expression was quantified by qRT-PCR and normalised to mRNA levels of 18S. Data are shown 
as mean + SD. Percentage of CD11b+Gr1-F4/80+ and CD11b+Gr1+F4/80- cells in the pancreas was 
measured by flow cytometry. Each individual data point represents an individual mouse and mean 
values are depicted by horizontal lines, *p<0.05, **p<0.01, n=10. 
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Figure 3.16 A illustrates the immune cell types present in the pancreases of 2-month 
old mice. For the infiltrated immune cell populations analysed, no difference between 
the three mouse strains was observed. However, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx 
mice had reduced mRNA levels of f4/80 and cxcr1, indicating a lower number of 
macrophages and neutrophils. This was confirmed by flow cytometry analysis. At 5 
months of age, f4/80 and cxcr1 expression levels in pancreases from krasG12D/tnfa∆Pdx 
mice were elevated compared with 2-month old mice (Figure 3.16 B). Flow 
cytometry analysis also confirmed these results (Figure 3.16 A and B). 
3.4.5.2 Adoptive transfer 
To investigate the role of TNF-α secreted by the immune cells, tnfaf/f/Mx-cre mice 
were generated. In these mice, Cre expression is under the control of the promoter of 
the Mx gene. This gene is silent in healthy mice but its expression can be induced by 
IFN-α, IFN-β or synthetic dsRNA such as poly(I:C), mimicking a viral infection 
(Hug et al., 1988; Kuhn et al., 1995; Staeheli et al., 1986). This model, where tnfa 
deletion was temporally controlled by treating the mice with the immunostimulant 
poly(I:C), was used to obtain bone marrow cells lacking tnfa. tnfaf/f/Mx-cre mice 
treated with poly(I:C) are abbreviated as tnfa∆Mx mice. 
 
Bone marrow-derived cells from female tnfaf/f or tnfa∆Mx mice were transplanted into 
previously lethally irradiated 6-week old krasG12D or krasG12D/tnfa∆Pdx female mice, 
therefore generating two chimera strains. Peripheral leukocytes from these 
transplanted mice, but also from kras, krasG12D, kras/tnfa and krasG12D/tnfa∆Pdx mice 
(used as negative controls), were collected and cultured in vitro. Chimeras were 
generated in Barts Cancer Institute Biological Services Unit with the help of Dr 
Thorsten Hagemann.  
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The levels of TNF-α released in the culture medium upon ex vivo LPS stimulation 
were measured by ELISA (Figure 3.17). As expected, immune cells from tnfa∆Mx 
mice transplanted into krasG12D or krasG12D/tnfa∆Pdx mice were not able to secrete  
TNF-α. 
 
 
 
 
 
 
 
Figure 3.17: Ex vivo TNF-α  secretion from immune cells 
Lethally irradiated krasG12D and krasG12D/tnfa∆Pdx mice were transplanted with bone marrow cells from 
tnfaf/f or tnfa∆Mx mice. Immune cells were collected and the levels of secreted TNF-α were measured by 
ELISA upon ex vivo LPS stimulation (16 hours). Control cells were generated from kras, krasG12D, 
kras/tnfa and krasG12D/tnfa∆Pdx mice. Data are shown as mean + SD of triplicate experiments and are 
representative of three independent experiments, n=10.  
 
The proportion of the pancreas occupied by PanIN lesions and their histological 
stage were assessed in the generated chimeras (Figure 3.18). As opposed to tnfa 
deletion in the pancreas only, tnfa deletion in the pancreas as well as in the immune 
cells resulted in a significant decrease in the frequency of PanIN lesions at all time 
points. PanIN profiles were similar to those observed for krasG12D/ikk2∆Pdx mice in 
Figure 3.10. 
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Figure 3.18: Proportion of pancreas occupied by PanIN lesions in chimeras 
Quantification of the proportion of pancreas occupied by normal tissue (nl, no lesion) and PanIN 
lesions. Frequency and grade of the lesions were assessed at 2, 5 and 8 months of age. Data are shown 
as mean + SD, **p<0.01, n=10. 
 
These results confirm previous observations and conclusions that IKK2 signalling is 
important for the development and progression of PanIN lesions in the context of 
mutant kras. Moreover, the development of PanIN lesions observed from 5 months of 
age in krasG12D/tnfa∆Pdx mice is due to the production of TNF-α by the immune cells 
recruited in the tumour site. Therefore, production of TNF-α by transformed 
epithelial cells, as opposed to immune cell-derived TNF-α secretion, is a critical step 
in the initial steps and early stages of pancreatic cancer promotion.  
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3.5 Discussion and conclusion 
This chapter describes how new triple mutant mice were generated and what the 
phenotypic characteristics of these new mouse models were, in the context of 
pancreatic cancer. 
 
In the triple mutant mice, Cre expression is under the control of the pancreas specific 
promoter Pdx. Its expression is therefore restricted to Pdx expressing cells (pancreatic 
progenitors), allowing recombination events in a specific tissue. ikk2 or tnfa genes 
were flanked by two loxP sites and were subsequently knocked out upon CRE-
recombination, while a mutated kras allele had an upstream STOP cassette flanked 
by two loxP sites and its expression was activated upon CRE-recombination.  
 
In the endogenous krasG12D model, Cre expression, and therefore KRASG12D 
production, has previously been shown to create a genetic mosaicism in the organ, 
inducing PanIN formation in a focal manner (Hingorani et al., 2003). This 
observation implies that PanIN lesions might have a cell-specific origin. This 
mosaicism was useful in this model, allowing a better comparison with human 
disease, where kras mutations occur spontaneously and randomly in different cells. It 
should be noted that although Pdx is predominantly expressed in the pancreas, it can 
also be found in other cell types and organs. A recent publication suggests that Pdx is 
also expressed in the skin (Mazur et al., 2010b) and that recombination events can 
also occur in leukocytes (personal communication Dr David Tuveson, Cancer 
Research UK Cambridge Research Institute, Cambridge, UK). This suggests that 
KRASG12D production and ikk2 or tnfa genetic deletion can occur in the skin and/or in 
the leukocyte compartment of the different mouse models. However, in the three 
mouse models used (krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice) no 
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recombination events were identified in the skin or in the leukocytes (unpublished 
data from Dr Thorsten Hagemann’s group, Barts Cancer Institute, Queen Mary, 
University of London, London, UK).  
 
NF-κB is a classical target of TNF-α and is activated via IKK2. This signalling 
pathway is activated during inflammation but several studies have also demonstrated 
the requirement of IKK2 in tumour formation, such as in a model of colitis-associated 
cancer (Greten et al., 2004) and more recently in a spontaneous mouse model of 
melanoma (Yang et al., 2010). The TNF-α/IKK2/NF-κB pathway has been shown to 
be activated in pancreatic cancer cell lines (Basseres and Baldwin 2006; Lu et al., 
2011). However, the role of this pathway in pancreatic cancer progression has so far 
been unexplored.  
 
Epithelial cell lines derived from the pancreases of the different mouse models were 
generated to create a simplified and controlled in vitro system to initially identify 
malignant cell autonomous cytokine secretion and also to study the role of TNF-α 
signalling on pancreatic cancer cells. Constitutive secretion of TNF-α is an 
interesting finding, as this major inflammatory cytokine can have a tumour-
promoting role (Balkwill 2002) and has been shown to be secreted by many different 
cancer cells (Balkwill 2006; Szlosarek et al., 2006). Moreover, previous work 
performed in our laboratory describes how ovarian cancer cells also produce TNF-α 
in a constitutive manner (Kulbe et al., 2007; Kulbe et al., 2011), thus providing and 
maintaining a tumour-promoting environment. Production of IL-6 and IL-1β by the 
PanIN and PDAC cell lines tested was not surprising as their expression is known to 
be induced by NF-κB signalling (Naugler and Karin 2008) and also because 
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constitutive secretion of IL-1β by pancreatic cancer cells has already been observed 
(Arlt et al., 2002; Lu and Stark 2004).  
 
The combination of oncogenic mutations and chronic inflammation has already been 
proven to be necessary for the development of pancreatic cancer (Guerra et al., 2007; 
Guerra et al., 2011). In order to investigate whether a similar process is operating in 
the context of kras-driven pancreatic cancer in absence of an exogenous inflammatory 
insult, the hypothesis that autocrine TNF-α secreted by pre-malignant epithelial cells 
can drive pancreatic cancer progression was tested. Histological analysis of the 
pancreases of the mutant mice indicated that tnfa deletion had a positive effect on 
young mice only. This suggests that production of TNF-α by transformed epithelial 
cells facilitates the development and progression of PanIN lesions at the onset of the 
disease. However, by 5 months of age, krasG12D/tnfa∆Pdx mice had already developed 
PanIN lesions similar to the ones observed in krasG12D mice. Genetic deletion of ikk2 
had a greater effect on the development and progression of PanIN lesions. Indeed, 
the pancreases of 4-month old krasG12D mice presented high numbers of PanIN lesions 
at quite advanced stages, whereas the pancreases of age-matched krasG12D/ikk2∆Pdx 
mice presented only a few numbers of low-grade PanIN lesions (Figure 3.9). Genetic 
deletion of ikk2 delays pancreatic tumour formation but no significant differences in 
terms of histological grade and metastatic potential were observed (Figure 3.5 and 
Figure 3.6).  
 
The tumour microenvironment plays an important role in many cancers (reviewed in 
section 1.1.4) (Hezel et al., 2006; Mahadevan and Von Hoff 2007). Secretion of 
cytokines and chemokines such as CSF1 and CCL2 by the small amount of low-
grade PanIN lesions present in 2-month old krasG12D/tnfa∆Pdx mice was probably 
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sufficient to trigger immune cell recruitment (primarly macrophages and neutrophils) 
(Hagemann et al., 2008). Inflammatory cells, especially macrophages, secrete high 
levels of a range of inflammatory cytokines including IL-6, IL-1β and TNF-α (Qian 
and Pollard 2010). As the disease progressed, these cytokines probably compensated 
for the early protective effect of the tnfa genetic deletion in the pre-malignant 
epithelial cells. Analysis of the immune cell infiltrate analysis confirmed this process. 
Infiltration of macrophages and neutrophils was low in the pancreases of 
krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice at 2 months of age. However, the infiltrate 
appeared to be increased in 5-month old krasG12D/tnfa∆Pdx mice but not in 
krasG12D/ikk2∆Pdx mice (Figure 3.16). 
 
The role of infiltrating immune cells, in particular macrophages, in promoting tumour 
development, progression and metastasis is well documented (Hagemann et al., 2005; 
Mantovani et al., 2006) and has been described in section 1.1.4.3. The reduced 
infiltration of macrophages in krasG12D/tnfa∆Pdx mice and more profoundly in 
krasG12D/ikk2∆Pdx mice may represent an important factor for the delayed disease 
progression observed. Besides leukocytes, fibroblasts are also a main component of 
the tumour stroma and are also involved in the generation of a tumour-promoting 
microenvironment by releasing additional soluble factors that enhance tumour 
growth. Fibroblasts mostly secrete growth factors and angiogenic factors and nothing 
is known regarding a potential secretion of TNF-α (Angeli et al., 2009). Nevertheless, 
fibroblasts within the tumour stroma are likely to be responsive to the presence of 
cytokines such as TNF-α and further contribute to tumour progression. Investigation 
of the role of these cells in the context of tnfa or ikk2 genetic deletion is however 
beyond the scope of the work presented here.  
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In krasG12D/ikk2∆Pdx mice, not only could pancreatic transformed epithelial cells not 
secrete TNF-α, but they could not be activated by this cytokine, as the ikk2 gene 
coding for the IKK2 kinase from the TNF-α/IKK2/NF-κB signalling pathway is 
deleted. Genetic deletion of ikk2 impairs the recruitment of immune cells, 
contributing to a less inflammatory tumour microenvironment that may explain the 
absence of PanIN lesions. However, to identify whether the TNF-α/IKK2 signalling 
pathway is solely implicated in this phenomenon, additional experiments, described 
in the following chapters, were performed. Inactivation of this pathway has been 
shown to influence other signalling pathways which have a direct link with cytokine 
or chemokine production (Oeckinghaus et al., 2011).  
 
The impact of TNF-α derived from immune cells, as opposed to from malignant cells 
was further addressed with adoptive transfer experiments, where the immune system 
of krasG12D/tnfa∆Pdx mice was reconstituted with bone marrow cells from tnfa∆Mx mice. 
These mice had a significant reduction in the number and grade of PanIN lesions 
compared with the krasG12D/tnfa∆Pdx mice reconstituted with bone marrow cells with 
intact tnfa expression (Figure 3.18). This result highlights the importance of 
malignant cell-derived TNF-α during the early process of pancreatic carcinogenesis.  
 
The mouse Mx gene, also called influenza virus-resistance gene, is not activated in 
healthy mice, but can be expressed upon treatment with IFN-α, IFN-β or poly(I:C), 
an inducer of IFN production (Finkelman et al., 1991), mimicking the cell response 
when infected by a virus (Hug et al., 1988; Staeheli et al., 1986). Combining the 
properties of this Mx gene with the Cre-lox system was the first step in controlling 
gene inactivation over time, but Cre recombination occurs in every cell type in the 
whole animal. Mx-cre mice have been generated, where CRE recombinase is 
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expressed only when the mice are exposed to viral infections or stimulated with IFN 
or poly(I:C) (Kuhn et al., 1995). These mice were specifically used to delete tnfa in 
each circulating immune cell, regardless of its specific functions and markers. 
Although tnfa knockout animals do not have a lethal phenotype (Pasparakis et al., 
1996), tnfa expression may play a role during the development of the mouse immune 
system. The use of bone marrow-derived cells from tnfa∆Mx mice, rather than tnfaf/f 
mice, was then favoured, to avoid the introduction of more genetic disruption and to 
remain as close as possible to the wild type phenotype.  
 
Cre activation was induced by three injections of the immunostimulant poly(I:C). 
However, the impact poly(I:C) could have on PanIN initiation and PDAC 
progression was not assessed due to time constraints. Its effects were considered as 
negligible because poly(I:C) was injected at a low dose (5 µg/g body weight) and 
because the mice were sacrificed quite rapidly afterwards. Moreover, the main scope 
of the project was to investigate the role of autocrine TNF-α, and not of poly(I:C) on 
pancreatic cancer initiation and progression.  
 
To further characterise the krasG12D/ikk2∆Pdx mutant mice generated, the presence of 
various markers, to assess cell lineage, cell proliferation and apoptosis, was analysed 
by immunohistochemistry (Figure 3.11 to Figure 3.15). Immunohistochemistry data 
for SOX9 suggest an endocrine origin for the PanIN lesions observed in the 
pancreases of krasG12D mice as they stained positive. However, as explained in section 
1.2.8.3, the origin of PanIN lesions is still unknown and may require a combination of 
genetic and non-genetic events in one or several cell types. In addition, SOX9 
expression could reflect the overexpression of the protein in the transformed cells and 
thereby not be indicative of their origin.  
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The analysis of two cell proliferation markers (BrdU and PCNA) suggests that 
malignant cell proliferation was reduced in the pancreas of krasG12D/ikk2∆Pdx mice in 
vivo. To further confirm these results, other methods of measuring cell proliferation 
can be used, such as immunohistochemistry staining for Ki-67, which is frequently 
assessed for tumour diagnosis. Ki-67 is a human nuclear protein, so antibodies have 
been developed to recognise the mouse equivalent. In-situ hybridisation can also be 
performed to detect histone mRNA on tissue sections. It has been shown that histone 
protein synthesis occurs only during the S-phase of the cell cycle, therefore providing 
another specific technique to evaluate cell proliferation (Heintz et al., 1983). A study 
comparing these four methods, performed by Muskhelishvili et al., identified a 
suitable technique to substitute immunohistochemistry staining for BrdU in paraffin 
sections of rat tissues (Muskhelishvili et al., 2003). Immunohistochemistry staining 
for Ki-67 and in-situ hybridisation for histone mRNA were the two best substitutes. 
Neither of these techniques were performed due to time and cost constraints but they 
would have provided additional data to better estimate the effect of ikk2 genetic 
deletion on cell proliferation.  
 
Apoptotic events were not frequent in the pancreases of the krasG12D mice and genetic 
deletion of ikk2 did not appear to affect apoptotic levels. Caspase activation is a 
characteristic for apoptosis, but cell death could also have been evaluated by other 
methods, including measurement of DNA fragmentation (identification of a ladder 
pattern on an agarose gel), staining with Annexin V, which has a high affinity for 
phosphatidylserine residues normally hidden within the plasma membranes but 
which are revealed on the cell surface during apoptosis, or to measure the release of 
cytochrome C from the mitochondria to the cytosol, as mitochondrial physiology and 
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permeability is also affected during apoptosis (Goldstein et al., 2005; Martin et al., 
1995; Oberhammer et al., 1993).  
 
All immunohistochemical analyses were qualitative rather than quantitative. The 
presence or absence of the protein of interest was more relevant in order to identify 
the effects of ikk2 genetic deletion on the different cellular processes analysed. When 
the protein of interest was detectable, the differences between the phenotypes were 
not noticeable and thus quantification was not necessary. 
 
Overall, in this chapter, it was demonstrated that genetic inactivation of ikk2 blocks 
the progression of PanIN lesions in the context of kras-driven pancreatic 
carcinogenesis, and that the production of TNF-α by transformed pancreatic 
epithelial cells is a critical step in pancreatic cancer promotion and progression. To 
unravel the mechanisms causing the delayed PanIN development profile observed in 
the krasG12D/ikk2∆Pdx mice, additional analyses investigating the role of TNF-α/IKK2 
signalling in pancreatic carcinogenesis were required. Its cooperation with the Notch 
signalling pathway, known to be upregulated in pancreatic cancer, is addressed in the 
next chapter. 
  
 
 
 
 
 
 
 
4CHAPTER FOUR: THE NF-κB AND THE NOTCH SIGNALLING 
PATHWAYS 
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4.1 Introduction 
A critical role of NF-κB signalling in pancreatic cancer promotion was described in 
the previous chapter. Even though the NF-κB and the Notch signalling pathways are 
respectively the archetypical pathways of inflammation and development, they are 
both implicated in cancer (Bolos et al., 2007; Oeckinghaus et al., 2011; Roy et al., 
2007). As described in section 1.4.4, Notch can act as an oncogene, but also as a 
tumour suppressor in different types of cancer. Normally quiescent in the adult 
pancreas, the Notch signalling pathway is reactivated in pancreatic carcinogenesis 
and a specific role in pancreatic cancer tumour promotion and progression in the 
context of mutated kras has been identified (De La et al., 2008; Mazur et al., 2010a; 
Miyamoto et al., 2003; Plentz et al., 2009). It is thought to be required throughout 
PanIN and PDAC development, but the exact mechanisms behind the activation of 
this pathway at the early stages of the disease are not very clear. Activation of the 
EGF receptor in the exocrine pancreas induces neoplasia and the formation of PanIN 
lesions, and this is associated with an activation of Notch signalling (Miyamoto et al., 
2003). Activation of the Notch pathway is evaluated by measuring the expression 
levels of hes1, a Notch target gene (Hingorani et al., 2003; Miyamoto et al., 2003).  
 
The Notch pathway can also be activated following experimental induction of 
pancreatitis, in a cancer-independent context (Gomez et al., 2004; Jensen et al., 2005; 
Siveke et al., 2008). Upon caerulein-induced pancreatitis, the Notch signalling 
pathway normally expressed during pancreatic organogenesis is reactivated to allow 
pancreatic regeneration. This has been demonstrated by the measurement of 
increased levels of different components of the Notch pathway, including ligands 
(Dll1), receptors (Notch1), transcription factors (RBPjκ) and targets (HES1) 
(Gomez et al., 2004). Inhibition of the Notch pathway impairs pancreas regeneration 
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after caerulein-induced pancreatitis and this is associated with a cooperation between 
Notch and Wnt signalling, characterised by an inhibition of β-catenin-mediated gene 
activation (Siveke et al., 2008).  
 
The existence of a link between the Notch and the NF-κB signalling pathways is well 
documented in the scientific literature. For example, Notch1 can activate NF-κB in 
different cancers such as T cell leukaemia (Vilimas et al., 2007) or cervical cancer 
(Song et al., 2008). Moreover, Notch can regulate the transcription of different 
members of the NF-κB signalling pathway (Cheng et al., 2001) and protein-protein 
interactions between these two partners have been shown in cell specific contexts 
(Wang et al., 2001). However, the reciprocal crosstalk from NF-κB to Notch is less 
well described. Expression of the Jagged1 gene, encoding for one of the Notch 
receptor ligand, has been shown to be controlled by NF-κB subunits in B cells (Bash 
et al., 1999). In marginal zone B cells, NF-κB can also cooperate with the Notch 
signalling pathway, regulating the transcription of some of its target genes (Moran et 
al., 2007).  
 
Upon consideration of the role of Notch signalling in cancer and especially its 
activation in pancreatic carcinogenesis, the impact of NF-κB activation in the 
regulation of downstream Notch targets was investigated in this chapter. The main 
hypothesis tested in this chapter was whether TNF-α/IKK2 activation can synergise 
with Notch signalling during pancreatic tumour development and progression. In this 
chapter, the Notch pathway is shown to be activated in the different mouse models 
during pancreatic cancer progression and its direct cooperation with the             
TNF-α/IKK2 signalling pathway in the context of mutant kras in pancreatic 
carcinogenesis is demonstrated.  
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4.2 Activation of the Notch pathway in pancreatic cancer  
In the krasG12D mouse model developed by Hingorani et al., activation of the Notch 
signalling pathway has been shown by immunohistochemistry staining of the 
transcription factor HES1 (Hingorani et al., 2003). To evaluate the activation of the 
Notch signalling pathway in the mouse models, the Notch target gene expression 
levels of hes1 and hey1 were measured (Figure 4.1).  
 
Notch can also activate the transcription of other genes, such as vegf (Chadwick et al., 
2009) tenascin-c (Sivasankaran et al., 2009), the transcription factor c-myc (Mazur et 
al., 2010a; Palomero et al., 2006; Sharma et al., 2006; Weng et al., 2006) and the AP-1 
family transcription factor batf (Johansen et al., 2003; Strobl et al., 2000). To assess 
the expression of Notch target genes in PanIN bearing krasG12D, krasG12D/ikk2∆Pdx and 
krasG12D/tnfa∆Pdx mice, mRNA levels for batf, c-myc, hes1, hey1, tenascin-c and vegf were 
measured in whole pancreases by qRT-PCR (Figure 4.1). In agreement with 
previous studies (Hingorani et al., 2003), hes1 and hey1 genes were highly expressed in 
the pancreases of krasG12D PanIN bearing mice. However, their expression was 
decreased in the pancreases of age-matched PanIN bearing krasG12D/ikk2∆Pdx and 
krasG12D/tnfa∆Pdx mice, with a more profound reduction for krasG12D/ikk2∆Pdx mice 
(Figure 4.1). Among other Notch target genes, a significant reduction of vegf and 
tenascin-c expression was also observed in the pancreases of krasG12D/ikk2∆Pdx mice 
only, whereas expression levels for c-myc and batf were not altered (Figure 4.1). 
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Figure 4.1: Notch target genes mRNA levels in pancreases 
Relative mRNA expression of batf, c-myc, hes1, hey1, tenascin-c and vegf in the pancreases of PanIN 
bearing krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice at 3 months of age measured by qRT-PCR. 
Data are shown as mean + SD of duplicate experiments, *p<0.05, **p<0.01, n=6.  
 
Therefore, expression levels of most Notch target genes are affected following ikk2 
inactivation, whereas tnfa genetic deletion has a lower impact. These results indicate a 
concurrent activity between the classical NF-κB and Notch signalling pathways and 
that activation of the NF-κB signalling pathway can differentially regulate the 
expression of Notch target genes. 
 
HES1 protein levels were also assessed by immunofluorescent staining on pancreatic 
tissue sections from PanIN bearing krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx 
mice at 3 months of age (Figure 4.2). To enhance the visualisation of the tissue 
structure and the cell outline, sections were co-stained with the epithelial cell marker 
E-cadherin (red) and cell nuclei were counterstained with DAPI (blue).  
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PanIN lesions from 3-month old krasG12D mice were found to be positive for HES1, 
confirming data obtained by others (Hingorani et al., 2003). Similar levels of HES1 
were found in the pancreas sections of krasG12D/tnfa∆Pdx mice but a significant 
reduction was observed in age-matched krasG12D/ikk2∆Pdx animals (Figure 4.2).  
 
 
 
Figure 4.2: Immunofluorescent staining for HES1 in tissue sections 
Pancreas sections of 3-month old krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice stained for 
HES1, E-cadherin and counterstained with DAPI. Magnification X40. blue = DAPI, red = E-cadherin 
and green = HES1. HES1 is expressed in krasG12D and krasG12D/tnfa∆Pdx mice but absent in 
krasG12D/ikk2∆Pdx mice. Each picture is representative of three mice examined for each genotype. 
 
CHAPTER FOUR THE NF-κB AND THE NOTCH SIGNALLING PATHWAYS 
187 
Taken together, these data suggest that the Notch signalling pathway is activated in 
PanIN bearing krasG12D and krasG12D/tnfa∆Pdx mice at 3 months of age but not in age-
matched krasG12D/ikk2∆Pdx mice. The genetic deletion of ikk2 is therefore sufficient to 
block the activation of the Notch pathway in the context of kras-driven pancreatic 
carcinogenesis, suggesting a cooperation between the TNF-α/IKK2 and the Notch 
signalling pathways. The effects of pharmacological inhibition of NF-κB signalling on 
the activation of the Notch signalling pathway, rather than those of genetic 
inactivation, are described in Chapter 6 of this thesis.  
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4.3 Cooperation between the TNF-α /IKK2 and the Notch 
signalling pathways 
To further dissect and analyse the link between the TNF-α/IKK2 and the Notch 
signalling pathways, the response of the cell lines derived from PanIN bearing 
krasG12D, krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx mice to recombinant mouse TNF-α 
(rTNF-α) stimulation in vitro was examined.  
4.3.1 The expression of Notch target genes over time  
The expression of hes1 and hey1 was first measured over a full time-course of 12 hours 
upon stimulation with rTNF-α (Figure 4.3), to confirm the link previously observed 
between TNF-α and the Notch signalling pathway.  
 
 
 
 
 
 
Figure 4.3: Time course of hes1 and hey1 expression upon rTNF-α  stimulation 
mRNA expression of hes1 and hey1 in cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice and 
stimulated with 1 ng/ml of rTNF-α over 12 hours. Relative expression was calculated by setting 
expression of untreated krasG12D samples as 1. Data are shown as mean + SD of triplicate determinants 
and one representative experiment out of three is shown. 
 
Upregulation of gene expression occurred within 30 minutes and reached a plateau 
between 6 to 12 hours after treatment. Detection of a significant increase in hes1 
expression after 30 minutes of stimulation with rTNF-α suggests that another 
intermediate protein is not involved in this process. The effects of rTNF-α 
stimulation were analysed after 6 hours for the other experiments desribed in this 
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thesis, as beyond this time point, the gene expression of hes1 and hey1 reaches a 
plateau.  
4.3.2 Notch target genes are expressed upon stimulation with rTNF-α  
On completion of the initial experiment described above, the expression profile of 
hes1 and hey1, the main Notch target genes, as well as of other target genes (batf,        
c-myc, tenascin-c and vegf) was assesssed by qRT-PCR after rTNF-α stimulation in 
cells derived from PanIN bearing krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice 
(Figure 4.4). The expression of each Notch target gene tested was increased in cells 
derived from krasG12D and krasG12D/tnfa∆Pdx mice after rTNF-α stimulation. In contrast, 
rTNF-α failed to upregulate expression of these genes in cells derived from 
krasG12D/ikk2∆Pdx mice.  
 
HES1 and HEY1 protein levels were also analysed after rTNF-α stimulation in cell 
lines derived from PanIN bearing krasG12D mice (Figure 4.5). Immunofluorescent 
staining revealed basal Notch activity, demonstrated by nuclear location of the HES1 
and HEY1 transcription factors. After stimulation with rTNF-α, HES1 and HEY1 
protein expression was increased. In Figure 4.5, F-actin was stained in red in order to 
improve the visualisation of the cell outline.  
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Figure 4.4: mRNA levels of Notch target genes in cell lines 
Relative mRNA expression of batf, c-myc, hes1, hey1, tenascin-c and vegf in PanIN cell lines derived from 
the indicated mouse strains and stimulated with 1 ng/ml of rTNF-α for 6 hours. Relative expression 
was calculated by setting expression of untreated krasG12D samples as 1. Notch target genes are 
upregulated upon rTNF-α except in cells derived from krasG12D/ikk2∆Pdx mice. Data are shown as mean 
+ SD of triplicate determinants and one representative experiment out of three is shown.  
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Figure 4.5: Immunofluorescent staining for HES1 and HEY1 in PanIN derived 
cell lines 
Cell lines derived from PanIN bearing krasG12D mice were stained by immunofluorescence for HES1 or 
HEY1 as well as F-actin and counterstained with DAPI. Cells were left unstimulated or were 
stimulated with 1 ng/ml of rTNF-α for 24 hours. Magnification X40. blue = DAPI, red = F-actin, 
green = HES1 or HEY1. HES1 and HEY1 expression is enhanced after rTNF-α stimulation. One 
representative experiment out of three performed is shown. 
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4.3.3 rTNF-α  stimulation enhances the promoter activity of the hes1 gene  
To analyse TNF-α-induced hes1 upregulation, the promoter activity of the hes1 gene 
was studied in cell lines transiently transfected with a hes1 luciferase reporter 
construct, allowing luciferase expression under the control of the hes1 gene promoter 
(Takebayashi et al., 1994) (Figure 4.6).  
 
The stimulation of cells derived from PanIN bearing krasG12D/tnfa∆Pdx mice with 
rTNF-α resulted in enhanced luciferase activity and consequently enhanced 
transcriptional activity of the hes1 promoter (Figure 4.6). Similar activity was not 
observed after stimulating cells derived from PanIN bearing krasG12D/ikk2∆Pdx mice 
(Figure 4.6).  
 
 
 
 
 
 
Figure 4.6: Transcriptional activity of the hes1 promoter 
hes1 luciferase reporter assay in cells derived from PanIN bearing krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx 
mice stimulated with 1 ng/ml of rTNF-α for 6 hours. rTNF-α induced activation of the hes1 promoter 
in cells derived from krasG12D/tnfa∆Pdx mice only. Results were normalised to firefly luciferase activity 
relative to internal control and expressed as mean + SD from triplicate transfections, ***p<0.001. One 
representative experiment out of three performed is shown.  
 
In pre-malignant epithelial cells, IKK2 signalling is required for an increase in hes1 
promoter activity. The expression of other Notch target genes may be regulated in a 
similar manner.  
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4.3.4 rTNF-α  stimulation does not increase the expression of Notch receptors 
and ligands  
Notch receptors and ligands are both expressed in PanIN and PDAC cells. Several 
studies have shown that they can be upregulated following activation of different 
signalling pathways, in particular the NF-κB pathway (Bash et al., 1999; Fung et al., 
2007; Monsalve et al., 2006; Palaga et al., 2008). However, in the context of pancreatic 
carcinogenesis, it has not been described whether or not the Notch pathway can be 
regulated by NF-κB signalling.  
 
The next step was to assess whether the enhanced expression of Notch target genes 
observed upon stimulation with rTNF-α is due to an upregulation of Notch receptors 
and ligands. If more receptors and ligands are expressed, the signalling downstream 
of Notch would consequently be reinforced and this would explain the enhanced 
expression of Notch target genes.  
 
In order to demonstrate the potential requirement of de novo protein synthesis for the 
induction of gene expression, cells derived from PanIN bearing krasG12D/tnfa∆Pdx mice 
were treated with cycloheximide, an inhibitor of protein synthesis. hes1 and hey1 gene 
expression was measured by qRT-PCR with or without stimulation with rTNF-α 
(Figure 4.7). To validate the results from this experiment better, the expression levels 
of genes which are known to be induced by cyclohexamide, such as c-myc (Yokota et 
al., 1995), should have also been measured by qRT-PCR.  
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Figure 4.7: Effect of cycloheximide treatment on the expression of Notch target 
genes  
mRNA expression of hes1 and hey1 in cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice and 
stimulated with 1 ng/ml of rTNF-α for 6 hours in the presence or absence of cycloheximide (CHX) at 
15 µg/ml. The expression of Notch target genes is independent of de novo protein synthesis. Relative 
expression was calculated by setting expression of untreated krasG12D samples as 1. Data are shown as 
mean + SD of triplicate determinants and one representative experiment out of three is shown. 
 
As shown in Figure 4.7, stimulation with rTNF-α could induce and enhance hes1 and 
hey1 gene expression, independently of cycloheximide. De novo protein synthesis is 
therefore not essential for TNF-α-induced Notch target gene expression. The 
enhanced expression of Notch target genes observed upon stimulation with rTNF-α 
is independent of de novo protein synthesis and not due to an upregulation of the 
production of Notch receptors and ligands by the pancreatic epithelial cells. In 
addition, the levels of the Jagged1 and Dll4 Notch ligands were evaluated by flow 
cytometry and no differences were observed between the cell lines derived from 
PanIN bearing krasG12D, krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx mice (personal 
communication Dr Eleni Maniati, Barts Cancer Institute, Queen Mary, University of 
London, London, UK).  
 
The idea of a potential direct link between the TNF-α/IKK2 and the Notch pathways 
is supported by the fact that the upregulation of hes1 and hey1 is independent of new 
protein synthesis and because it occurs at an early time point after rTNF-α 
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stimulation (Figure 4.3). If an intermediate protein or signalling pathway was 
required, the upregulation of the Notch target genes upon rTNF-α stimulation would 
have been detected at later time points. 
4.3.5 Canonical Notch signalling is required  
The Notch pathway is initiated by proteolytic cleavage of NICD following receptor-
ligand interactions. This cleavage is mediated by the γ-secretase activity of a 
multiprotein complex (Gordon et al., 2008). Canonical Notch signal transduction 
occurs via the NICD/RBPjκ complex (Kopan and Ilagan 2009; Lai 2002). The 
requirement for canonical Notch signalling following TNF-α-induced upregulation of 
Notch target genes was investigated next. The effect of the synthetic γ-secretase 
inhibitor (GSI) L685458 (Shearman et al., 2000) on the upregulation of expression of 
Notch target genes upon rTNF-α stimulation was assessed (Figure 4.8).  
 
After blocking the Notch signalling pathway with L685458 at 5 µM for 6 hours, hes1 
and hey1 expression were attenuated in rTNF-α-stimulated cells derived from PanIN 
bearing krasG12D/tnfa∆Pdx mice. However, the transcription levels of il1b, cox2 and 
mmp13, NF-κB target genes (Hiscott et al., 1993; Liacini et al., 2002; Mauviel 1993; 
Yamamoto et al., 1995), remained unaffected (Figure 4.8). The upregulation of Notch 
target genes after stimulation with rTNF-α is therefore dependent on the activation 
of the Notch signalling pathway. This experiment demonstrates that an active Notch 
signalling pathway is required for hes1 and hey1 expression upon rTNF-α stimulation. 
As expected, gene expression levels of NF-κB target genes remain unaffected when 
inhibiting the Notch signalling pathway, especially upon rTNF-α stimulation which 
is the main activator of this signalling pathway.  
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Figure 4.8: Effect of pharmacological inhibition of Notch signalling on the 
expression of TNF-α-induced Notch and NF-κB target genes  
Relative mRNA expression of hes1, hey1, il1b, cox2 and mmp13 in cell lines derived from PanIN bearing 
krasG12D/tnfa∆Pdx mice and stimulated with 1 ng/ml of rTNF-α for 6 hours in the presence or absence of 
the γ-secretase inhibitor L685458 (5 µM). Relative expression was calculated by setting expression of 
untreated krasG12D samples as 1. Data are shown as mean + SD of triplicate determinants and one 
representative experiment out of three is shown. 
 
The effects of maximal engagement of the Notch receptors on the expression levels of 
hes1 and hey1 were also explored. Cells derived from PanIN bearing krasG12D mice 
were incubated with classical Notch ligands, either by treating the cultures with 
recombinant Jagged-2 or by performing some co-culture experiments with the OP9-
DL1 cells, a bone-marrow-derived stromal cell line that ectopically expresses the 
Dll1 Notch ligand (Schmitt and Zuniga-Pflucker 2002). After 6 hours, hes1 and hey1 
mRNA levels were evaluated by qRT-PCR (Figure 4.9).  
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Figure 4.9: Expression of Notch target genes when maximally engaging Notch 
receptors  
Relative mRNA expression of hes1 and hey1 in cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx 
mice and either treated with 1 ng/ml of rTNF-α, or 20 µg/ml of recombinant Jagged-2, or co-cultured 
with OP9-DL1 cells, all for 6 hours. Relative expression was calculated by setting expression of 
untreated krasG12D samples as 1 (control). Data are shown as mean + SD of triplicate determinants and 
one representative experiment out of three is shown.  
 
As shown in Figure 4.9, rTNF-α was more efficient at inducing the expression of hes1 
and hey1 than ligand-mediated Notch activation of the pathway. As mentioned 
earlier, the cell lines tested already express the Notch ligands. The presence of high 
concentrations of Notch ligands, to saturate the Notch signalling pathway, slightly 
increases the expression of the Notch target genes hes1 and hey1. However, rTNF-α 
stimulation induces a higher expression of these genes, suggesting that their 
expression is not only dependent on the Notch signalling pathway and that activation 
of the TNF-α/IKK2 signalling pathway also plays an important additional role.  
 
The availability of the additional Notch ligands in vitro can be questioned, as 
stimulation with recombinant Jagged2 provides a soluble form of the ligand, and 
ligands and receptors normally involved in the activation of the Notch pathway are 
present on the cell surface. However, soluble forms of the ligands have also been 
shown to activate the pathway (D'Souza et al., 2008). Moreover, even though OP9-
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DL1 cells are not adherent cells per se, such immune cells tend to “stick” to the 
bottom of the plate when in culture and cell-cell contact is also probably facilitated by 
cellular projections, which have been shown to be enriched in Notch ligands 
(D'Souza et al., 2008). 
 
Finally, the requirement of canonical Notch signalling for TNF-α-mediated 
upregulation of hes1 and hey1 was further examined using siRNAs to knockdown the 
expression of rbpj. As mentioned earlier, RBPjκ is the nuclear transcription factor 
essential for canonical Notch target gene expression (Kopan and Ilagan 2009; Lai 
2002) (Figure 4.10). siRNA technology was used to silence specific target genes. 
Three different commercially validated rbpj siRNAs and a non-targeting control were 
used to transfect cells derived from PanIN bearing krasG12D/tnfa∆Pdx mice. The ability 
of each individual construct to inhibit rbpj expression was first assessed by checking 
mRNA levels by qRT-PCR (Figure 4.10 A) and protein levels by Western blot 
(Figure 4.10 B). Transfection with a single siRNA construct was sufficient to induce 
significant knockdown of the rbpj target gene.  
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Figure 4.10: siRNA knockdown of rbpj in cell lines derived from PanIN bearing 
krasG12D/tnfa∆Pdx mice 
Cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice were transfected with rbpj specific 
siRNAs. rbpj knockdown was verified by (A) qRT-PCR and (B) Western blot. (C and D) 48 hours 
after transfection, cells were stimulated with 1 ng/ml of rTNF-α for 6 hours and expression of (C) hey1 
and (D) hes1 was quantified by qRT-PCR. Relative expression was calculated by setting expression of 
krasG12D/tnfa∆Pdx cells transfected with non-targeting siRNAs as 1. Expression of Notch target genes is 
RBPjκ-dependent. All data are shown as mean + SD of triplicate experiments and are representative 
of three independent experiments. 
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Cells derived from PanIN bearing krasG12D/tnfa∆Pdx mice were transfected with 
individual siRNA constructs and the expression levels of Notch target genes were 
assessed by qRT-PCR (Figure 4.10 C and D). The specific knockdown of rbpj 
resulted in a 4-fold decrease of hes1 and hey1 expression levels upon rTNF-α 
stimulation. In light of these data, it seems that the requirement of the NICD/RBPjκ 
complex is essential to induce hes1 and hey1 expression upon rTNF-α stimulation. 
The requirement of rbpj confirms the importance of canonical Notch signalling for the 
rTNF-α-induced Notch target gene expression, shown in Figure 4.8. However, 
downregulation of Notch target gene expression upon rbpj knockdown was expected, 
considering its essential role in canonical Notch signalling.  
 
Taken together, the data presented in Figure 4.8, Figure 4.9 and Figure 4.10 
demonstrate that the upregulation of the Notch target genes (hes1 and hey1) after 
stimulation with rTNF-α is, in the context of kras-mutant pancreatic carcinogenesis, 
dependent on canonical Notch signalling. 
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4.3.6 Activation of the Notch pathway is IKK2-dependent 
To further investigate the role of induced TNF-α/IKK2 signalling in the activation of 
the Notch signalling pathway, siRNAs were used to knockdown the expression of 
different components of the IKK complex: IKK1, IKK2 and NEMO. Even though 
these three kinases share some homology, their role and function have shown to be 
different and context-specific (Hacker and Karin 2006).  
 
The role of IKK2 was first explored by knocking down its expression (Figure 4.11). 
Three different commercially validated ikk2 siRNAs and a non-targeting control were 
used to transfect cells derived from PanIN bearing krasG12D/tnfa∆Pdx mice. After 
checking their specificity and efficiency at inhibiting ikk2 gene expression by       
qRT-PCR (Figure 4.11 A) and Western blot (Figure 4.11 B), gene expression levels 
for hes1 and hey1 in response to rTNF-α stimulation were measured by qRT-PCR 
(Figure 4.11 C and D). Specific siRNA inhibition of ikk2 resulted in a 
downregulation of hes1 and hey1 expression following rTNF-α treatment. This is 
consistent with previous observations that cells derived from PanIN bearing 
krasG12D/ikk2∆Pdx mice lose the capacity to upregulate hes1 and hey1 upon rTNF-α 
stimulation (Figure 4.4). 
 
The role of IKK1 was then investigated by knocking down its expression (Figure 
4.12). Once again, the ability of each individual siRNA construct to inhibit ikk1 
expression was verified by qRT-PCR (Figure 4.12 A). Gene expression levels of hes1 
in response to rTNF-α stimulation were measured (Figure 4.12 B) and were similar 
whether ikk1 was expressed or not.  
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Figure 4.11: siRNA knockdown of ikk2 in cell lines derived from PanIN bearing 
krasG12D/tnfa∆Pdx mice 
Cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice were transfected with ikk2 specific 
siRNAs. ikk2 knockdown was verified by (A) qRT-PCR and (B) Western blot. (C and D) 48 hours 
after transfection, cells were stimulated with 1 ng/ml of rTNF-α for 6 hours and expression of (C) hey1 
and (D) hes1 was quantified by qRT-PCR. Relative expression was calculated by setting expression of 
krasG12D/tnfa∆Pdx cells transfected with non-targeting siRNAs as 1. Expression of the Notch target 
genes is IKK2-dependent. All data are shown as mean + SD of triplicate determinants and are 
representative of three independent experiments. 
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Figure 4.12: siRNA knockdown of ikk1 in cell lines derived from PanIN bearing 
krasG12D/tnfa∆Pdx mice 
Cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice were transfected with ikk1 specific 
siRNA. (A) ikk1 knockdown was verified by qRT-PCR. (B) 48 hours after transfection, cells were 
stimulated with 1 ng/ml of rTNF-α for 6 hours and expression of hes1 was quantified by qRT-PCR. 
Relative expression was calculated by setting expression of krasG12D/tnfa∆Pdx cells transfected with non-
targeting siRNAs as 1. Expression of the Notch target genes is IKK1-independent. All data are shown 
as mean + SD of triplicate determinants and are representative of three independent experiments.  
 
Finally, the role of NEMO was studied (Figure 4.13). The three siRNA constructs 
used were able to silence the gene expression of nemo (Figure 4.13 A). Similarly to 
ikk2 knockdown, nemo specific siRNA inhibition results in a downregulation of hes1 
and hey1 expression following rTNF-α treatment (Figure 4.13 B).  
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Figure 4.13: siRNA knockdown of nemo in cell lines derived from PanIN bearing 
krasG12D/tnfa∆Pdx mice 
Cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice were transfected with nemo specific 
siRNA. (A) nemo knockdown was verified by qRT-PCR. (B) 48 hours after transfection, cells were 
stimulated with 1 ng/ml of rTNF-α for 6 hours and expression of hes1 was quantified by qRT-PCR. 
Relative expression was calculated by setting expression of krasG12D/tnfa∆Pdx cells transfected with non-
targeting siRNAs as 1. Expression of the Notch target genes is NEMO-dependent. All data are shown 
as mean + SD of triplicate determinants and are representative of three independent experiments.   
 
To summarise this section, the upregulated expression of the Notch target genes (hes1 
and hey1) upon rTNF-α stimulation was demonstrated to be independent of IKK1 
but dependent on the IKK2 and NEMO kinases.  
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4.4 Analysis of the crosstalk between NF-κB and Notch  
In section 4.3, TNF-α-induced IKK2-dependent activation of the Notch pathway in 
kras-derived pancreatic epithelial cells was demonstrated. These data suggest a direct 
interaction downstream of the TNF-α/IKK2 and the Notch signalling pathways. This 
section will focus on further deciphering the mechanisms involved in this 
cooperation.  
4.4.1 rTNF-α  stimulation induces NICD cleavage 
As described in Chapter 1, following receptor-ligand interaction, Notch signalling is 
initiated by proteolytic cleavage of the intracellular domain of Notch (NICD). 
Cleaved NICD translocates to the nucleus and along with the RBPjκ transcription 
factor forms a short-lived nuclear transcription complex, which mediates the 
expression of a number of genes including hes1 and hey1 (Gordon et al., 2008).  
 
Notch target genes are expressed in the krasG12D mouse model of pancreatic 
carcinogenesis (mRNA and protein levels - Figure 4.1 and Figure 4.2) and rTNF-α 
stimulation can increase their levels of expression in vitro (Figure 4.4 and Figure 4.5). 
Following these observations, the role of the activation of the NF-κB signalling 
pathway by stimulation with rTNF-α in the cleavage and release of NICD was 
investigated. NICD protein levels were measured by Western blot in cells derived 
from PanIN bearing krasG12D mice in the absence or presence of rTNF-α (Figure 
4.14).  
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Figure 4.14: NICD and HES1 protein levels by Western blot in PanIN derived 
cells 
Protein lysates from cell lines derived from PanIN bearing krasG12D mice were analysed for NICD and 
HES1 expression with or without stimulation with rTNF-α at 1 ng/ml for the time indicated. rTNF-α 
stimulation increases HES1 protein levels from 2 hours of treatment but also the levels of NICD from 
1 to 8 hours of treatment. β-actin was used as a loading control. One representative experiment out of 
two performed is shown.  
 
Expression of Notch receptors and ligands in PanIN lesions and PDAC has 
previously been demonstrated (Mazur et al., 2010a; Miyamoto et al., 2003). Basal 
Notch activity, as evidenced by the expression of NICD and HES1 in cells derived 
from PanIN bearing krasG12D mice, was detected (Figure 4.14). This is consistent with 
previous observations of Notch activity by others (Hingorani et al., 2003) and in 
sections 4.2 and 4.3.2. Upon rTNF-α stimulation, a rapid increase in NICD and 
HES1 protein levels was observed (Figure 4.14).  
 
Taken together, these in vitro data confirm previous in vivo observations that the 
Notch signalling pathway is activated in kras-mutant pancreatic adenocarcinoma and 
that rTNF-α can enhance Notch target gene expression. Moreover, the activation of 
the TNF-α/IKK2 signalling pathway contributes to an increase of NICD cleavage 
and release. These data suggest a cooperation between the TNF-α/IKK2 and the 
canonical Notch signalling pathways. 
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In section 3.4.5, it was demonstrated that in vivo, the production of TNF-α by the 
transformed pancreatic epithelial cells, rather than by the immune cells recruited on 
site, is critical for the early stages of PanIN promotion and progression, suggesting an 
autocrine role for this cytokine. However, in this experiment, transformed pancreatic 
epithelial cells derived from PanIN bearing krasG12D mice were stimulated in vitro with 
rTNF-α, mimiking a paracrine source of the cytokine. This is because, as shown in 
Figure 4.14, autocrine TNF-α is not sufficient to induce significant HES1 protein 
expression. Treatment with rTNF-α was used to enhance the response, to identify 
the mechanisms involved in the upregulation of the expression of Notch target genes.  
4.4.2 Interaction between NICD and IKK2 in vitro 
Post-translational modifications of NICD have been demonstrated to play a critical 
role in its stabilisation and therefore in the control of the Notch pathway (Guarani et 
al., 2011). To test whether IKK2 can directly phosphorylate NICD and contribute to 
Notch pathway upregulation by enhancing the stability or the proteolytic release of 
NICD, co-immunoprecipitation experiments were performed to identify a possible 
direct interaction between IKK2 and NICD.  
 
pCR-FLAG-IKK2, pCR-FLAG-IKK2-KM and pDEST40-NICD-V5 plasmids were 
transfected into cells derived from PDAC bearing krasG12D mice, allowing the 
overexpression of the protein fusion FLAG/IKK2, FLAG/IKK2-KM and NICD/V5 
respectively. FLAG and V5 are peptide sequences used as a tag to facilitate the 
protein immunoprecipitation with high affinity antibodies. IKK2-KM is an inactive 
mutant protein in which a lysine residue in the ATP binding site of the kinase domain 
of the protein has been substituted by an alanine (K44A), therefore preventing ATP 
binding and phosphorylation of the IKK2 substrates (Nakano et al., 1998).  
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Protein immunoprecipitations were performed with anti-FLAG or anti-V5 antibodies 
and presence of NICD or IKK2 was tested by Western blot to identify whether these 
two proteins interact. As a control to assess both the antibody specificity and success 
of precipitating protein complexes, the presence of FLAG or IKK2 and V5 or NICD 
was verified by Western blot after immunoprecipitation with anti-FLAG or anti-V5 
antibodies respectively (Figure 4.15 A and B). As a positive control, protein 
complexes immunoprecipitated with anti-FLAG also contained IKK2 and similarly, 
the protein complexes immunoprecipitated with anti-V5 also included NICD.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Protein levels by Western blot after co-immunoprecipitations in 
transfected cells 
(A) Proteins from cells derived from PanIN bearing krasG12D mice transfected with the pCR-FLAG-
IKK2, pCR-FLAG-IKK2-KM and pDEST40-NICD-V5 plasmids were immunoprecipitated with an 
anti-FLAG or an anti-V5 antibody and immunoblotted with anti-FLAG, anti-V5, anti-IKK2, anti-
NICD, anti-p-Tyr and anti-p-Thr antibodies. (B) Proteins from cells derived from PanIN bearing 
krasG12D mice transfected with the pCR-FLAG-IKK2 or pCR-FLAG-IKK2-KM plasmids were 
immunoprecipitated with an anti-FLAG antibody and immunoblotted with anti-FLAG, anti-IKK2 and 
anti-NICD antibodies. One representative experiment out of two performed is shown.  
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Immunoblotting with an anti-NICD antibody seemed to reveal the presence of 
NICD in the immunocomplexes purified from cells transfected with the pCR-FLAG-
IKK2 plasmid only (Figure 4.15 B). This is, to our knowledge, the first report 
suggesting a direct interaction between NICD and IKK2. It should be noted that the 
signal for NICD was weak and not always visible in the two experiments performed 
(one experiment is represented in Figure 4.15 A). This may be due to poor binding of 
the anti-NICD antibody. There is, however, a limited number of other commercially 
available clones that could have been tested.  
 
To support and to try to confirm this result, the presence of phosphorylated residues 
was assessed by Western blot (Figure 4.15 A). The main target residues for 
phosphorylation are serine (Ser), threonine (Thr) and tyrosine (Tyr) (Bannister and 
Kouzarides 2011). However, no clear signal was obtained using an anti-phospho-
serine antibody despite the number of different antibody clones tested (data not 
shown). Immunoblotting for phospho-threonin (p-Thr) residues did not show a 
specific pattern, however phospho-tyrosine (p-Tyr) residues were present in all 
precipitated samples, with an increased level in the immunocomplexes purified from 
cells transfected with the pDEST40-NICD-V5 plasmid (Figure 4.15 A). This may be 
due to the increased amount of NICD protein following transfection with the 
plasmid. These phosphorylated residues are likely to be part of NICD and not IKK2. 
It is well known now that the activation of the IKK2 kinase is triggered by the 
phosphorylation of two serine residues (Ser177/Ser181) (Delhase et al., 1999) and 
not by the phosphoryation of tyrosine or threonine residues.  
 
The lower levels observed of p-Tyr and p-Thr residues in the immunocomplexes 
purified from cells transfected with the pCR-FLAG-IKK2-KM plasmid are likely to 
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be due to the presence of the inactive form of the IKK2 kinase in the complex, 
thereby suggesting that these phosphorylation events are IKK2-mediated.  
 
To confirm the co-immunoprecipitation of NICD and IKK2, but also to clarify 
whether phosphorylation events also occur, cells derived from PDAC bearing 
krasG12D mice were transfected with the pCR-FLAG-IKK2, pCR-FLAG-IKK2-KM 
or pDEST40-NICD-V5 plasmids and proteins were immunoprecipitated with an 
anti-FLAG or an anti-V5 antibody. Immunocomplexes purified from these cells were 
analysed by mass spectrometry to identify the different protein partners                     
co-immunoprecipitated. The purity of the samples after immunoprecipitation was 
first assessed by performing a Coomassie brilliant blue stain on the resolved proteins 
(Figure 4.16).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Coomassie brilliant blue staining of purified immunocomplexes  
Cells derived from PDAC bearing krasG12D mice were transfected with the pCR-FLAG-IKK2, pCR-
FLAG-IKK2-KM or pDEST40-NICD-V5 plasmids and immunoprecipitated with an anti-FLAG or 
an anti-V5 antibody. Immunocomplexes were resolved on an SDS-NuPAGE® pre-cast 4-12 % w/v 
gradient bis tris gel by electrophoresis and proteins were stained with Coomassie brilliant blue.  
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The purity of the samples was satisfactory and immunocomplexes were once again 
resolved by electrophoresis but over a shorter distance. Lanes were cut out into 1 to 2 
mm3 cubes and sent for mass spectrometry analysis, which was performed by Dr 
Benjamin Thomas and Dr Fernando Martinez-Estrada, Central Proteomics Facility, 
Oxford University, Oxford, UK. 
 
However, after mass spectrometry analysis, the proteins of interest could not be 
found (personal communication Dr Fernando Martinez-Estrada, Central Proteomics 
Facility, Oxford University, Oxford, UK). Even after immunoprecipitation using a 
very specific antibody against the FLAG or V5 tags, the proteins fused with the tag 
(IKK2 and NICD respectively) were not identified. The samples contained high 
levels of keratin, which could originate from the cell lines themselves, as they were 
epithelial cell lines, but also from contamination during sample preparation. 
However, due to time constraints, this experiment could not be repeated. Protein 
complexes were adequately immunoprecipitated as shown on Figure 4.15 but sample 
preparation and maybe the amount of starting material will need to be optimised to 
enhance the chances of detection of the proteins of interest by mass spectrometry.  
4.4.3 Phosphorylation of histone H3 upon rTNF-α  stimulation 
As mentioned in section 4.3.6, the IKK2 kinase plays a critical role in the activation 
of the Notch signalling pathway in pancreatic cancer. To my knowledge, the classical 
Notch target gene hes1 has so far not been shown to be regulated by an activated  
NF-κB signalling pathway (Bray 2006). The results from the co-immunoprecipitation 
experiments described in section 4.4.2 suggest a direct interaction between IKK2 and 
NICD, but subsequent experiments failed to confirm this interaction, possibly due to 
assay limitations. However, this remains a topic for further investigation in order to 
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explain the upregulated expression of the Notch target genes upon rTNF-α 
stimulation.  
 
Another potential route downstream of IKK2 that could lead to hes1 enhanced 
transcription could be IKK2-mediated histone modifiations, which would favour gene 
transcription. Activation of gene expression following histone modification, mainly 
through phosphorylation, acetylation or methylation, is a very well-described 
phenomenon (Bannister and Kouzarides 2011; Karlic et al., 2010; Kouzarides 2007). 
Moreover, it has already been shown that IKK1 can phosphorylate histone H3, 
allowing the expression of NF-κB-regulated target genes (Anest et al., 2003; 
Yamamoto et al., 2003). The phosphorylation of histone H3 at serine 10 has been 
shown to control cell cycle progression and to be involved in gene transcription 
(Nowak and Corces 2004). To investigate whether IKK2 can phosphorylate histone 
H3 at serine 10, chromatin immunoprecipitation (ChIP) assays were carried out 
using an antibody directed against histone H3 (Figure 4.17) or against phospho-
histone H3 (Ser10) (Figure 4.18). Immunoprecipitated DNA was analysed by qRT-
PCR using hes1 promoter-specific primers.  
 
1 % of the sonicated chromatin was set aside as the input (representing the amount of 
chromatin used in the ChIP) and was not processed through the 
immunoprecipitation step. qRT-PCR with hes1 promoter-specific primers was 
performed on the input and on the samples immunoprecipitated with histone H3 or 
phospho-histone H3 antibodies. The Ct values obtained for the 1 % input were 
adjusted to 100 %. This adjusted input is called ∆Ct. The values for the percent 
recovery of the input were calculated using the formula 100 x 2-∆Ct - Ct, where Ct 
represents the Ct value obtained for each sample.  
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Figure 4.17: Chromatin immunoprecipitation of histone H3 to the hes1 promoter 
Cells derived from PanIN bearing krasG12D, krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx mice were stimulated 
with rTNF-α (1 ng/ml) for 6 hours. ChIP assays were performed with anti-histone H3 antibody or 
anti-rabbit IgG antibody as a control. Immunoprecipitated DNA was analysed by qRT-PCR using 
hes1 promoter-specific primers and compared with unstimulated cells. Results are shown as mean + SD 
of triplicate determinants and are representative of three independent experiments. 
 
A high percentage of the recovery of the input indicates that the samples were 
enriched with the hes1 target gene. Histone H3 occupies the hes1 promoter locus in 
cells derived from PanIN bearing krasG12D, krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice 
in presence or absence of rTNF-α stimulation (Figure 4.17).  
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Figure 4.18: Chromatin immunoprecipitation of phospho-histone H3 (Ser10) to 
the hes1 promoter 
Cells derived from PanIN bearing krasG12D, krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx mice were stimulated 
with rTNF-α (1 ng/ml) for 6 hours. ChIP assays were performed with anti-phospho-histone H3 
(Ser10) antibody or anti-rabbit IgG antibody as a control. Immunoprecipitated DNA was analysed by 
qRT-PCR using hes1 promoter-specific primers and compared with unstimulated cells. Results are 
shown as mean + SD of triplicate determinants and are representative of three independent 
experiments. 
 
However, phosphorylated histone H3 on Ser10 was detected at the hes1 promoter 
locus only when cells derived from PanIN bearing krasG12D and krasG12D/tnfaΔPdx mice 
were stimulated with rTNF-α. This phosphorylation was abolished in cells derived 
from PanIN bearing krasG12D/ikk2ΔPdx mice (Figure 4.18).  
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Taken together, these results show that activation of the TNF-α/IKK2 signalling 
pathway via rTNF-α stimulation can induce the phosphorylation of the histone H3 
already present at the hes1 promoter locus, which possibly enhances the trancriptional 
activity of a classical Notch target gene. IKK2 appears to be essential for the 
phosphorylation of the Ser10 residue on histone H3 at the hes1 promoter locus.  
 
Data described in this section show that IKK2 is involved in the phosphorylation of 
histone H3 on Ser10, which leads to the upregulation of the transcription of Notch 
target genes upon rTNF-α stimulation. However, little is known about a nuclear role 
for IKK2 and how this kinase would translocate to the nucleus. This would provide 
important information and would contribute to explain how the nuclear histone 
protein H3 is phosphorylated. Otherwise, intermediate protein partners will need to 
be characterised in order to identify another possible kinase downstream of IKK2 
with a known nuclear role.  
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4.5 Discussion and conclusion 
In this chapter, the cooperation between the TNF-α/IKK2 and the Notch signalling 
pathways in the pancreatic cancer models used was examined.  
 
The pancreases of PanIN bearing krasG12D mice presented an active Notch signalling 
pathway (demonstrated by Notch target gene and protein expression levels in Figure 
4.1 and Figure 4.2) whereas for PanIN bearing krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx 
mice, this activation was respectively reduced or abolished. Immunofluorescent data 
for HES1 and HEY1 after the stimulation of the cells derived from PanIN bearing 
krasG12D mice with rTNF-α in vitro (Figure 4.5) showed a higher ratio for nuclear 
location compared with cytoplasmic location, attesting the activation of the Notch 
pathway. Similar results were also obtained at the gene expression level after 
stimulating the corresponding cell lines with rTNF-α (Figure 4.4). The 
downregulation of the HES1 protein in krasG12D/ikk2∆Pdx mice suggests a cooperation 
between the NF-κB and the Notch signalling pathways. It should be noted that in 
different cell types and settings, the expression of hes1 has also been demonstrated to 
be regulated by Notch-independent mechanisms involving the RAS/RAF/MAPK 
and/or the JNK signalling pathways (Curry et al., 2006; Katoh 2007; Stockhausen et 
al., 2005). The data and findings described in this chapter do not exclude that, in 
pancreatic epithelial cells, hes1 expression may be regulated by other signalling 
pathways.   
 
Activation of TNF-α/IKK2 signalling leads to an upregulated transcriptional 
expression of the classical Notch target genes hes1 and hey1 (Figure 4.3). siRNA 
experiments showed that this upregulation requires canonical Notch signalling and is 
IKK2-dependent (Figure 4.8 to Figure 4.13). The knockdown of NEMO also affects 
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the upregulation of hes1 but its role was not further investigated. More importantly, 
further analysis of the mechanisms involved reveal that TNF-α stimulation enhances 
NICD release (Figure 4.14) and additionally that IKK2 induces the phosphorylation 
of histone H3 at the hes1 promoter locus, therefore activating the transcription of this 
Notch target gene (Figure 4.17 and Figure 4.18).  
 
Chromatin remodelling is important in regulating the initiation of the transcription 
process. Histones are assembled into nucleosomes around which the DNA is tightly 
packed and ordered, forming the chromatin. Chromatin structure can be more or less 
condensed, depending on the phase of the cell cycle (Li and Reinberg 2011). For 
example, to allow the transcription machinery to access the DNA strand, the 
chromatin needs to be opened. These changes in chromatin organisation are mainly 
regulated by histone modifications (Bannister and Kouzarides 2011).  
 
Histone proteins can often be acetylated, phosphorylated or methylated. Several 
histone modifications, particularly on histone H3, are involved in the activation of 
gene transcription (Bannister and Kouzarides 2011; Berger 2007; Kouzarides 2007; 
Li et al., 2007). For example, acetylation of specific residues on histone H3 (Lys56) 
contributes to chromatin disassembly (Williams et al., 2008). The hyperacetylated 
status of histone H3 in general also allows transcriptional activation through 
decondensation of the chromatin (Schubeler et al., 2000). Methylation of arginine 
(Arg) and lysine (Lys) residues is also associated with gene activation; Arg17 on 
histone H3 (Bauer et al., 2002) or Lys9 on histone H3 (Vakoc et al., 2005). 
Phosphorylation of histone H3 on Ser10 also correlates with the activation of gene 
transcription in Drosophila melanogaster (Nowak and Corces 2000) and mouse 
fibroblasts (Strelkov and Davie 2002). Phosphorylated histone H3 on Ser10 is also a 
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marker for mitosis (Goto et al., 1999; Hendzel et al., 1997). The phosphorylation of 
histone H3 on Ser28 was recently shown to increase the transcription of the RNA 
polymerase III target genes, usually involved in the translation of proteins required 
for cell proliferation (Zhang et al., 2011). A combination of phosphorylation and 
acetylation of histone H3 in response to EGF-stimulation has been shown to induce 
c-fos and c-jun gene transcription (activated via the MAPK/ERK pathway) and lysine 
methylation has also recently been proven to be involved in this process (Cheung et 
al., 2000; Edmunds et al., 2008).  
 
There is therefore a huge complexity and diversity in histone modifications for gene 
activation. These modifications are not only involved in controlling and regulating 
transcription, but they have also been shown to be involved in other cellular 
processes such as chromosome condensation and DNA repair or replication 
(Kouzarides 2007).  
 
MSK1, MSK2 (Davie 2003; Soloaga et al., 2003) and IKK1 (Anest et al., 2003; 
Yamamoto et al., 2003) have been shown to be the kinases responsible for histone H3 
phosphorylation on Ser10. These data lead to particular interest in IKK1 as they 
suggested a new unidentified nuclear role for this protein and a new regulatory 
process for NF-κB-activated genes. However, the main question remains of how 
these modifying proteins (kinases, acetylases and methylases) are recruited into the 
nucleus. Only few examples have been described, such as the discovery of a DNA-
binding site in the well-studied kinase ERK (Hu et al., 2009). Modifying proteins can 
also translocate into the nucleus in association with transcription factors or their 
coactivators.  
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This chapter attempts to identify whether IKK2 can directly interact with NICD and 
whether this interaction can contribute to the upregulation of the Notch target genes 
observed by either enhancing the proteolytic release of the NICD or its stability. The 
second hypothesis tested a potential role for IKK2 in enhancing Notch target gene 
transcription via histone modifications, inducing chromatin remodelling at the hes1 
gene locus and finally leading to the increased gene transcription observed 
throughout the experiments performed. The potential mechanisms described are 
represented in a simplified version in the Figure 4.19 below.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: The link between the IKK2 and the Notch signalling pathways  
Activation of the NF-κB signalling pathway upon TNF-α stimulation activates IKK2 and leads to an 
upregulation of the expression of the Notch target genes. Two hypotheses were tested: 1) whether 
IKK2 can interact with NICD and phosphorylate some NICD residues therefore favouring the 
translocation of NICD into the nucleus for an enhanced activation of the pathway or 2) whether 
activated-IKK2 can directly or indirectly induce histone phosphorylation, favouring transcriptional 
activity.  
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Activation of the transcription of Notch target genes upon rTNF-α stimulation 
occurs following histone H3 modification (phosphorylation on Ser10) at the hes1 
promoter locus and requires the IKK2 kinase (Figure 4.17 and Figure 4.18). A direct 
interaction between IKK2 and NICD was demonstrated (Figure 4.15), but additional 
experiments need to be performed to confirm this novel interaction. 
 
Further experiments also need to be performed to show whether IKK2 can localise at 
the nucleus in cells derived from PanIN and PDAC bearing krasG12D mice and 
stimulated with rTNF-α. Immunofluorescent staining and/or nuclear and cytoplasmic 
protein extraction to identify IKK2 by Western blot would provide preliminary 
insights on a possible nuclear location. Using bioinformatics, it would also be 
interesting to screen for potential non-identified nuclear translocation domains or 
DNA-binding sites within the IKK2 protein.  
 
If a direct interaction between IKK2 and NICD occurs, it may indicate that this 
association can facilitate and mediate the translocation of IKK2 into the nucleus to 
induce histone modification or that IKK2 can directly phosphorylate NICD in the 
cytoplasm. It has recently been shown that post-translational modifications of NICD 
(such as acetylation) have an impact on its stabilisation and therefore on Notch target 
gene responses (Guarani et al., 2011).  
 
Phosphoproteomics technology could be used to identify the presence of phosphate 
groups on NICD and whether stimulation with rTNF-α induces significant changes 
in their numbers. Another possible route for further investigation would be to 
perform labelling experiments using phosphorus-32 (32P) to study NICD 
phosphorylation upon rTNF-α stimulation. As phosphorylation is known to be an 
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important regulatory mechanism involved in many cellular processes (Johnson 
2009), these experiments can indicate whether phosphorylation of NICD induces its 
stabilisation. In this case, a more stable NICD protein would contribute to explain 
the upregulation of the expression of the Notch target genes observed. However, 
phosphorylation of NICD in the C-terminal region is known to target it for 
ubiquitination and proteasomal degradation (Fryer et al., 2004; Tsunematsu et al., 
2004).  
 
It is possible that the TNF-α/IKK2/NF-κB signalling pathway had an effect 
upstream of NICD and could, for example, affect the activity of the enzymatic 
complexes involved in the release of NICD. The data shown in Figure 4.14 indicate 
that more NICD was released upon rTNF-α stimulation. An interesting question 
would be whether this stimulation can enhance the activity of the TACE and/or the γ-
secretase complex. The activity of these enzymes can be measured by incubating cell 
membrane fractions with specific fluorogenic peptide probes and their substrate and 
using fluorescence resonance energy transfer (FRET) for example.  
 
Another point of possible regulation following rTNF-α stimulation would be that the 
stability of the NICD protein is increased, either by some additional translational 
modifications such as acetylation or by modifying its proteosomal degradation. 
Acetylated residues can be identified using specific antibodies after co-
immunoprecipitation and inhibition of the proteasome can be performed in vitro using 
the natural compound lactacystin or the synthetic peptide MG132.  
 
A direct crosstalk between the TNF-α/IKK2 and the Notch signalling pathways is 
described in this chapter, showing that TNF-α can increase hes1 gene expression. 
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HES1 can activate its own expression by binding to N-box sequences within its own 
promoter region (Takebayashi et al., 1994) and this could contribute to the creation of 
a positive feedback loop leading to increased HES1 levels in pancreatic cancer cells. 
Moreover, HES1 is also known to promote inflammation. The effects of induced hes1 
expression on inflammatory processes in pancreatic carcinogenesis is investigated in 
the next chapter.  
 
  
 
 
 
 
 
 
 
5CHAPTER FIVE: HES1 AND INFLAMMATION 
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5.1 Introduction 
The previous chapter describes how the TNF-α/IKK2 and the Notch signalling 
pathways cooperate in the context of kras-mutant pancreatic carcinogenesis and the 
potential mechanisms involved in the upregulation of the expression of the Notch 
target gene hes1 upon TNF-α stimulation.  
 
Basic helix-loop-helix (bHLH) genes, such as hes1, are the main regulators of the 
different developmental processes during embryogenesis and are highly conserved in 
multicellular organisms (Skinner et al., 2010). The hes1 gene is mostly involved in the 
differentiation processes of a variety of different cell types, mainly regulating neural 
development and segregation of the endocrine and exocrine compartments of the 
pancreas (Kageyama et al., 2000). HES1 is a transcription factor, more particularly a 
transcription repressor, which functions as a homodimer or a heterodimer 
(Kageyama et al., 2000), binding to N- and E-box sequences (CACNAG or 
CANGTG respectively) with high and low affinities respectively (Jarriault et al., 
1995; Sasai et al., 1992). This transcription factor negatively regulates the expression 
of genes containing E-box and/or RBPj sites within their promoters (Fischer and 
Gessler 2007; Iso et al., 2003; Tanigaki and Honjo 2007; Tun et al., 1994).  
 
Interestingly, HES1 has been shown to bind to E-box sequences within the promoter 
region of the peroxisome proliferator-activated receptor gamma (pparg) gene and this 
binding acts as a negative regulator for the pparg gene as it suppresses its expression 
(Herzig et al., 2003). PPAR-γ is a ligand-dependent transcription factor, which 
regulates immunity and inflammatory processes (Glass and Saijo 2010). To further 
investigate the link between epithelial cell intrinsic inflammation and the Notch 
signalling pathway in pre-malignant pancreatic cells, the regulation of pparg gene 
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expression in the context of kras-induced pancreatic carcinogenesis is explored in the 
present chapter.  
 
The PPAR-γ nuclear receptor has been shown to be activated by a variety of lipid 
ligands and to regulate fatty acid metabolism (Evans et al., 2004; Kliewer et al., 2001). 
Natural and synthetic ligands for PPAR-γ include prostaglandins (PG), such as 
PGJ2 (Forman et al., 1995; Kliewer et al., 1995), antidiabetic agents from the 
thiazolidinedione class (TZD) (Lehmann et al., 1995) and non-steroidal anti-
inflammatory drugs (Lehmann et al., 1997). PPAR-γ receptors, also called adopted 
orphan receptor for non-steroidal ligands, form a heterodimer with a retinoid X 
receptor and bind to hormone response elements (HRE) within the promoter region 
of the target genes, in the presence or absence of their ligands (Glass and Saijo 2010). 
 
The anti-inflammatory role of PPAR-γ agonists has been demonstrated by a 
reduction in the production of inflammatory cytokines by monocytes, therefore 
suggesting that PPAR-γ is a transcriptional repressor of inflammatory genes (Jiang et 
al., 1998). The classical IL-12 production by macrophages upon LPS stimulation is 
inhibited by treatment with an oxidised low density lipoprotein. This inhibition has 
been shown to be related to modifications in the interactions between NF-κB and the 
DNA, but also to a direct interaction between NF-κB and PPAR-γ (Chung et al., 
2000). Recently, this receptor has also been shown to inhibit the differentiation of a 
subset of T helper cells (Th17) which are involved in autoimmune diseases (Klotz et 
al., 2009). Finally, its role in anti-inflammation has been described in a model for 
colitis where PPAR-γ ligands can reduce the levels of cytokine production and this is 
related to an inhibition of the NF-κB transcription factor (Su et al., 1999). 
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The hypothesis tested in this chapter was whether the HES1 upregulation observed 
in pre-malignant pancreatic cells following TNF-α stimulation leads to the 
suppression of pparg gene expression, which would in turn have an effect on 
inflammatory gene expression, therefore contributing to a sustained pro-
inflammatory profile for the pre-malignant cells.  
 
CHAPTER FIVE HES1 AND INFLAMMATION 
227 
5.2 Link between HES1 and PPAR-γ  in pancreatic cancer  
5.2.1 Gene expression levels of pparg  
The expression of the nuclear receptor pparg was evaluated in the pancreases of the 
three mouse models studied at 2 and 5 months of age (Figure 5.1).   
 
As shown in Figure 5.1, at 2 months of age, pparg mRNA expression levels were 
upregulated in the pancreases of krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice compared 
with krasG12D mice. However, by 5 months of age, pparg expression remained 
significantly elevated in the pancreases of krasG12D/ikk2∆Pdx mice only.  
 
 
 
 
 
 
 
Figure 5.1: Nuclear receptor pparg gene expression in vivo 
Relative mRNA expression of pparg in the pancreases of 2- and 5-month old krasG12D/ikk2∆Pdx and 
krasG12D/tnfa∆Pdx mice. Relative expression was calculated by setting expression of the pancreases of 
krasG12D mice as 1. Data are shown as mean + SD of duplicate experiments, ***p<0.001, n=6. 
 
The profile of pparg gene expression was also examined in the cell lines derived from 
PanIN bearing krasG12D, krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx mice upon stimulation 
with rTNF-α (Figure 5.2).  
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Figure 5.2: Nuclear receptor pparg gene expression upon rTNF-α  stimulation in 
vitro 
Relative mRNA expression of pparg in cell lines derived from PanIN bearing krasG12D/ikk2∆Pdx and 
krasG12D/tnfa∆Pdx mice, stimulated with 1 ng/ml of rTNF-α for 6 hours. Relative expression was 
calculated by setting expression of untreated krasG12D samples as 1. Data are shown as mean + SD of 
triplicate determinants and one representative experiment out of two performed is shown. 
 
After rTNF-α stimulation, cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx 
mice had reduced pparg mRNA expression levels. However, rTNF-α stimulation in 
cell lines derived from PanIN bearing krasG12D/ikk2∆Pdx mice had no impact on the 
previously observed upregulation.  
 
The gene expression profile observed for pparg in the pancreases of the different 
mouse models is inversely correlated with the gene expression profile for hes1 (see 
Figure 4.1): high expression levels of hes1 in krasG12D mice are associated with low 
levels of pparg and vice versa in the krasG12D/tnfa∆Pdx and krasG12D/ikk2∆Pdx mice.  
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5.2.2 Expression of pparg is inhibited by HES1 
As mentioned earlier, HES1 has been demonstrated to negatively regulate the 
expression of pparg in hepatocytes (Herzig et al., 2003). To investigate whether this 
also occurs in pancreatic cancer cells, the effect of hes1 specific siRNA knockdown in 
cells derived from PanIN bearing krasG12D mice was investigated.  
 
Three different commercially validated hes1 siRNAs and a non-targeting control were 
used to transfect cells derived from PanIN bearing krasG12D mice. Their specificity 
and efficiency in inhibiting hes1 gene expression and HES1 protein production were 
assessed by qRT-PCR and Western blot (Figure 5.3).  
 
 
 
 
 
Figure 5.3: siRNA knockdown of hes1 in cell lines derived from PanIN bearing 
krasG12D mice 
Cell lines derived from PanIN bearing krasG12D mice were transfected wih hes1 specific siRNA. hes1 
knockdown was verified by qRT-PCR and Western blot. Data are shown as mean + SD of triplicate 
determinants and are representative of three independent experiments.  
 
To directly evaluate the impact of hes1 knockdown, gene expression levels for pparg 
were measured and are shown in Figure 5.4.  
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Figure 5.4: Gene expression levels for pparg following hes1 knockdown 
Cell lines derived from PanIN bearing krasG12D mice were transfected wih hes1 specific siRNA or non-
targeting control siRNAs. pparg gene expression was quantified by qRT-PCR. Data are shown as 
mean ± SD of triplicate determinants and are representative of three independent experiments.  
 
Specific hes1 knockdown results in a robust upregulation of pparg gene expression, 
indicating that HES1 can negatively regulate this transcription factor in cells derived 
from pancreatic PanIN lesions.  
 
Expression of cebpa, a corepressor of inflammatory genes whose expression is also 
regulated by PPAR-γ (Li et al., 2010; Zuo et al., 2006), was also assessed and 
significantly upregulated after hes1 knockdown (Figure 5.5). 
 
 
 
 
 
Figure 5.5: Gene expression levels for cebpa following hes1 knockdown 
Cell lines derived from PanIN bearing krasG12D mice were transfected wih hes1 specific siRNA or non-
targeting control siRNAs. cebpa gene expression was quantified by qRT-PCR. Data are shown as 
mean ± SD of triplicate determinants and are representative of three independent experiments. 
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To further investigate the effects of HES1 on the activity of the pparg promoter, cells 
derived from PanIN bearing krasG12D and krasG12D/tnfa∆Pdx mice were cotransfected 
with a hes1 expression plasmid or a control vector with a pparg luciferase reporter 
construct (Figure 5.6).  
 
 
 
 
 
 
Figure 5.6: Effects of HES1 on the activity of the pparg promoter 
Cells derived from PanIN bearing krasG12D and krasG12D/tnfa∆Pdx mice were cotransfected with a hes1 
expression plasmid or a control vector and a pparg luciferase reporter construct. Luciferase activity 
was analysed 24 hours post-transfection. Data are shown as mean + SD from duplicate transfections 
and are representative of three independent experiments. 
 
As shown in Figure 5.6, luciferase activity was significantly increased in cells derived 
from PanIN bearing krasG12D/tnfa∆Pdx mice cotransfected with the control vector and 
the pparg luciferase reporter construct compared with cells derived from PanIN 
bearing krasG12D mice. Cells were generated from 2-month old PanIN bearing mice 
and have a hes1 profile similar to that observed in Figure 4.4 (lower expression of hes1 
in cells derived from PanIN bearing krasG12D/tnfa∆Pdx mice compared with cells 
derived from PanIN bearing krasG12D mice). This is in agreement with the results 
presented in Figure 5.2, with high expression of pparg in cells derived from PanIN 
bearing krasG12D/tnfa∆Pdx mice in absence of rTNF-α stimulation. However, when 
cotransfecting the cells with the hes1 plasmid, luciferase activity decreases in a dose 
dependent manner. These results confirm the negative regulation of pparg expression 
by HES1 previously observed in Figure 5.4.  
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5.2.3 HES1 is present at the pparg promoter 
HES1 has already been shown to bind to the promoter region of the pparg gene in 
hepatocytes (Herzig et al., 2003). To investigate whether similar binding occurs in 
pancreatic cells, ChIP assays were carried out using an antibody directed against 
HES1 (Figure 5.7). Immunoprecipitated DNA was analysed by qRT-PCR using 
pparg promoter-specific primers and input recovery calculation is explained in section 
4.4.3.  
 
 
 
 
 
 
 
Figure 5.7: Chromatin immunoprecipitation of HES1 to the pparg promoter 
Cells derived from PanIN bearing krasG12D mice were stimulated with rTNF-α at 1 ng/ml for 6 hours. 
ChIP assays were performed with anti-HES1 antibody or anti-rabbit IgG antibody as a control. 
Immunoprecipitated DNA was analysed by qRT-PCR using pparg promoter-specific primers. Results 
are shown as mean + SD of triplicate determinants and are representative of three independent 
experiments. 
 
In Figure 5.7, a high percentage of the recovery of the input indicates that the 
samples immunoprecipitated with anti-HES1 antibody are enriched in the pparg 
target gene. HES1 was found to bind to the pparg promoter locus in cells derived 
from PanIN bearing krasG12D mice in the presence or absence of rTNF-α stimulation, 
in agreement with another study (Herzig et al., 2003). A higher percentage of the 
recovery of the input upon rTNF-α stimulation was observed which is in agreement 
with HES1 production being upregulated in these conditions. 
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5.3 Discussion and conclusion 
Pre-malignant epithelial pancreatic cells constitutively secrete the TNF-α cytokine 
which, in an autocrine manner, can upregulate and increase hes1 gene expression and 
HES1 protein production. This chapter describes and investigates the role and the 
effects of these amplified levels of HES1 in the context of pancreatic cancer.  
 
Interaction between HES1 and the pparg promoter has been demonstrated in hepatic 
cells (Herzig et al., 2003) and similar data in pancreatic cancer cells were described in 
this chapter. HES1 can bind to the pparg promoter and negatively regulate its 
expression (Figure 5.4, Figure 5.6 and Figure 5.7).  
 
The CEBP and PPAR transcription factors have initially been described to be 
involved in the adipogenesis process (Farmer 2006; Rosen and MacDougald 2006). 
In this context of adipocyte differentiation, a crosstalk and a crossregulation between 
CEBP-α and PPAR-γ has been suggested more than ten years ago (Wu et al., 1995; 
Wu et al., 1999), but the full mechanism has only been described recently. CEBP-β 
can bind to the cebpa promoter and inhibit its activity when associated to an histone 
deacetylase complex. PPAR-γ can target this complex to the proteasome, therefore 
releasing the inhibition and allowing cebpa expression (Salma et al., 2006; Zuo et al., 
2006).  
 
The expression of pparg is not only restricted to the adipose tissue and does not only 
play a role in lipid metabolism. PPAR-γ is also produced in rat pancreatic acinar cells 
and its activation with prostaglandin can induce apoptosis (Masamune et al., 2002). 
This apoptotic role, in addition to its anti-inflammatory role has also been observed in 
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endothelial cells and macrophages (Bishop-Bailey and Hla 1999; Chinetti et al., 
1998).  
 
PPAR-γ ligands have also been demonstrated to have an effect on different tumour 
cell lines with inhibition of tumour growth in vivo of prostate cancer cells as well as 
induction of necrosis in vitro (Kubota et al., 1998) and a reduction in tumour growth 
in xenograft models with human colon cancer cells (Sarraf et al., 1998). 
 
The gene expression levels of pparg in the pancreases of the mouse models studied 
during this thesis correlate with the progression of the disease: krasG12D mice have a 
high tumour incidence and do not express pparg; krasG12D/tnfa∆Pdx mice have a similar 
but delayed pattern in disease progression compared with krasG12D mice and this is 
also reflected by a shift from high to low pparg expression between 3 and 5 months of 
age; krasG12D/ikk2∆Pdx mice have a significantly lower tumour incidence, but higher 
expression of this transcription factor (Figure 3.5 and Figure 5.1). It seems that 
TNF-α secreted by the pre-malignant epithelial cells leads to HES1 production in 
krasG12D and krasG12D/tnfa∆Pdx mice, which allows pparg suppression. This can retain an 
inflammatory profile for the pre-malignant cells at the early stages of the disease, and 
therefore enhance PanIN progression and PDAC development.  
 
Considering the previously described anti-inflammatory role of PPAR-γ, the next and 
final chapter of this thesis will investigate the effects of anti-inflammatory agents, 
such as PPAR-γ ligands, in pancreatic cancer progression in vivo.  
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IN PANCREATIC CANCER 
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6.1 Introduction 
The previous chapter describes how TNF-α-induced upregulation of HES1 in 
pancreatic cancer leads to pparg suppression and examines the potential mechanisms 
involved in this regulation.  
 
Prostaglandins (PG), such as PGJ2, are the main natural ligands for PPAR-γ, but 
synthetic ligands belonging to the thiazolidinediones (TZD) medication class are also 
effective. These TZD agonists (rosiglitazone, pioglitazone and troglitazone) are 
mostly used for the treatment of type II diabetes mellitus, to restore an anti-
inflammatory response (Nosjean and Boutin 2002).  
 
In colon cancer cell lines, PPAR-γ ligands can reduce the levels of cytokine 
production by inhibiting NF-κB activation, representing ideal candidates for the 
restoration of anti-inflammatory signalling pathways in inflammatory bowel disease 
(Su et al., 1999). A similar mechanism has been highlited when inhibiting TNF-α in 
mice with chronic colitis (Han et al., 2007). The natural ligand PGJ2 has been shown 
to be able to inhibit IKK (Rossi et al., 2000) and a physical and direct interaction has 
been demonstrated between PPAR-γ and NF-κB (Chung et al., 2000). One 
mechanism by which PPAR-γ ligands repress the expression of inflammatory genes 
controlled by NF-κB has been shown in a mouse leukemic monocyte macrophage cell 
line. It involves SUMOylation of the PPAR-γ ligand binding domain, which induces 
its translocation to the nucleus and in particular its interaction with corepressor 
proteins present at the promoter region of inflammatory genes. The presence of 
PPAR-γ therefore represses the removal of these corepressors, which is required to 
allow the activation of gene transcription (Pascual et al., 2005).  
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PPAR-γ is also expressed in pancreatic acinar cells (Masamune et al., 2002) and anti-
inflammatory effects of PPAR-γ agonists on caerulein-induced pancreatitis have been 
investigated (Lee et al., 2003; Wan et al., 2008). The IL-6 expression and apoptotic 
cell death induced after caerulein treatment of rat pancreatic acinar cells is inhibited 
if the cells have previously been transfected with IκB mutant gene or hras mutant 
gene, demonstrating a role for the NF-κB and the MAPK signalling pathways in 
these processes (Lee et al., 2003). Further analysis using the same cell line shows that 
treating the cells with a PPAR-γ agonist has several effects on the components of the 
NF-κB signalling pathway. Caerulein treatment induces Rel A DNA binding activity 
and increases its level of expression, which are both inhibited upon incubation with 
PPAR-γ ligand. Moreover, the phosphorylation-dependent proteolytic degradation of 
IκB required for NF-κB activation is induced by caerulein and inhibited when 
treating the cells with a PPAR-γ ligand. Furthermore, the activation of the IKK 
complex involved in the phosphorylation of IκB is decreased in the presence of the 
PPAR-γ agonist and finally, nuclear accumulation of NF-κB heterodimers is also 
reduced upon treatment with a PPAR-γ ligand (Wan et al., 2008).  
 
In conclusion, the PPAR-γ nuclear receptor plays a major role in suppressing 
inflammation in different models, including colitis and pancreatitis, by repressing 
inflammatory gene expression induced by other classes of transcription factors such 
as NF-κB (Blanquart et al., 2003).  
 
The interplay between TNF-α/IKK2, Notch and PPAR-γ observed and described in 
the previous chapters was suggested to retain the pre-malignant cells in a state of 
constitutive production of pro-inflammatory cytokines and chemokines and to 
promote tumour growth in krasG12D and krasG12D/tnfa∆Pdx mice.  
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In this chapter, pharmacological inhibitors were used to evaluate whether targeting 
Notch signalling in vivo can influence the inflammatory profile of the pre-malignant 
cells at the tumour site. A PPAR-γ ligand was also tested to investigate whether 
restoring anti-inflammaotry signals in krasG12D mice can modify and reduce PanIN 
progression.  
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6.2 Inhibition of the Notch and the NF-κB signalling pathways  
The impact of the inhibition of the Notch or the NF-κB signalling pathways on hes1 
expression was assessed in vitro. Cells derived from PanIN bearing krasG12D/tnfa∆Pdx 
mice were treated with the γ-secretase inhibitor (GSI) L685458 (Shearman et al., 
2000) at 5 µM for 6 hours or the synthetic inhibitor Bay11-7082 at 1 µM for 6 hours 
(Figure 6.1). This compound inhibits the phosphorylation of IκB in an irreversible 
manner, therefore preventing the release of NF-κB, which remains sequestered in the 
cytoplasm without being able to induce the expression of its target genes upon 
activation (Pierce et al., 1997). 
 
 
 
 
 
 
 
 
Figure 6.1: Changes in hes1 expression levels upon inhibition of the Notch or the 
NF-κB signalling pathways in vitro 
Relative mRNA expression of hes1 in cell lines derived from PanIN bearing krasG12D/tnfa∆Pdx mice and 
stimulated with 1 ng/ml of rTNF-α for 6 hours in the presence or absence of L685458 (5 µM) or 
Bay11-7082 (1 µM). Relative expression was calculated by setting expression of untreated krasG12D 
samples as 1. Data are shown as mean + SD of triplicate determinants and one representative 
experiment out of three performed is shown. 
 
 
 
CHAPTER SIX INFLAMMATION AND TUMOUR PROGRESSION IN PANCREATIC CANCER 
240 
As shown in Figure 6.1, in the presence of rTNF-α, both inhibitors were able to 
block hes1 gene expression. These data confirm that canonical Notch signalling is 
essential in the upregulation of hes1 expression and also that the NF-κB signalling 
pathway regulates hes1 gene expression. Inhibition of either of these pathways is 
sufficient to prevent hes1 expression upon rTNF-α stimulation.  
 
To confirm these observations, pharmacological inhibition of these pathways was 
performed in vivo in krasG12D mice and compared with untreated kras, krasG12D and 
krasG12D/ikk2∆Pdx mice (Figure 6.2).  
 
 
 
 
 
 
 
 
Figure 6.2: Changes in hes1 expression levels upon inhibition of the Notch or the 
NF-κB signalling pathways in vivo 
Relative mRNA expression of hes1 in the pancreases of 5-month old untreated krasG12D, 
krasG12D/ikk2∆Pdx mice and of age-matched krasG12D mice treated with anti-TNF-α (10 mg/kg/day), 
control IgG (10 mg/kg/day), DAPT (100 mg/kg/day), Bay11-7082 (10 mg/kg/day) or the vehicle 
control for seven days. Relative expression was calculated by setting expression of untreated kras Cre 
negative mice as 1. Data are shown as mean + SD of duplicate experiments, n=6, **p<0.01.  
 
Inhibition of the Notch signalling pathway in vivo was achieved using the γ-secretase 
inhibitor DAPT (Dovey et al., 2001), and of the NF-κB signalling pathway by using 
either an anti-murine-TNF-α antibody or the synthetic inhibitor Bay11-7082, which 
blocks the TNF-α-induced phosphorylation of IκB, therefore preventing NF-κB 
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nuclear translocation (Pierce et al., 1997). The use of DAPT was favoured over 
L685458 because this inhibitor is commonly used in vivo as opposed to L685458 and 
also for cost reasons. 
 
As already mentioned, hes1 gene expression is upregulated in the pancreases of 
krasG12D mice and reduced in the pancreases of krasG12D/ikk2∆Pdx mice. However, this 
increased expression is abolished if the krasG12D mice are treated with anti-TNF-α, 
DAPT or Bay11-7082. These in vivo data are in agreement with the previous in vitro 
data (Figure 6.1), reinforcing the hypothesis that NF-κB signalling is important for 
the gene expression of the Notch target gene hes1.  
 
Cell lines derived from the treated or untreated krasG12D mice, described in Figure 6.2, 
were established and mRNA and protein levels of the TNF-α cytokine were 
evaluated after culture in vitro for 24 hours (Figure 6.3).  
 
 
 
 
 
 
 
Figure 6.3: TNF-α  cytokine levels 
Relative mRNA expression of tnfa and protein levels of secreted TNF-α in cells derived from PanIN 
bearing krasG12D mice treated or untreated with DAPT or Bay11-7082 measured by qRT-PCR and 
ELISA respectively. Relative expression was calculated by setting expression of untreated kras Cre 
negative mice as 1. Data are shown as mean + SD of triplicate experiments and are representative of 
three independent experiments. 
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Reduced tnfa gene expression and TNF-α cytokine production were observed in 
pancreatic cells derived from krasG12D mice treated with both inhibitors, DAPT or 
Bay11-7082.  
 
These results confirm that Bay11-7082 is efficiently blocking the NF-κB signalling 
pathway as shown by the downregulation of tnfa gene expression and TNF-α 
production and that a similar effect is obtained upon treatment with a GSI inhibitor. 
Considering all the data described so far, a reduction in TNF-α levels can lead to a 
reduction in HES1 production and therefore an upregulation of pparg expression. 
These inhibitors can consequently be used to restore the expression of anti-
inflammatory proteins, which would provide a less inflamed environment and 
potentially delay or prevent PanIN progression. To test this hypothesis, the 
inflammatory status of the pancreases in different conditions was investigated in 
section 6.3. 
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6.3 Inflammatory status of the pancreas after DAPT treatment  
The interplay between the TNF-α/IKK2 and the Notch signalling pathways, 
associated with a downregulation of the anti-inflammatory nuclear receptor PPAR-γ 
in krasG12D and krasG12D/tnfa∆Pdx mice, was shown in the previous chapters. This 
cooperation was inhibited using DAPT to treat krasG12D mice and the effects on the 
production of inflammatory cytokines and chemokines by the pancreatic cells was 
evaluated. Protein levels in the pancreases of untreated or DAPT-treated krasG12D 
mice were measured with cytokine and chemokine arrays and normalised to data 
obtained for wild type mice (Figure 6.4).  
 
 
 
 
 
Figure 6.4: Cytokines and chemokines array data 
Cytokine and chemokine levels in the pancreases of PanIN bearing krasG12D mice at 5 months of age 
and treated or untreated with DAPT (intraperitoneally at 100 mg/kg/day for seven days, n=5) 
measured by protein array. The data is represented graphically as normalised to the signal intensity 
obtained for wild type mice.  
 
The pancreases of untreated krasG12D mice were previously shown to express high hes1 
mRNA and HES1 protein levels (Figure 4.1 and Figure 4.2), but also low gene 
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expression levels for pparg (see section 5.2.1). High levels of inflammatory cytokines 
such as IL-1β, IL-6 and TNF-α in the pancreases of krasG12D mice confirm the 
inflammatory signature of the PanIN lesions. The cytokine array data reveal that 
krasG12D mice treated with DAPT have lower levels of pro-inflammatory cytokines 
and chemokines, compared with untreated krasG12D mice (Figure 6.4). Namely, the 
production levels of the cytokines/chemokines CX3CL1, CXCL16, IGFBP3, 
IGFBP5, IL-1β, IL-4, IL-6, MCSF, TIMP1, TNF-α and sTNFRI were reduced in 
treated animals. However, the production of VEGF was increased upon DAPT 
treatment and this is in contradiction with the mRNA level results presented in 
Figure 4.1. The expression of this Notch target gene was reduced in the pancreases of  
PanIN bearing krasG12D/ikk2∆Pdx mice compared with PanIN bearing krasG12D mice. 
Due to time constraints, this discrepancy was not further investigated but it could 
result from a dual regulation of vegf expression by the Notch and NF-κB signalling 
pathways.  
 
To further investigate the impact of the Notch signalling pathway on the 
inflammatory state of the pre-malignant epithelial cells, krasG12D mice carrying the 
ROSA26-LSL-EYFP allele were used. The ROSA26-LSL-EYFP mice allow the 
visualisation of Cre activity in vivo (Srinivas et al., 2001). The ROSA26 locus is 
ubiquitously expressed and the eyfp gene (coding for the enhanced yellow fluorescent 
protein) was inserted under the control of the promoter of this gene, but with an 
upstream STOP cassette flanked by two loxP sites (LSL). eyfp gene expression occurs 
in ROSA26 and Cre expressing cells. After crossing the krasG12D mice with the 
ROSA26-LSL-EYFP mice, the expression of eyfp was therefore concomitant to the 
oncogenic expression of the mutated kras allele in pdx1 positive cells. It was then 
possible to sort the EYFP positive cells by fluorescence-activated cell sorting 
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(FACS), which was performed by Dr Guglielmo Rosignoli, Barts Cancer Institute, 
Queen Mary, University of London, London, UK. 
 
Cohorts of krasG12D mice (n=12) were treated or untreated with DAPT and the EYFP 
positive cells were isolated by FACS and analysed for cytokine gene expression levels 
(Figure 6.5). Expression of mutated kras was confirmed by PCR on the EYFP 
positive sorted cells (unpublished data from Dr Thorsten Hagemann’s group, Barts 
Cancer Institute, Queen Mary, University of London, London, UK).  
 
 
 
 
 
Figure 6.5: Cytokine gene expression levels upon DAPT treatment in krasG12D 
mice 
Relative mRNA expression of il1b, il6 and tnfa in FACS sorted EYFP positive cells from PanIN 
bearing krasG12D mice treated or untreated for one week with DAPT (100 mg/kg/day). Data are shown 
as mean + SD of duplicate experiments, *p<0.05, **p<0.01, ***p<0.001, n=12.  
 
mRNA level analysis of the sorted cells showed a significant reduction in il1b, il6 and 
tnfa gene expression levels in the pancreases of PanIN bearing krasG12D mice treated 
with DAPT. This is in agreement with the protein data from the cytokine and 
chemokine array (Figure 6.4) and confirms the capacity of a Notch inhibitor to 
reduce cytokine and chemokine expression, mediated by pparg expression, in pre-
malignant pancreatic epithelial cells derived from krasG12D mice.  
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6.4 Effects of rosaglitazone treatment on the progression of 
pancreatic cancer  
Using Notch inhibitors in vivo may have adverse effects, as this pathway is known to 
be involved in the development of many organs and at different stages (Bolos et al., 
2007; Roy et al., 2007). Rather than inhibiting this pathway to restore pparg 
expression, PPAR-γ ligands, known to have anti-inflammatory properties (see section 
6.1), can be used to re-activate anti-inflammatory reactions.  
 
Rosiglitazone, a TZD compound, has been approved for the treatment of type II 
diabetes mellitus in humans. This non-insulin-dependent diabetes is characterised by 
high levels of glucose in the blood due to insulin resistance. This hormone is 
produced by the β-cells of the pancreas in large quantities and fat and muscle cells 
are not sensitive to this hormone, reducing their glucose uptake. These TZD agents 
reduce insulin resistance (Berger and Moller 2002; Berger et al., 2005; Kota et al., 
2005b; Michalik et al., 2006). In addition, these PPAR-γ agonists also have anti-
inflammatory properties with effects on different models of inflammatory diseases 
such as colitis or pancreatitis (Cuzzocrea et al., 2004; Ivashchenko et al., 2007; Plutzky 
2003; Straus et al., 2000; Straus and Glass 2007).  
 
The effects of rosiglitazone on PanIN development and pancreatic cancer 
progression were evaluated in vivo using the krasG12D mice. A cohort of 40 krasG12D 
mice was monitored for nearly two years while being treated with 3 mg/kg/day of 
rosiglitazone, which was added to their daily diet (Appendix F). Mice were sacrificed 
when they developed any signs of distress or reached the UK Home Office limits. 
For each mouse, tumour incidence and histology grade were evaluated, but also the 
sites of metastasis (liver or lung), the presence of peritoneal disease, ascites, skin 
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lesions (such as papilloma) and biliary obstruction. The body weight of the mice was 
monitored weekly over a period of 20 weeks and no difference was found between 
treated and untreated groups (Figure 6.6). 
 
 
 
 
 
 
Figure 6.6: Body weight monitoring upon rosiglitazone treatment 
The percentage of the initial body weight was assessed weekly for kras, kras/ikk2, krasG12D and 
krasG12D/ikk2∆Pdx mice. Data are shown as mean ± SD, n = 10.  
 
As explained previously (see section 3.4.3), the proportion of the pancreas occupied 
by PanIN lesions and their stage were histologically assessed in krasG12D treated or 
left untreated with rosiglitazone (Figure 6.7). PanIN progression was significantly 
delayed in rosiglitazone treated krasG12D mice compared with the untreated controls 
(p<0.01, n=12).  
 
This PPAR-γ agonist appears to be sufficient to reduce PanIN progression and 
development when the anti-inflammatory responses associated with the pparg gene 
expression are activated.  
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Figure 6.7: Proportion of the pancreas occupied by PanIN lesions  
Quantification of the proportion of the pancreas occupied by normal tissue (nl, no lesion) and PanIN 
lesions in krasG12D mice treated with rosiglitazone (3 mg/kg/day) compared with untreated controls. 
Frequency and grade of the lesions were assessed at 2, 5 and 8 months of age. Data are shown as mean 
+ SD, **p<0.01, ***p<0.001, n=12. 
 
Tumour incidence and histology grade were also evaluated in the krasG12D mice 
treated with rosiglitazone and compared with the previous data from krasG12D and 
krasG12D/ikk2∆Pdx mice (Figure 6.8).  
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Figure 6.8: Tumour incidence and histology grade 
Tumour incidence and histology grade in rosiglitazone-treated krasG12D (n=40) mice (3 mg/kg/day) 
compared with untreated krasG12D (n=40) and krasG12D/ikk2∆Pdx (n=50) mice, *p<0.05. Respectively,     
50 % and 20 % of krasG12D and of krasG12D/ikk2∆Pdx mice developed PDAC, while tumour incidence was 
reduced to 27.5 % in krasG12D (n=40) mice treated with rosiglitazone. The number of mice presenting 
undifferentiated tumours was also reduced after treatment with rosiglitazone.  
 
Figure 6.8 shows that krasG12D and krasG12D/ikk2∆Pdx mice presented a 50 % and 20 % 
tumour incidence respectively. After treatment with rosiglitazone, tumour incidence 
in krasG12D mice was reduced compared with the untreated krasG12D mice (11/40 and 
20/40 respectively). However, this reduction was not significant as opposed to the 
difference between krasG12D and krasG12D/ikk2∆Pdx mice. Histology grade also showed a 
reduction in the number of PDAC presented with undifferentiated tumours, 
confirming the delay in PanIN progression. In addition, the frequency of liver 
metastasis was also reduced in krasG12D mice treated with rosiglitazone (63.6 %) 
compared with the untreated krasG12D mice (75 %) (Figure 6.9). As previously 
observed and discussed between krasG12D and krasG12D/ikk2∆Pdx mice, no significant 
effects on histological grade and metastatic potential were observed. 
 
Deletion of ikk2 is sufficient to significantly delay PDAC development and similar 
effects can be achieved by treating the mice with rosiglitazone, a PPAR-γ agonist.  
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Figure 6.9: Liver metastasis 
Liver metastasis in rosiglitazone-treated krasG12D (n=40) mice (3 mg/kg/day) was reduced to a similar 
level than krasG12D/ikk2∆Pdx (n=50) mice, compared with untreated krasG12D (n=40). 
 
To investigate whether rosiglitazone affects the infiltration of inflammatory cells at 
the tumour site, the pancreases of krasG12D mice were analysed by flow cytometry for 
infiltrating macrophages, which are typically present in the pancreas of diseased 
animals (Figure 6.10). 
 
 
 
 
 
 
 
 
Figure 6.10: Macrophage infiltrate 
Percentage of F4/80+CD11b+Gr1- cells in the pancreases of 2, 5 and 8-month old krasG12D mice treated 
with rosiglitazone (3 mg/kg/day) or untreated measured by flow cytometry. Each individual data point 
represents an individual mouse and mean values are depicted by horizontal lines, *p<0.05, n=10. 
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Previous data show that macrophages and neutrophils do not infiltrate the pancreases 
of krasG12D/ikk2∆Pdx mice (see section 3.4.5.1), and this is consistent with a lower 
inflamed state. In a similar manner, as shown in Figure 6.10, there was a reduction in 
the frequency of macrophages infiltrating the pancreases of rosiglitazone treated 
animals. This reduction is significant at 5 and 8 months of age. These data further 
support an anti-inflammatory effect of rosiglitazone treatment on krasG12D mice.  
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6.5 Discussion and conclusion 
To summarise, the data presented in this chapter show that pharmacological 
inhibition of the Notch or the NF-κB signalling pathways can inhibit hes1 gene 
expression upon treatment with two different Notch signalling inhibitors (DAPT and 
L685458) and two NF-κB signalling pathways inhibitors (Bay11-7082 and anti-
TNF-α antibody). In addition, the treatment of krasG12D mice with DAPT has an anti-
inflammatory effect in their pancreases by reducing cytokine and chemokine 
production (Figure 6.4).  
 
Activation of the PPAR-γ anti-inflammatory responses by treating the krasG12D mice 
with rosiglitazone, similar to the effects of DAPT treatment, reduces the immune 
infiltrate into the pancreas and significantly delays PanIN progression. It would be 
interesting to evaluate cytokine and chemokine expression and production in the 
pancreas of rosiglitazone treated mice to confirm the ability of this PPAR-γ ligand to 
reduce pancreatic inflammation.  
 
One limitation of the route of administration chosen for rosiglitazone is that its 
incorporation into the rodent’s diet prevents monitoring of the exact amount of drug 
absorbed by the animals. However, daily administration of a natural PPAR-γ ligand, 
such as PGJ2, by oral gavage or intravenous injections over two years would not 
have been feasible and is also not authorised under Home Office regulations. In 
addition, PGJ2 cannot be incorporated into the rodent’s diet. The use of 
rosiglitazone, a synthetic PPAR-γ ligand, added to the daily diet of the mice was then 
favoured. Rosiglitazone is an anti-diabetic drug and can therefore modify the mouse’s 
daily food absorption. However, no significant change in the weight of the animals 
was observed, suggesting that this compound does not influence their usual diet. 
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Another member of the TZD class compounds (pioglitazone or troglitazone) could 
have potentially been used.  
 
Natural and synthetic PPAR-γ ligands have proven to be effective in reducing the 
inflammation process in mouse models of caerulein-induced acute pancreatitis 
(Ivashchenko et al., 2007; Konturek et al., 2005; Rollins et al., 2006; Weber and Adler 
2001) but also in chronic pancreatitis models (Shimizu et al., 2002). This attenuation 
of inflammation is associated with suppression of NF-κB activation (Wan et al., 
2008). The effects of rosiglitazone on the delayed PanIN progression observed in the 
krasG12D treated mice may therefore be due to a suppression of the NF-κB signalling 
pathway.  
 
Two TZD compounds (rosiglitazone and pioglitazone) have been shown to inhibit 
human pancreatic cancer cell invasiveness (Galli et al., 2004) and growth in vitro 
(Elnemr et al., 2000). The natural ligand PGJ2 is also able to inhibit the invasion of 
human pancreatic cancer cells (Sawai et al., 2006). The first anti-tumour effects of 
activating PPAR-γ with small molecules in vivo have been observed on orthotopic 
xenograft models with human colorectal tumour cell lines and thyroid tumour cell 
lines in nude mice (Shimazaki et al., 2008). Additional orthotopic xenograft models 
inoculating human pancreatic cancer cell lines into nude mice showed that 
rosiglitazone can suppress tumour progression by inhibiting angiogenesis (Dong et 
al., 2009). However, little has previously been described regarding a role for PPAR-γ 
agonists in the context of spontaneous genetic mouse models of cancer, such as 
krasG12D mice. In addition, orthotopic xenograft models do not allow the study of the 
role of the tumour microenvironment in tumour progression and development, which 
is not the case in genetic mouse models (Richmond and Su 2008).  
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Nevertheless, the hypothesis tested whether an anti-inflammatory response can 
inhibit PanIN progression and PDAC development was verified in vivo upon 
rosiglitazone treatment.  
 
In addition to anti-inflammatory properties, rosiglitazone is also an anti-diabetic drug 
which reduces glucose concentration in the blood (Kahn et al., 2006). Metformin, 
another glucose lowering drug, has been studied in patients suffering from type II 
diabetes and reduces the risk of developing pancreatic cancer by 62 % (Li and 
Abbruzzese 2010). Due to the increased risk for diabetic patients to develop 
pancreatic cancer (see section 1.2.3) and considering the clinical data obtained upon 
metformin treatment, a prophylactic treatment with rosiglitazone in a specific subset 
of diabetic patients may provide a protective effect against pancreatic cancer.  
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Many cancers are driven by oncogenic expression of RAS, but this pathway 
represents a difficult molecular target as it is also expressed in normal cells. Studies 
reveal that drug combinations targeting additional molecules which are also 
abnormally expressed by malignant cells or by the surrounding microenvironment 
might be an alternative (De Raedt et al., 2011). Oncogenic KRAS has a tumour-
promoting role through activation of the NF-κB signalling pathway (see section 
1.3.2.2) but it has also been recently demonstrated that it contributes to the cellular 
metabolism switch observed in cancer cells (Gaglio et al., 2011). Tumours use 
glycolysis to produce ATP rather than the classic oxidative phophorylation 
metabolism, even in the presence of oxygen. This process, also known as the 
“Warburg effect”, contributes to cancer progression and has been described as an 
emerging hallmark of cancer (Hanahan and Weinberg 2011; Warburg 1956).  
 
KRAS mutations are characteristic of human pancreatic cancer, which remains a 
cancer with one of the poorest survival rates due to late diagnosis, a high frequency 
of relapse in curative setting of surgery and ineffective therapies. Great efforts are 
being carried out in order to further understand the mechanisms involved during its 
development. For this, genetic mouse models that mimic the human disease have 
been useful in understanding the mechanisms during pancreatic carcinogenesis 
(Hingorani et al., 2003; Ijichi 2011). In this thesis, two variants of pancreatic cancer 
mouse models were generated: krasG12D/ikk2∆Pdx and krasG12D/tnfa∆Pdx mice. These mice 
were used to study the role of the TNF-α/IKK2 signalling pathway on the early 
stages of kras-driven pancreatic carcinogenesis. The development of PanIN lesions is 
delayed in young krasG12D/tnfa∆Pdx mice compared with krasG12D mice and contrasts 
with the profound reduction in the frequency of the high-grade PanIN lesions 
observed in krasG12D/ikk2∆Pdx mice compared with krasG12D mice (Figure 3.5 and Figure 
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3.10). This demonstrates that genetic inactivation of ikk2 delays the progression of 
malignant epithelial cell lesions towards higher-grade PanIN lesions and PDAC.  
 
The role of IKK2 in carcinogenesis is context- and cell type-dependent. This kinase is 
required for the development of lung adenocarcinoma, induced by oncogenic kras and 
associated with activation of the NF-κB signalling pathway (Basseres et al., 2010; 
Meylan et al., 2009). In a spontaneous mouse model of skin carcinogenesis, 
characterised by mutant kras expression and inactivation of a tumour suppressor 
gene, genetic deletion of ikk2 impairs the development of melanoma (Yang et al., 
2010). In the setting of inflammation-induced carcinogenesis (colitis-associated 
cancer), ikk2 deletion reduces tumour growth and incidence (Greten et al., 2004). 
Mice with a genetic inactivation of ikk2 in hepatocytes alone are more susceptible to 
chemically-induced hepatocarcinogenesis, suggesting a protective role for this kinase 
in the setting of liver carcinogenesis (Maeda et al., 2005). However, in the same 
study, it has been shown that deletion of ikk2 in hepatocytes and macrophages can 
reduce chemically-induced hepatocarcinogenesis (Maeda et al., 2005). 
 
In the context of cancer-associated inflammation, activation of inflammatory 
signalling pathways can have two origins: inflammatory conditions (intrinsic 
pathway) or genetic alterations such as oncogene activation (extrinsic pathway) (see 
section 1.1.3) (Mantovani et al., 2008). The intrinsic network of inflammatory 
mediators can act in an autocrine and/or paracrine manner on the malignant cells 
and/or on the surrounding stroma, to further enhance the activation of these 
pathways and to activate and stimulate different cellular processes, such as cell 
proliferation and migration (Grivennikov et al., 2010). The main inflammatory 
signalling pathways involved are the NF-κB pathway, activated by TNF-α or IL-1 
CHAPTER SEVEN CONCLUSIONS AND FUTURE PLANS 
 
258 
cytokines and inducing the secretion of mainly TNF-α and IL-6 and the STAT3 
signalling pathway, activated by IL-6 (Grivennikov and Karin 2010; Naugler and 
Karin 2008). This inflammatory microenvironment can contribute to tumour 
initiation and progression. Cooperation between pro-inflammatory cytokines, 
transcription factors and oncogenic mutations are well described in the literature (see 
section 1.3.2.2). Oncogenic ras induces the secretion of IL-6, a highly inflammatory 
and angiogenic cytokine, which when inhibited contributes to slowing down the 
progression of cancers associated with ras mutations (Ancrile et al., 2007). The 
activation of another oncoprotein, Src, which contributes to cellular transformation 
of normal breast cells, can induce an inflammatory response in breast cancer cells 
characterised by IL-6 production (Iliopoulos et al., 2009). The IL-6 signalling 
pathway is a potential link between inflammation and cancer (Naugler and Karin 
2008).  
 
The TNF-α cytokine in the tumour microenvironment can be secreted by the tumour 
infiltrating immune cells or by the malignant cells. In the krasG12D mouse model of 
pancreatic cancer, the immune reaction is well described and shows that 
inflammatory immune cells, mainly macrophages and neutrophils, progressively 
infiltrate the pancreas as the disease progresses (Clark et al., 2007). The results 
presented in Figure 3.16 are in agreement with this study and the krasG12D/ikk2∆Pdx 
mice generated present a reduction of the infiltrating immune cells (macrophages and 
neutrophils) at the tumour site. Pancreatic cells with a genetic deletion for ikk2 have 
an impaired NF-κB signalling, which normally controls the production of 
inflammatory mediators involved in the recruitment of immune cells (Grivennikov et 
al., 2010). In addition, the delayed PanIN progression observed in krasG12D/tnfa∆Pdx 
mice is suggested to be due to the TNF-α secretion by the recruited immune cells 
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(Figure 3.18). To further assess the impact of inhibiting the TNF-α/IKK2 pathway, it 
would have been interesting to determine the profile of the inflammatory cytokines 
and chemokines within the pancreases of the different mouse models generated. 
MSD assays or cytokine array technologies could have been used and considering 
the data summarised in this thesis, a reduction in the inflammatory cytokines such as 
TNF-α and IL-6 in the pancreases of the krasG12D/ikk2∆Pdx mice should be expected.  
 
PanIN and PDAC cell lines generated from krasG12D mice constitutively secrete  
TNF-α, showing NF-κB activation upon oncogenic kras expression. Constitutive 
secretion of TNF-α by ovarian epithelial cancer cells has previously been shown to 
sustain a network of inflammatory molecules and to promote invasion and 
neovascularisation of ovarian tumours in vivo (Balkwill 2009; Kulbe et al., 2007; Kulbe 
et al., 2011). A similar effect is possibly occurring in the pancreatic tumour 
microenvironment. In the early stages of the carcinogenic process, TNF-α secreted 
by the pre-malignant cells is critical for their growth, while at later stages, an influx 
of immune cells constitutes the major source of this cytokine. This is supported by the 
delayed pattern of pancreatic cancer progression observed in krasG12D/tnfa∆Pdx mice, 
where the absence of TNF-α production by the pre-malignant epithelial cells is 
compensated once the immune cells secreting this cytokine infiltrate the pancreas, in 
response to other cytokines such as CCL2 and CSF1. However, in krasG12D/ikk2∆Pdx 
mice, this compensation does not occur, as the recruitment of inflammatory cells is 
impaired (see Figure 3.16).  
 
In krasG12D/ikk2∆Pdx mice, genetic deletion of ikk2 correlates with a decrease in the 
expression of the classical Notch target genes hes1 and hey1 (Figure 4.1 and Figure 
4.2). This observation is in agreement with the scientific literature, which shows that 
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Notch signalling is reactivated during pancreatic carcinogenesis and which suggests 
oncogenic properties in this context. In kras-mutant pancreatic carcinogenesis, 
activation of Notch signalling can cooperate with oncogenic kras promoting faster 
PanIN lesions formation (De La et al., 2008). In addition to mutated kras, when an 
inflammatory environment is provided following chemically-induced pancreatitis, the 
development of PanIN lesions is accelerated (Carriere et al., 2007; Guerra et al., 
2007). In response to inflammatory insult, the Notch and Hedgehog signalling 
pathways, which are normally expressed during pancreatic development, are 
transiently reactivated for pancreatic regeneration (Fendrich et al., 2008; Jensen et al., 
2005; Siveke et al., 2008). However, when oncogenic kras is expressed their 
reactivation is not transient but persists throughout time and during PanIN 
development (Morris et al., 2010a). A separate line of evidence shows that even 
though Notch signalling is overexpressed in pancreatic carcinogenesis, Notch2 
inhibition, as opposed to that of Notch1, can stop PanIN progression, therefore 
suggesting a tumour suppressive role (Mazur et al., 2010a).  
 
Stimulation of pre-malignant pancreatic epithelial cells with TNF-α in vitro induces 
an upregulation of hes1 and hey1 (Figure 4.4 and Figure 4.5). This upregulation is 
independent of de novo protein synthesis, requires canonical Notch signalling and is 
dependent of IKK2 (see sections 4.2 and 4.3). These data suggest that activation of 
NF-κB signalling can synergise with basal Notch signals to induce maximal 
expression of the Notch target genes during pancreatic carcinogenesis. 
 
Activation of the NF-κB signalling pathway upon Notch signalling is well described 
in various types of cancer: constitutive activation of Notch results in NF-κB pathway 
activation in T cell leukaemia (Vilimas et al., 2007) or cervical cancer (Song et al., 
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2008). Another group has demonstrated that the Notch/HES1 signalling pathway 
sustains the NF-κB pathway activation by repressing the deubiquitinase CYLD, a 
negative IKK complex regulator (Espinosa et al., 2010). However, interactions by 
NF-κB to Notch signalling are less well described and the results described in this 
thesis suggest a novel cooperation between these two signalling pathways in the 
context of kras-driven pancreatic carcinogenesis.  
 
The effect of a cancer-related inflammatory microenvironment on the activation of 
the Notch signalling pathway has also recently been demonstrated in human high-
grade serous ovarian cancer. A “TNF network”, including TNF-α, CXCL12 and   
IL-6, produced by ovarian cancer cells has been described to have different paracrine 
actions contributing to tumour growth. Inhibition of these cytokines is associated 
with a reduction in Notch signalling (Kulbe et al., 2011). This work reinforces the 
data presented in this thesis, showing that inflammatory and developmental signalling 
pathways can cooperate during carcinogenesis.  
 
The effects of stimulating malignant epithelial cells with rTNF-α in vitro on the Notch 
target genes’ expression occurs at the transcription level: IKK2 can mediate the 
phosphorylation of histone H3 (Figure 4.17 and Figure 4.18), which is a modification 
often associated with transcriptional activation (Anest et al., 2003; Yamamoto et al., 
2003). Kinases, such as IKK1, are able to translocate to the nucleus to phosphorylate 
histone proteins, contributing to transcriptional regulation (Anest et al., 2003; Baek 
2011). IKK2 may act in a similar manner. However, IKK2 nuclear location was not 
demonstrated in this thesis and could have been shown by performing 
immunofluorescent staining or cytosolic and nuclear protein extraction in pre-
malignant pancreatic epithelial cells stimulated with rTNF-α. To explain a potential 
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IKK2 nuclear location, it would be interesting to find out whether this kinase 
possesses an unknown DNA-binding site or whether it can interact with NICD, 
which will then allow its nuclear translocation. However, the experiments performed 
so far have not confirmed a physical interaction between these two proteins. This 
needs to be repeated in the future as it was only performed once and sample 
preparation for mass spectrometry analysis should be optimised. These additional 
experiments would help to provide supplementary information regarding a complete 
and more detailed mechanism to explain the transcriptional activation of the hes1 gene 
locus upon TNF-α stimulation.  
 
Another study shows that the NEMO-like kinase (NLK) negatively regulates the 
Notch signalling pathway by interacting and phosphorylating NICD. This 
phosphorylation impairs the binding of NICD to the coactivators required for its role 
in transcriptional activation. However, this mechanism has been shown in 
neurogenesis in zebrafish embryos (Ishitani et al., 2010). This study shows how 
NICD post-translational modifications, such as phopshorylation, are important in 
regulating the activity of the pathway, as it is the case with acetylation (Guarani et al., 
2011). Considering the existence of such phenomena, it would be interesting to 
investigate further whether IKK2 can interact and modify NICD in the context of 
kras-driven pancreatic cancer.  
 
The crosstalk between NF-κB and Notch signalling is mediated by IKK2 and HES1, 
which in turn can repress the expression of the anti-inflammatory nuclear receptor 
pparg by binding its promoter region (Figure 5.2, Figure 5.6 and Figure 5.7). PPAR-γ 
is a transcriptional repressor, which binds to DNA to repress the transcription of 
inflammatory genes. This repression has been demonstrated to be an important 
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mechanism by which cells can regulate inflammatory responses and homeostasis 
(Glass and Saijo 2010). The cooperation between activated NF-κB and Notch 
signalling and repression of the pparg gene provides an inflammatory context in which 
expression of inflammatory genes is sustained. This leads to a constitutive production 
of inflammatory mediators and chemokines by the transformed cells, retaining them 
in an inflammatory state, which favours pancreatic cancer progression.  
 
Pharmacological inhibition of the Notch pathway in krasG12D mice using DAPT, a      
γ-secretase inhibitor, results in a reduction of hes1 gene expression (Figure 6.2), an 
attenuated expression of genes coding for different cytokines (Figure 6.3 and Figure 
6.5) and a reduction in cytokine production in the pancreases of the treated mice 
(Figure 6.4). Inhibition of the Notch pathway has already been shown to significantly 
attenuate the development of PanIN lesions towards PDAC (Plentz et al., 2009). To 
corroborate this, additional gene expression analysis should be performed to confirm 
that Notch inhibition could also restore pparg gene expression, which would partially 
explain the reduction in cytokine production.  
 
Restoring an anti-inflammatory profile in the tumour microenvironment by re-
activating the PPAR-γ receptor can reduce the frequency of the PanIN lesions and 
their progression into invasive carcinoma (Figure 6.7). This is associated with a 
reduction of the macrophage infiltrate (Figure 6.10). Such effects were observed 
after using rosiglitazone to treat krasG12D mice. This PPAR-γ ligand, like most 
synthetic ligands, induces conformational changes to the receptor allowing it to 
effectively repress gene expression (Zoete et al., 2007). In the krasG12D mice, pparg 
expression is repressed (Figure 5.1), but this nuclear receptor is already present prior 
to cell transformation, providing a basal level of this protein in the nucleus. 
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Activating this receptor with the TZD agonist may be sufficient to inhibit the 
expression of inflammatory genes.  
 
PPAR-γ ligands, and rosiglitazone in particular, have an anti-inflammatory effect in 
many mouse models of acute and chronic inflammation, such as inflammatory bowel 
disease (Dubuquoy et al., 2006), arthritis (Cuzzocrea et al., 2003; Shiojiri et al., 2002) 
or caerulein-induced pancreatitis (Cuzzocrea et al., 2004; Ivashchenko et al., 2007). 
They appear to reduce chemokine expression in LPS-induced macrophages and to 
impair lymphocyte recruitment to the site of inflammation (Straus and Glass 2007).  
 
The PPAR-γ nuclear receptor does not only play a role in inflammation but it can 
also affect adipocyte differentiation and glucose metabolism (Kota et al., 2005a). TZD 
drugs are originally used for the treatment of type II diabetes as they have an insulin-
sensitising action (Nosjean and Boutin 2002). Moreover, other glucose-lowering 
drugs, such as metformin, are used to treat patients with type II diabetes mellitus and 
also reduce the risk for these individuals to develop cancer (Currie et al., 2009; Evans 
et al., 2005; Phielix et al., 2011). The effects of rosiglitazone on the prevention of 
cancer incidence are not significant and additional clinical studies need to be 
performed, as so far most of the trials have been conducted upon metformin 
treatment (Monami et al., 2008).  
 
Data in this thesis suggest that a TNF-α/HES1 mechanism of pparg inhibition 
operates in pre-malignant pancreatic epithelial cells, therefore sustaining an inflamed 
state which contributes to the formation of PanIN lesions and to the progression of 
pancreatic cancer (Figure 7.1).  
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Figure 7.1: TNF-α/IKK2 is suggested to cooperate with Notch to sustain an 
inflammatory environment favouring pancreatic carcinogenesis 
In the krasG12D genetic mouse model of pancreatic carcinogenesis, activation of IKK2 upon TNF-α 
stimulation induces the expression of the classical Notch target genes. This overexpression is mediated 
by phosphorylation of the H3 histone at the hes1 locus. HES1 represses pparg gene expression, 
therefore allowing expression of inflammatory genes. This inflamed microenvironment is sustained and 
contributes to pancreatic cancer progression.  
 
The use of PPAR-γ ligands, such as rosiglitazone, can potentially provide a protective 
effect and/or reduce pancreatic carcinogenesis. However, in order to effectively use 
such compounds in human patients, it is important to be able to clearly identify the 
patients presenting higher risk of developing pancreatic cancer and to improve early 
methods of diagnosis.  
 
The data presented in this thesis highlight the involvement of inflammatory signalling 
pathways as well as the role of the tumour microenvironment in pancreatic cancer 
development, revealing potential new key molecular targets to assist current 
treatments. 
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APPENDIX A: SOLUTIONS 
Solutions are listed in alphabetical order. Unless indicated, the pH of buffers was 
adjusted using either 1 M NaOH or 1 M HCl and reagents were dissolved in 
deionised water. 
 
Agarose Gel  
1.2 % w/v agarose 
4 % v/v GelRedTM Nucleic Acid Gel Stain 
Dissolved in 1X TAE  
 
Antibody dilution 
3 % w/v BSA 
0.01 % w/v sodium azide 
Dissolved in 1X TBS/T 0.05 % 
 
ChIP dilution buffer  
16.7 mM Tris-HCl pH 8.1 
1.2 mM EDTA 
167 mM NaCl 
1.1 % v/v Triton®-X-100  
0.01 % w/v SDS 
 
ChIP lysis buffer  
5 µl 200X Protease inhibitor cocktail II (Millipore - 20-283) 
Volume adjusted to 1 ml with PBS 
 
ChIP SDS lysis buffer  
50 mM Tris pH 8.1 
10 mM EDTA 
1 % w/v SDS 
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FACS buffer 
1 % v/v FCS 
0.01 % w/v sodium azide 
Dissolved in PBS 
 
Kinase buffer 
20 mM Tris pH 7.5 
1 mM EDTA 
1 mM DTT (add just before use) 
 
Loading buffer (6X) (DNA) 
0.3 % w/v bromophenol blue 
0.3 % w/v xylene cyanol 
30 % v/v glycerol 
 
Loading buffer (6X) (Protein) 
350 mM Tris-HCl pH 6.8  
30 % v/v glycerol  
10 % w/v SDS  
0.02 % w/v bromophenol blue  
 
Before use, add 1 volume 1 M DTT to 2 volumes loading buffer  
Once the DTT is added, store at - 20 °C 
 
L. agar 
15 mg/ml agar 
Dissolved in lysogeny broth  
 
Lysogeny broth (L. broth) 
10 mg/ml typtone 
5 mg/ml yeast extract 
85 mM NaCl 
Adjust to pH 7.4 and autoclave 
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Lysis buffer 
50 mM Tris-HCl pH 7.5  
250 mM NaCl  
3 mM EDTA pH 8  
3 mM EGTA pH 8  
1 % v/v Triton®-X-100 
0.5 % v/v igepal CA-630  
10 % v/v glycerol  
 
Add 1 Complete Mini Protease Inhibitor cocktail (Roche - 11836153001) per 10 ml 
of lysis buffer. This solution can be stored at - 20 °C. 
Before use, add 10 µl of phosphatase inhibitor cocktail (Sigma Aldrich - P5726) per   
1 ml of lysis buffer.  
 
MOPS SDS running buffer (1X) (Electrophoresis) 
50 ml 20X MOPS SDS running buffer  (Invitrogen - NP0001) 
Volume adjusted to 1 l with deionised water 
 
Running buffer (10X) (Electrophoresis) 
0.25 M Tris base 
1.92 M glycine 
1 % w/v SDS 
 
Running buffer (1X) (Electrophoresis) 
100 ml 10X running buffer  
Volume adjusted to 1 l with deionised water 
 
TAE (50X) 
2 M Tris base 
1 M acetic acid 
50 mM EDTA 
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TAE (1X)  
20 ml 50X TAE  
Volume adjusted to 1 l with deionised water 
 
TBS (10X) 
200 mM Tris base  
1.5 M NaCl 
 
TBS/T 0.05 % (1X) 
100 ml 10X TBS  
500 µl Tween 20 
Volume adjusted to 1 l with deionised water 
 
Transfer buffer (10X) (Electrophoresis)  
0.27 M Tris base  
1.92 M glycine 
 
Transfer buffer (1X) (Electrophoresis)  
100 ml 10X transfer buffer  
200 ml methanol 
Volume adjusted to 1 l with deionised water 
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APPENDIX B: PLASMID MAPS 
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APPENDIX C: QUANTITATIVE RT-PCR ASSAYS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table describes the qRT-PCR assays used listing the gene, species, quencher, reporter and assay 
identification number (ID).  
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APPENDIX D: DISEASE SPECTRUM IN KRASG12D MICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table describes the identification number (ID), age, presence or absence of PDAC, histology grade, 
liver and lung metastasis, peritoneal disease (PD), ascites and biliary obstruction (BO) for each 
mouse. Other sites of metastasis include the lymph nodes (LN).  
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APPENDIX E: DISEASE SPECTRUM IN KRASG12D/IKK2∆PDX 
MICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table describes the identification number (ID), age, presence or absence of PDAC, histology grade, 
liver and lung metastasis, peritoneal disease (PD), ascites, skin lesions, biliary obstruction (BO) and 
atrophy for each mouse. 
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APPENDIX F: DISEASE SPECTRUM IN KRASG12D MICE 
TREATED WITH ROSIGLITAZONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table describes the identification number (ID), age, presence or absence of PDAC, histology grade, 
liver and lung metastasis, peritoneal disease (PD), ascites, skin lesions and biliary obstruction (BO) 
for each mouse. 
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The	majority	of	human	pancreatic	cancers	have	activating	mutations	in	the	KRAS	proto-oncogene.	These	muta-
tions	result	in	increased	activity	of	the	NF-κB	pathway	and	the	subsequent	constitutive	production	of	proin-
flammatory	cytokines.	Here,	we	show	that	inhibitor	of	κB	kinase	2	(Ikk2),	a	component	of	the	canonical	NF-κB	
signaling	pathway,	synergizes	with	basal	Notch	signaling	to	upregulate	transcription	of	primary	Notch	target	
genes,	resulting	in	suppression	of	antiinflammatory	protein	expression	and	promotion	of	pancreatic	carcino-
genesis	in	mice.	We	found	that	in	the	KrasG12DPdx1-cre	mouse	model	of	pancreatic	cancer,	genetic	deletion	of	Ikk2	
in	initiated	pre-malignant	epithelial	cells	substantially	delayed	pancreatic	oncogenesis	and	resulted	in	down-
regulation	of	the	classical	Notch	target	genes	Hes1	and	Hey1.	Tnf-α	stimulated	canonical	NF-κB	signaling	and,	
in	collaboration	with	basal	Notch	signals,	induced	optimal	expression	of	Notch	targets.	Mechanistically,	Tnf-α	
stimulation	resulted	in	phosphorylation	of	histone	H3	at	the	Hes1	promoter,	and	this	signal	was	lost	with	Ikk2	
deletion.	Hes1	suppresses	expression	of	Pparg,	which	encodes	the	antiinflammatory	nuclear	receptor	Pparγ.	
Thus,	crosstalk	between	Tnf-α/Ikk2	and	Notch	sustains	the	intrinsic	inflammatory	profile	of	transformed	cells.	
These	findings	reveal	what	we	believe	to	be	a	novel	interaction	between	oncogenic	inflammation	and	a	major	
cell	fate	pathway	and	show	how	these	pathways	can	cooperate	to	promote	cancer	progression.
Introduction
Cancer-related inflammation has been shown to be critically linked 
with malignant disease — either by being the initiating, extrinsic 
cause or by supporting the intrinsic microenvironment during 
tumor progression (1). Most solid tumors are characterized by an 
intrinsic tumor-promoting inflammatory response (1). Activation 
of proto-oncogenes such as ras and/or inactivation of tumor sup-
pressors orchestrates a proinflammatory transcriptional program 
and constitutive production of inflammatory cytokines and che-
mokines that shape a tumor-promoting microenvironment. Onco-
genes and tumor suppressor genes are, however, difficult molecular 
targets in cancer therapy (2). In contrast, inflammatory cytokines 
and signaling pathways affected by the genetic changes occurring 
in malignant diseases are attractive druggable targets.
Activating mutations of the KRAS proto-oncogene are found in 
more than 90% of pancreatic ductal adenocarcinomas (PDACs), 
the most prevalent form of pancreatic cancer (3). Histological and 
molecular studies have demonstrated that disease progression 
occurs through a series of preinvasive lesions, pancreatic intraepi-
thelial neoplasias (PanINs), that progress into invasive carcinoma 
(4). Mouse models with pancreas-specific activation of oncogenic 
Kras display the full spectrum of PanINs and recapitulate the fea-
tures of human PDAC (5, 6). NF-κB, a major transcription fac-
tor for inflammatory responses, is found activated in Kras-trans-
formed epithelial cells (7, 8). NF-κB activation is regulated through 
the inhibitor of κB kinase (Ikk) complex, which consists of two 
catalytic subunits, Ikk1 and Ikk2 and the regulatory protein Ikk3 
(or Nemo) (reviewed in ref. 9). During canonical NF-κB signaling, 
inflammatory stimuli including cytokines such as Tnf-α generate 
signals that converge at the Ikk complex, phosphorylating Ikk2, 
which in turn phosphorylates the inhibitory molecule inhibitor 
of κB (IκB), resulting in its proteasomal degradation. This releases 
the p65/p50 NF-κB heterodimer, allowing its nuclear transloca-
tion and promoter binding for inflammatory gene transcription. 
A series of studies has indicated a requirement of Ikk2 and p65 
in both murine and human Kras-induced transformation of lung 
epithelial cells and in models of inflammation-induced carcino-
genesis (7, 8, 10, 11). However, the implication of the pathway in 
pancreatic cancer has so far been unexplored.
Interestingly,  in many types of cancer,  including pancreatic 
cancer, the NF-κB and Notch pathways are activated (12–15). 
Classical activation of Notch signaling is triggered by ligation of 
Notch receptors and ligands. This leads to proteolytic cleavage of 
Notch and the release of the Notch intracellular domain (NICD). 
NICD subsequently translocates to the nucleus and binds to the 
DNA-binding protein Rbp-j. This interaction results in assembly 
of a transcriptional activation complex that drives the expression 
of Notch target genes (16). Among the best-characterized direct 
Notch target genes are the Hes and Hey families of transcriptional 
repressors. These genes are found to be upregulated in early PanINs 
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and throughout PDAC but not in normal pancreatic epithelium 
(5, 15). In the context of mutant Kras, Notch pathway activation 
has been shown to have a tumor-promoting role and has been 
implicated in mediating metaplasia of acinar to ductal epithelium, 
a critical process in pancreatic carcinogenesis (17–19).
In the present study we showed that genetic deletion of Ikk2 
in Kras+/LSL-G12DPdx1-cre mice blocked the progression of PanIN 
lesions. We further demonstrated that Tnf-α stimulation of initi-
ated pre-malignant epithelial cells via Ikk2 engaged with canonical 
Notch signaling to upregulate the expression of primary Notch 
target genes. The crosstalk between NF-κB and Notch downreg-
ulated Pparγ, a repressor of inflammatory gene expression and 
retained a constitutive production of proinflammatory mediators 
and cytokines by the transformed cells.
Results
Pancreas-specific deletion of Ikk2 blocks PanIN progression in KrasG12D 
mice. Kras+/LSL-G12DPdx1-cre (abbreviated as KrasG12D) mice express an 
endogenous oncogenic KrasG12D allele initially in pancreatic pro-
genitors and later in the adult pancreas (5). We generated ductal 
epithelial cell lines from PanIN- and PDAC-bearing KrasG12D mice 
and identified constitutive secretion of Tnf-α (Figure 1A), simi-
lar to previous data indicating Tnf-α production by initiated pre-
malignant ovarian epithelial cells (20). To determine the role of 
Ikk2/NF-κB signaling in formation and progression of PanINs, 
we generated Kras+/LSL-G12DIkk2fl/flPdx1-cre (KrasG12DIkk2ΔPdx) mice. 
In parallel, we assessed the contribution of malignant cell–derived 
Tnf-α using Kras+/LSL-G12DTnfafl/flPdx1-cre (KrasG12DTnfaΔPdx) mice.
The compound strains were generated by interbreeding C57BL/6 
mice carrying floxed Ikk2 or Tnfa alleles with the Kras+/LSL-G12D and 
Pdx1-cre strains (Supplemental Figure 1A; supplemental material 
available online with this article; doi:10.1172/JCI45797DS1). No 
gross pathology was observed in the pancreas of Ikk2ΔPdx or TnfaΔPdx 
mice (Supplemental Figure 1B). Activity of the Ikk complex was 
abolished in cells derived from KrasG12DIkk2ΔPdx mice, confirming 
excision of the Ikk2 locus (Figure 1B). Secretion of Tnf-α and Il-6 
in the pancreas was also significantly decreased (P < 0.01, n = 6, 
Figure 1C). Similarly, cell lines derived from PanIN- and PDAC-
bearing KrasG12DTnfaΔPdx mice secreted minimal levels of Tnf-α, 
confirming Tnfa inactivation (Figure 1D).
We assessed the development of PanIN lesions in cohorts (n = 12 per 
time point) of KrasG12D, KrasG12DIkk2ΔPdx, and KrasG12DTnfaΔPdx mice at 2, 
5, and 8 months of age. Histological assessment for the proportion of 
pancreas occupied by PanINs was carried out as previously described 
(4). Ikk2 deletion in KrasG12DIkk2ΔPdx mice resulted in a profound 
decrease in the frequency of high-grade PanINs (PanINs 2 and 3) 
at all time points (P < 0.01; Figure 1E). Only low-grade PanINs were 
present in 5-month-old KrasG12DIkk2ΔPdx mice, while approximately 
80% of the pancreatic parenchyma retained normal exocrine tissue. 
Even at 8 months of age, formation of grade 2 and 3 lesions was min-
imal, and the frequency of grade 1 PanINs was lower compared with 
both KrasG12D and KrasG12DTnfaΔPdx mice (P < 0.01; Figure 1E).
Two-month-old KrasG12DTnfaΔPdx mice exhibited a significant reduc-
tion in early PanIN lesions (P < 0.01, n = 12). However, by 5 months of 
age, PanINs had formed and progressed in a pattern similar to that in 
KrasG12D mice (Figure 1E). These results indicated that, in the context 
of mutant Kras, Ikk2 signaling was important for the development and 
progression of PanINs. Activation of the pathway by Tnf-α provided 
by the transformed epithelial cells was important early during the 
carcinogenic process. However, as the disease progressed, an influx of 
tumor-associated immune cells, primarily macrophages and neutro-
phils, compensated Tnf-α cytokine levels. To address the importance 
of the inflammatory infiltrate to compensate for the lack of inflam-
matory cytokines, we generated chimeras using Mx1-cre mice to target 
Tnf-α deletion in the leukocyte compartment (Supplemental Figure 
2, A–D). Infiltration of these cells was minimal in KrasG12DIkk2ΔPdx pan-
creases, indicating that Ikk2 inactivation impaired their capacity to 
attract other cell types (Supplemental Figure 2, A and B).
To assess whether Ikk2 depletion affected PDAC development, 
we followed cohorts of 50 KrasG12DIkk2ΔPdx and 40 KrasG12D mice for 
nearly 2 years (Table 1 and Supplemental Table 1). Mice were sacri-
ficed when they developed signs of distress. 20% of KrasG12DIkk2ΔPdx 
mice had PDAC, while there was a 50% tumor incidence in KrasG12D 
mice (Figure 1F). Interestingly, deletion of Ikk2 changed the histo-
pathological feature of the observed tumors, as shown by the ratio 
of undifferentiated to glandular morphology in these mice (Figure 
1G) at end point (Table 1 and Supplemental Table 1).
Further histological  analyses of KrasG12DIkk2ΔPdx  pancreases 
showed a profound delay in stromal reaction (Figure 1, H and I). 
Proliferation of acinar cells was assessed by PCNA expression. As 
shown in Figure 1, J and K, there was a reduction in proliferating 
acinar cells in KrasG12DIkk2ΔPdx compared with KrasG12D pancreases. 
No difference was noted in the levels of apoptosis, measured by 
cleaved caspase-3 staining (data not shown). Collectively, these 
data indicated that PanIN progression and development of PDAC 
were dependent on epithelial Ikk2 depletion.
Notch target genes Hes1 and Hey1 are downregulated in KrasG12DIkk2ΔPdx 
PanINs. The Notch pathway, normally quiescent in the adult pan-
creas, is found to be reactivated in pancreatic cancer throughout 
PanIN and PDAC development (15, 17, 21). We assessed the regula-
tion of Notch downstream targets as indicators of disease develop-
ment (5). In accordance with previous studies, we found that the 
classical Notch target genes Hes1 and Hey1 were expressed in KrasG12D 
PanIN-bearing mice (5). However, there was a substantial decrease in 
their expression in age-matched KrasG12DTnfaΔPdx and  KrasG12DIkk2ΔPdx 
mice (Figure 2A). The pancreases of KrasG12DIkk2ΔPdx showed decreased 
expression of Igfr1, Vegf, and tenascin C, all Notch target genes, while 
expression of Myc and the AP-1 family transcription factor Batf was 
not altered (Figure 2A). Inactivation of Tnfa had little impact on 
the expression levels of these genes. Immunofluorescence analysis 
Figure 1
Genetic deletion of Ikk2 inhibits PanIN progression. (A) Tnf-α secre-
tion by ductal cell lines derived from KrasG12D PanIN- or PDAC-bearing 
mice measured by ELISA. Control cells were generated from Kras and 
Kras/Tnfa cre-negative pancreases. (B) Cellular Ikk2 kinase activity in 
cell lines derived from KrasG12D and KrasG12DIkk2ΔPdx mice. (C) Il-6 and 
Tnf-α secretion in pancreatic tissue of KrasG12D and KrasG12DIkk2ΔPdx 
mice. n = 6; **P < 0.01, ***P < 0.01. (D) Tnf-α secretion by cell lines 
derived from KrasG12D (PanIN 1) or KrasG12DTnfaΔPdx PanIN- or PDAC-
bearing mice. Cre-negative Kras and Kras/Tnfa control cells were 
included. Data in C are shown as mean + SD of n = 6 mice, and data in 
A, B, and D are mean + SD of triplicate experiments. (E) Quantification 
of the proportion of pancreas occupied by PanIN lesions. Frequency 
and grade of the lesions was quantified at 2, 5, and 8 months of age. 
Data are shown as mean + SD; P < 0.01. nl, no lesion. (F) Tumor inci-
dence and (G) histology grade in KrasG12D and KrasG12DIkk2ΔPdx mice. 
*P < 0.05. (H–K) KrasG12D and KrasG12DIkk2ΔPdx 4-month old pancre-
ases stained with (H) hematoxylin and eosin, (I) Masson’s trichrome 
(blue, collagen; red, muscle fibers and cytoplasm; black, nuclei) and 
(J and K) anti-PCNA. Original magnification, ×10 (H–J), ×20 (K).
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revealed Hes1-positive staining in PanIN lesions of 3-month-old 
KrasG12D mice. Similar levels of Hes1 were found in KrasG12DTnfaΔPdx 
mice (Figure 2B). In contrast, Hes1 protein was minimal in age-
matched KrasG12DIkk2ΔPdx animals (Figure 2B). These results indicated 
concurrent activity of the classical NF-κB and Notch pathways.
To further dissect the interaction of the Tnf-α/Ikk2 and Notch 
signaling pathways, we examined the response of cell lines derived 
from KrasG12D, KrasG12DTnfaΔPdx and KrasG12DIkk2ΔPdx mice to recom-
binant Tnf-α (rTnf-α) stimulation in vitro. Basal Notch activity 
in KrasG12D cell lines was demonstrated by nuclear localization of 
Table 1
Disease spectrum in KrasG12DIkk2ΔPdx mice
ID	 Age	(d)	 PDAC	 Histology	 Liver	 Lung	 PD	 Ascites	 Skin	 BO	 Atrophy
TH03-35 526 N  N N N N N N Y
TH03-58 599 N  N N N N N N Y
TH03-59 517 N  N N N N N N Y
TH03-61 422 Y Glandular Y Y Y N N Y
TH03-66 501 N  N N N N N N Y
TH03-67 449 N  N N N N N N Y
TH03-82 209 N  N N N N Y N 
TH03-88 297 N  N N N N Y N 
TH03-89 388 N  N N N N N N Y
TH03-115 436 Y Undifferentiated Y Y Y N N N 
TH03-131 587 N  N N N N N N Y
TH03-136 555 N  N N N N N N Y
TH03-148 475 N  N N N N N N Y
TH03-149 391 N  N N N N N N Y
TH03-167 155 N  N N N N Y N 
TH03-177 422 Y Glandular Y N N Y N N
TH03-181 448 N  N N N N N N Y
TH03-196 401 N  N N N N N N Y
TH03-197 412 Y Undifferentiated Y Y Y N N Y 
TH03-206 389 Y Undifferentiated N N N N N N 
TH03-207 455 N  N N N N Y N 
TH03-213 438 N  N N N N N N Y
TH03-344 264 N  N N N N Y N 
TH03-365 428 N  N N N N N N Y
TH03-374 417 N  N N N N N N Y
TH03-384 409 Y Glandular N N N N N N
TH03-402 337 N  N N N N N N Y
TH03-404 316 Y Undifferentiated Y Y Y Y Y Y 
TH03-405 406 N  N N N N N N Y
TH03-416 472 N  N N N N N N Y
TH03-425 515 N  N N N N N N Y
TH03-431 411 N  N N N N N N Y
TH03-452 509 Y Undifferentiated Y Y N Y N Y 
TH03-497 377 N  N N N N N N Y
TH03-499 482 Y Undifferentiated N Y Y N N Y 
TH03-503 568 N  N N N N N N Y
TH03-509 263 N  N N N N Y N 
TH03-515 174 N  N N N N Y N 
TH03-518 248 N  N N N N Y N 
TH03-522 315 N  N N N N N N 
TH03-546 427 N  N N N N N N Y
TH03-551 482 N  N N N N N N Y
TH03-552 517 N  N N N N N N Y
TH03-568 268 N  N N N N Y N 
TH03-574 216 N  N N N N Y N 
TH03-681 498 N  N N N N N N Y
TH03-682 571 N  N N N N N N Y
TH03-693 501 N  N N N N N N Y
TH03-699 585 Y Glandular N N N Y N Y Y
TH03-706 433 N  N N N N Y N N
Median 427.5 20% Y 60% undifferentiated,  12% 12% 10% 8% 24% 12% 58%
   40% glandular
PD, peritoneal disease; BO, biliary obstruction.
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Hes1 and low levels of cytoplasmic staining (Figure 3A). Stimula-
tion with rTnf-α increased expression of both nuclear and cytoplas-
mic Hes1 protein (Figure 3A). The expression of Hes1, Hey1, as well 
as Batf, Vegf, Igfr1, Myc, and tenascin C was increased in KrasG12D and 
KrasG12DTnfaΔPdx cells after rTnf-α stimulation. In contrast, rTnf-α 
failed to upregulate expression of these genes in KrasG12DIkk2ΔPdx cells 
(Figure 3B and Supplemental Figure 3A). We next transiently trans-
fected the cell lines with a Hes1 luciferase reporter construct and 
Figure 2
Molecular analysis of Notch and NF-κB 
target gene expression in KrasG12D 
TnfaΔPdx and KrasG12DIkk2ΔPdx pancre-
ases. (A) Relative mRNA expression 
of Hes1, Hey1, Batf, Vegf, Igfr1, Myc, 
and tenascin C in KrasG12DTnfaΔPdx and 
KrasG12DIkk2ΔPdx 3-month PanIN-bearing 
pancreases was measured by real-time 
PCR. Data are shown as mean + SD; 
n = 6. *P < 0.05, **P < 0.01. The experi-
ment was done in duplicate. (B) Immuno-
fluorescence staining for Hes1 and 
E-cadherin in PanIN-bearing pancreases 
from KrasG12DTnfaΔPdx, KrasG12DIkk2ΔPdx, 
and KrasG12D mice at 3 months of age. 
Original magnification, ×40. Blue, DAPI; 
red, E-cadherin; green, Hes1.
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stimulated them with 1 ng/ml rTnf-α. This resulted in enhanced 
transcriptional activity of the Hes1 promoter in KrasG12DTnfaΔPdx but 
not in KrasG12DIkk2ΔPdx cells (Figure 3C). These results showed that 
in initiated pre-malignant epithelial cells Ikk2 signaling enhanced 
the expression of Notch target genes.
Activation of the NF-κB pathway is known to upregulate Notch 
receptors and ligands, both of which are found to be expressed 
on PanIN and PDAC cells (17, 22–26). However, an interaction 
downstream of the two pathways has not been described. We next 
assessed whether this enhanced expression of Notch target genes 
upon stimulation with rTnf-α was due to upregulation of Notch 
receptors and ligands, which would reinforce downstream signal-
ing. We stimulated KrasG12DTnfaΔPdx cell lines with rTnf-α over a full 
12-hour time course and assessed mRNA expression of Hes1 and 
Hey1. Upregulation of gene expression occurred within 30 min-
utes and reached a plateau between 6 and 12 hours after treatment 
(Figure 3D and Supplemental Figure 3B). This rapid upregulation 
of Hes1 and Hey1 was independent of new protein synthesis and 
suggested a direct interaction between the pathways (Figure 3E 
and Supplemental Figure 3C).
Tnf-α–induced Notch target gene expression requires canonical Notch 
signaling and Ikk2-mediated histone phosphorylation. We next sought 
to determine whether Tnf-α–induced upregulation of Notch tar-
get genes required canonical Notch signaling. This is initiated by 
proteolytic cleavage of NICD following receptor-ligand interac-
tions, mediated by the γ-secretase activity of a multiprotein com-
plex (27). Pharmacological inhibition of γ-secretase using the 
synthetic inhibitor L685458 resulted in attenuation of Hes1 and 
Hey1 expression in rTnf-α–stimulated KrasG12DTnfaΔPdx PanIN cell 
lines (Figure 4A). While expression of both these genes was sensi-
tive to L685458, transcription levels of Il1b, Mmp13, and Cox2, 
all NF-κB targets, remained unaffected (Supplemental Figure 4). 
We maximally engaged Notch receptors by stimulating KrasG12D 
cells with the classical Notch ligands Jagged-2 and Delta-like–1 
(Dll1) and compared the levels of Hes1 and Hey1 expression with 
those after treatment with rTnf-α. rTnf-α induced higher Hes1 
and Hey1 levels than ligand-mediated Notch activation of the 
pathway (Figure 4B).
We further examined the requirement of Notch signaling for 
Tnf-α–mediated upregulation of Hes1 and Hey1 using siRNA to 
knock down the expression of Rbpj, a nuclear transcription fac-
tor essential for Notch target gene expression. Transfection of 
KrasG12DTnfaΔPdx cell  lines with Rbpj siRNA resulted in a 4-fold 
decrease in Hes1 and Hey1 transcripts, confirming the require-
ment of NICD–Rbp-j interaction for upregulation of target gene 
expression (Figure 4C and Supplemental Figure 5A). Expression 
of the NF-κB targets Il1b and Cox2 remained unaffected in Rbpj-
knockdown cells (data not shown). Specific siRNA inhibition of 
Ikk2 also resulted in a downregulation of Hes1 and Hey1 expres-
sion following rTnf-α treatment (Figure 4D and Supplemental 
Figure 5B). This was consistent with our previous observation 
that KrasG12DIkk2ΔPdx cell lines lost the capacity to upregulate Hes1 
and Hey1 upon rTnf-α  stimulation. Similarly, knockdown of 
Nemo blocked Hes1 and Hey1 expression (Supplemental Figure 
5C), while knockdown of Ikk1 (Supplemental Figure 5D) had no 
effect on Hes1 or Hey1 expression.
Hes1 expression is not known to be regulated by NF-κB (16). To 
investigate the pathways downstream of Ikk2 that lead to Hes1 
activation, we examined phosphorylation of histone H3 at serine 
10, a histone modification that is induced by Ikk2 and is linked 
with recruitment of RNA polymerase II and transcriptional acti-
vation (28–30). We carried out ChIP and real-time PCR assays 
and showed that rTnf-α stimulation induced phosphorylation 
of histone H3 at serine 10 at the Hes1 promoter (Figure 5). This 
inducible phosphorylation was abolished in KrasG12DIkk2ΔPdx cells 
(Figure 5). These results indicate a link between Tnf-α–stimulated 
Ikk2 signaling and the Hes1 locus, whereby Tnf-α enhanced the 
transcriptional activity of a classical Notch target gene via Ikk2 by 
inducing histone H3 phosphorylation.
Tnf-α–induced crosstalk between NF-κB and Notch pathways leads 
to Hes1-mediated Pparγ inhibition. Hes1 is known to bind to the 
promoter region of the nuclear receptor Pparγ and suppress its 
expression (31). Pparγ represses inflammatory gene expression 
induced by other classes of transcription factors including NF-κB. 
We observed higher Pparg mRNA expression  in 2-month-old 
KrasG12DTnfaΔPdx and KrasG12DIkk2ΔPdx compared with KrasG12D pan-
creases  (Figure 6A). However, by 5 months of age, expression 
of Pparg  in KrasG12DTnfaΔPdx was only marginally higher than in 
KrasG12D mice. In contrast, it remained elevated in KrasG12DIkk2ΔPdx 
pancreases (Figure 6A). Moreover, after rTnf-α stimulation, Pparg 
mRNA in KrasG12DTnfaΔPdx cells decreased to levels similar to those 
in KrasG12D cells (Figure 6B). Binding of Hes1 to the Pparg promoter 
in KrasG12D cells was confirmed by ChIP (Figure 6C). These data 
indicated that Tnf-α–induced Hes1 upregulation in initiated pre-
malignant cells resulted in Pparg suppression.
We further examined the interplay between Hes1 and Pparg using 
Hes1-specific siRNA to knock down Hes1 expression in KrasG12D 
PanIN cell lines. This resulted in robust upregulation of Pparg 
expression, which indicates Hes1-mediated inhibition of Pparg 
transcription (Figure 6D and Supplemental Figure 6, A and B). 
Similarly, Cebpa, a transcription factor whose expression requires 
Pparg, was also negatively regulated by Hes1 (Figure 6D and Sup-
plemental Figure 6C).
Hes proteins suppress gene expression by a number of mechanisms 
that include binding to N boxes or suppressing E box–mediated tran-
scription in promoters that contain tandem E boxes and Rbp-j sites 
(32–34). We investigated the mechanism by which Hes1 inhibits 
Pparg expression in our system by analyzing the effects of Hes1 on 
Figure 3
Tnf-α–induced Notch and NF-κB target gene expression in PanIN cell 
lines. (A) Expression of Hes1 and Hey1 in KrasG12D PanIN cell lines 
was examined by immunofluorescence staining; cells were left unstim-
ulated or were stimulated with 10 ng/ml rTnf-α for 24 hours. Original 
magnification, ×40. Blue, DAPI; red, actin; green, Hes1. One represen-
tative experiment of 3 performed is shown. (B) Relative mRNA expres-
sion of Hes1 and Il1b in PanIN cell lines stimulated with 1 ng/ml rTnf-α 
for 6 hours. Relative expression was calculated by setting expression 
of untreated KrasG12D samples as 1. (C) Hes1 luciferase reporter assay 
in KrasG12DTnfaΔPdx and KrasG12DIkk2ΔPdx PanIN cell lines stimulated 
with 1 ng/ml rTnf-α for 6 hours. Results were normalized to firefly 
luciferase activity relative to internal control and are expressed as 
mean + SD from triplicate transfections. ***P < 0.01. One representa-
tive experiment of 3 performed is shown. (D) Kinetic analysis of Hes1 
mRNA expression in KrasG12DTnfaΔPdx PanIN cell lines stimulated with 
1 ng/ml rTnf-α. (E) KrasG12DTnfaΔPdx PanIN cells were treated with 
1 ng/ml rTnf-α in the presence or absence of 15 μg/ml cycloheximide 
(CHX). Expression of Hes1 was quantified by real-time PCR. Relative 
expression was calculated by setting expression of untreated KrasG12D 
samples as 1. (B, D, and E) Data are shown as mean + SD of triplicate 
determinants, and 1 representative experiment of 3 is shown.
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the activity of a Pparg promoter–driven reporter gene. We confirmed, 
in transient transfection assays, that Hes1 suppressed expression of 
a Pparg promoter–driven reporter gene, in a dose-dependent manner 
(Figure 6E), through sequences from –1,500 to –160 that contain 6 
E-box elements (31). A truncated E box sequence abrogated the abil-
ity of Hes1 to inhibit Pparg promoter activity (Figure 6F).
Pharmacological intervention in Notch and Pparγ signaling modulates 
the inflammatory profile of malignant cells and inhibits PanIN growth. 
Pharmacological inhibition of NF-κB or Notch signaling by anti–
Tnf-α, the NF-κB inhibitor Bay11-7082, or the γ-secretase inhibi-
tor DAPT could block the expression of Hes1 in PanIN-bearing 
5-month-old mice. As shown in Figure 7, each of these approaches 
inhibited Hes1 in PanIN-bearing pancreases and reduced Tnf-α 
cytokine levels in KrasG12D cells (P < 0.01; Figure 7, A–C).
We hypothesized that this interplay between NF-κB and Notch 
signaling and a coordinated downregulation of Pparg acted as a 
forward feedback loop that sustains expression of inflammatory 
cytokines and chemokines by the transformed cells. To address 
this hypothesis, we treated KrasG12D mice with DAPT, a γ-secretase 
inhibitor. Cytokine arrays on whole pancreases of untreated and 
DAPT-treated mice revealed downregulation of proinflammatory 
cytokines and chemokines (Figure 7D). To further strengthen the 
impact of Notch signaling on the inflammatory state of the trans-
formed cells, we used KrasG12D mice carrying the Rosa26-LSL-Eyfp 
Figure 4
Tnf-α–induced Notch target gene expression requires expression of Rbpj and Ikk2. (A) Inhibition of Hes1 and Hey1 mRNA expression in Tnf-α– 
induced KrasG12DTnfaΔPdx PanIN cells treated with the γ-secretase inhibitor L685458 (5 μM). Cells were stimulated with 1 ng/ml rTnf-α. (B) 
KrasG12DTnfaΔPdx PanIN cells were treated with rTnf-α, 20 μg/ml Jagged-2/Fc, or cocultured with OP9-DL1 cells. Tnf-α was more efficient in 
inducing the expression of Hes1 and Hey1. The results were normalized to values obtained from KrasG12D cells. (C and D) KrasG12DTnfaΔPdx 
PanIN cell lines transfected with (C) Rbpj- or (D) Ikk2-specific siRNA. Forty-eight hours after transfection, cells were stimulated with 1 ng/ml 
rTnf-α for 6 hours, and expression of Hes1 was quantified by real-time PCR. Nontargeting siRNA and/or unstimulated controls were included. 
Results were normalized to uninfected and unstimulated KrasG12DTnfaΔPdx cells. All data are shown as mean + SD of triplicate determinants and 
are representative of 3 independent experiments.
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allele. In these mice, Eyfp expression was confined to the KrasG12D-
expressing epithelial cell pool. Cohorts of n = 12 mice were treated 
with DAPT or vehicle, and the Eyfp-positive cells were isolated by 
FACS. Analysis of the sorted cells showed significant downregula-
tion of Tnfa (P < 0.05), Il6 (P < 0.001), and Il1b expression (P < 0.01) 
in the DAPT-treated group (Figure 7E).
We finally asked whether treatment with rosiglitazone, a Pparγ 
agonist with antiinflammatory properties in vivo, would influence 
PanIN development in KrasG12D mice (35, 36). Mice were treated 
with 3 mg/kg/d rosiglitazone added to their daily diet, and cohorts 
of KrasG12D mice were followed for nearly 2 years (Table 2). Progres-
sion of PanINs was significantly delayed in rosiglitazone-treated 
mice compared with the untreated controls (P < 0.01, n = 12, Fig-
ure 8A). Tumor incidence was 2-fold lower (11 of 40) compared 
with that in untreated mice, greater than that observed in the Ikk2-
depleted KrasG12DIkk2ΔPdx animals (10 of 50) (Figure 8, B and C). 
Analysis of the macrophage infiltrate showed a reduction in the 
frequency of these cells in rosiglitazone-treated animals (Figure 
8D). In total, these data suggest that modulation of tumor-associ-
ated inflammatory networks can inhibit PanIN progression and 
restrain stromal inflammatory components.
Discussion
The integrative interactions among proinflammatory cytokines, 
transcription factors, and oncogenic signaling pathways are cur-
rently the focus of extensive investigation. Here we demonstrated 
that in the context of Kras-driven pancreatic carcinogenesis, genet-
ic inactivation of Ikk2 blocked the progression of PanIN lesions. 
Depletion of Ikk2 correlated with decreased expression of the clas-
sical Notch target genes Hes1 and Hey1. Our further work showed 
that Tnf-α–induced activation of the NF-κB pathway in initiated 
pre-malignant epithelial cells cooperated with basal Notch sig-
nals to enhance the expression of Notch target genes, in an Ikk2-
dependent manner. The interplay between Ikk2 and Notch, via the 
expression of Hes1, repressed the antiinflammatory nuclear recep-
tor Pparγ and created a forward feedback loop that retained the 
transformed cells in an inflammatory state.
Ikk2 is essential for canonical activation of NF-κB and has been 
shown to be required for carcinogenesis both in settings where 
NF-κB activation is driven by ras mutations and in inflammation-
induced cancer models (7, 8, 10, 11). However, the role of the Ikk2/
NF-κB axis is context and cell type dependent; in certain settings, 
such as those observed in hepatocarcinogenesis, Ikk2 depletion 
results in tumor promotion (37). Our data demonstrated that in the 
context of Kras-driven pancreatic carcinogenesis, genetic deletion of 
Ikk2 blocked the progression of malignant epithelial cell lesions.
Activation of NF-κB is known to regulate a number of cellular 
processes, including a malignant cell–intrinsic network of inflam-
matory cytokines and chemokines (38). These act in an autocrine 
and paracrine manner both on the malignant cells and on the sur-
rounding stroma and induce the activity of a number of oncogen-
ic transcription factors, including Stat3 and AP-1 as well as NF-κB 
itself (10, 11, 20, 39, 40). With deletion of Ikk2 in initiated pre-
malignant epithelial cells, an array of inflammatory cytokines and 
chemokines at the tumor site was significantly downregulated, 
and recruitment of macrophages and neutrophils was profoundly 
decreased (Supplemental Figure 2 and data not shown). Cell-
autonomous processes such as proliferation were also affected, 
Figure 5
Tnf-α–induced Notch target gene expression is dependent on Ikk2 and chromatin remodeling. ChIP was performed on rTnf-α–treated KrasG12D, 
KrasG12DTnfaΔPdx, and KrasG12DIkk2ΔPdx samples with anti–histone H3 (A) or anti–phospho–histone H3 at serine 10 (pH3) (B). Rabbit IgG was 
used as control. Precipitated DNA was measured by real-time PCR using primers specific for Hes1. Results are shown as mean + SD of triplicate 
determinants and are representative of 3 independent experiments.
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and downregulation of Notch target genes was observed. Notch 
signaling has oncogenic properties in pancreatic carcinogenesis; 
however, a link between this pathway and canonical NF-κB had 
not been previously appreciated (17–19).
Tnf-α is a major inflammatory cytokine that activates the NF-κB 
pathway and is regulated in its expression by NF-κB. We demon-
strated that Tnf-α stimulation of initiated pre-malignant epithe-
lial cells resulted in upregulated expression of classical Notch tar-
gets. This occurred at the level of transcription by Ikk2-mediated 
phosphorylation of histone H3, a modification that is linked with 
transcriptional activation (28–30). Accordingly, Tnf-α–mediated 
upregulation of Hes1 and Hey1 was independent of de novo protein 
synthesis but required canonical Notch signaling. Our data suggest 
that activation of NF-κB signaling can synergize with basal Notch 
signals to induce maximal expression of Notch target genes.
Conversely, Vilimas et al. have demonstrated that in T cell acute 
lymphoblastic leukemia, constitutively active Notch results in 
activation of the NF-κB pathway (13). Work from the same group 
demonstrated that the Notch/Hes1 signaling sustained NF-κB 
pathway activation by repressing the deubiquitinase CYLD, a nega-
tive Ikk complex regulator (41). In conjunction with our data, these 
studies indicate a bidirectional interaction between the NF-κB 
and Notch pathways that can result in bidirectional expression of 
target genes and enhanced malignant cell growth.
Within the tumor microenvironment, Tnf-α stems from two 
sources: the tumor-infiltrating immune cells and the malignant 
cells. In accordance with previous studies, we found an influx 
of inflammatory cells, predominantly macrophages and neutro-
phils, in KrasG12D mice as disease progressed (42). These cells were 
a major source of the cytokine in aged mice. We also showed that 
Kras-induced PanIN and PDAC cells constitutively secreted low 
levels of Tnf-α. Crosstalk between NF-κB and Notch signaling 
can therefore be fueled both by a constitutive autonomous activa-
tion of NF-κB signaling due to mutant Kras and by inflammatory 
cytokines provided by the immune cells. Our data suggested that 
early in the carcinogenic process, Tnf-α secreted by the malig-
nant cells is critical for their growth, while at later stages, influx 
of immune cells constitutes the major source of the cytokine.
Figure 6
Tnf-α/NF-κB and Notch crosstalk 
leads to Hes1-mediated Pparg inhibi-
tion. (A) Pparg mRNA expression in 
2- and 5-month-old KrasG12DTnfaΔPdx 
and KrasG12DIkk2ΔPdx pancreases. 
Data were normalized to KrasG12D 
pancreases. Data are shown as 
mean + SD; n = 6. ***P < 0.001. The 
experiment was performed in dupli-
cate. (B) Tnf-α stimulation (1 ng/ml) 
induced downregulation of Pparg in 
KrasG12DTnfaΔPdx PanIN cell lines. 
(C) ChIP was performed on KrasG12D 
cells using anti-Hes1 or a control 
IgG. Precipitated DNA was ampli-
fied by real-time PCR using primers 
specific for Pparg. (D) siRNA knock-
down of Hes1 upregulated Pparg 
and Cebpa expression in KrasG12D 
PanIN cells. (E) KrasG12D and 
KrasG12DTnfaΔPdx PanIN cells were 
cotransfected in duplicate with a 
Pparg reporter construct containing 
1,500 bases of the proximal Pparg 
promoter (full length) and a Hes1 
expression plasmid or empty vec-
tor control. Twenty-four hours after 
transfection, cells were analyzed 
for luciferase activity. (F) Transfec-
tion of KrasG12DTnfaΔPdx PanIN cells 
as described in E with a full-length 
Pparg reporter construct or a con-
struct with a truncated Hes1-binding 
sequence. All data are shown as 
mean + SD from duplicate transfec-
tions and are representative of 3 
independent experiments.
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 12      December 2011  4695
Inflammation induced extrinsically by tissue damage (i.e., pan-
creatitis) or inflammation related to metabolic stress has been 
shown to accelerate PanIN development (43–45). The underlying 
mechanism is a deregulated regeneration process whereby consti-
tutively active Notch permits PanIN formation. By identifying a 
direct link between NF-κB signaling and enhanced Notch activity, 
we provide evidence that a major proinflammatory and a develop-
mental signaling pathway can cooperate in the context of mutant 
ras to promote carcinogenesis.
Repression of inflammatory genes by the nuclear receptor Pparγ 
has been highlighted as an important mechanism by which cells can 
regulate inflammatory responses and homeostasis (46). Our find-
ings demonstrated that a Tnf-α/Hes1–driven mechanism of Pparγ 
inhibition operates in initiated pre-malignant pancreatic epithelial 
cells. Hes1 suppressed Pparg expression by targeting E box elements 
in the promoter of the gene. We propose that the coordinated activity 
of NF-κB and Notch along with a suppression of antiinflammatory 
transcription factors such as Pparγ leads to a sustained expression 
of inflammatory genes and transcription factors and a constitu-
tive production of inflammatory mediators and chemokines by the 
transformed cells. Pharmacological inhibition of the Notch pathway 
in KrasG12D mice with a γ-secretase inhibitor resulted in attenuation 
of inflammatory gene expression by the transformed cells and down-
regulation of cytokine production in the pancreas. It has also been 
shown to significantly attenuate the development of PanINs (21).
Synthetic Pparγ ligands induce allosteric changes to the receptor 
and allow it to enter into a repression pathway (47). These agents 
are shown to have antiinflammatory activity in a variety of models 
of acute and chronic inflammation, as reviewed in ref. 35. By using 
rosiglitazone, a Pparγ ligand of the thiazolidinedione class, to treat 
Table 2
Disease spectrum in KrasG12D mice treated with rosiglitazone
ID	 Age	(d)	 PDAC	 Histology	 Liver	 Lung	 PD	 Ascites	 Skin	 BO
CHS601-8 421 N  N N N N N N
CHS601-15 438 N  N N N N N N
CHS601-19 567 N  N N N N N N
CHS601-21 558 Y Glandular N N Y Y N Y
CHS601-25 621 N  N N N N N N
CHS601-27 521 Y Glandular Y N N Y N Y
CHS601-30 504 Y Glandular N N Y N N Y
CHS601-31 486 N  N N N N N N
CHS601-33 531 N  N N N N N N
CHS601-46 367 N  N N N N N N
CHS601-55 422 N  N N N N N N
CHS601-57	 394	 Y	 Undifferentiated Y Y N N N Y
CHS601-67	 357	 Y	 Glandular Y N N N N N
CHS601-68 547 Y Glandular Y N N Y N Y
CHS601-69 555 N  N N N N N N
CHS601-79 501 N  N N N N N N
CHS601-80 408 N  N N N N N N
CHS601-83 486 N  N N N N N N
CHS601-84 433 N  N N N N N N
CHS601-92 567 N  N N N N N N
CHS601-96 555 N  N N N N N N
CHS601-99 537 N  N N N N N N
CHS601-108 521 N  N N N N N N
CHS301-116	 482	 Y	 Glandular N N Y Y N Y
CHS601-127 444 N  N N N N N N
CHS601-128 518 N  N N N N N N
CHS601-142	 525	 Y	 Glandular Y N N N N Y
CHS601-144 367 N  N N N N N N
CHS601-161 418 N  N N N N N N
CHS601-167 632 N  N N N N N N
CHS601-170	 555	 Y	 Undifferentiated Y Y N N N N
CHS601-177 407 N  N N N N N N
CHS601-178 634 N  N N N N N N
CHS601-185	 524	 Y	 Glandular N N N Y N Y
CHS601-192 301 N  N N N N N N
CHS601-197 287 N  N N N N N N
CHS601-201 425 N  N N N N N N
CHS601-222 486 N  N N N N N N
CHS601-224	 411	 Y	 Glandular Y N N N Y N
CHS601-229 518 N  N N N N N N
Median 493.5	 27.5%	 18% undifferentiated,  17.5% 5% 7.5% 12.5% 2.5% 20%
   82%	glandular
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KrasG12D mice, we demonstrated a marked decrease in the frequency 
of PanINs and their progression into invasive carcinoma. Nev-
ertheless, Pparγ has a wide range of effects on metabolism (48). 
Thiazolidinedione drugs are best characterized by their insulin-
sensitizing action and have been used in the treatment of diabetes. 
Notably, individuals with type 2 diabetes receiving metformin, a 
glucose-lowering drug, have a decreased risk of developing pan-
creatic cancer (49, 50).
Our findings and an increasing body of studies highlight the 
requirement for inflammatory signaling pathways in the devel-
opment of pancreatic cancer and reveal key molecular targets to 
assist current treatments.
Methods
Mouse strains. Kras+/LSL-G12D, Pdx1-cre (5), Tnfafl/fl (51), and Ikk2fl/fl strains (52) 
were interbred to obtain KrasG12D, KrasG12DTnfaΔPdx , and KrasG12DIkk2ΔPdx tri-
ple mutant mice on a mixed 129/SvJaa/C57BL/6 background (see Supple-
ment Figure 1 for the breeding plan). Ikk2fl/fl mice were a gift from Toby 
Lawrence (Inflammation Biology Group, Centre d’Immunologie de Mar-
seille-Luminy, CNRS-INSERM-Université de la Méditerranée, Marseille, 
France). Mx1-cre mice were obtained from The Jackson Laboratory (53) and 
crossed to Tnfafl/fl mice. The mice were genotyped at weaning by a commer-
cial vendor (Transnetyx). Six-week-old KrasG12D and KrasG12DTnfaΔPdx female 
mice were lethally irradiated and underwent transplantation with bone 
marrow of female Tnfafl/fl or Tnfafl/flMx1-cre mice (n = 10 each group). Two-
month old mice were injected 3 times with 5 μg/g body weight poly(I:C) 
to delete Tnfa. Deletion was examined by Tnf-α ELISA of peripheral leuko-
cytes upon ex vivo LPS stimulation. For in vivo experiments, we used rosi-
glitazone (Cayman Chemical) incorporated into standard rodent chow 
(3 mg/kg/d; 8 weeks); the Notch antagonist N-[N-(3,5-difluorophenace-
tyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT/γ-secretase inhibitor IX, 
Calbiochem) at 100 mg/kg/d i.p.; L685458 (Sigma-Aldrich) and Bay11-
7082 (Alexis) at 10 mg/kg/d i.p. or vehicle; anti–murine Tnf-α (R&D Sys-
tems) at 10 mg/kg/d or respective IgG control antibody (R&D Systems). 
Five-month-old mice were treated for 1 week.
Cell lines and reagents. Primary pancreatic ductal cell lines were derived 
from KrasG12D, KrasG12DTnfaΔPdx, and KrasG12DIkk2ΔPdx mice as previously 
described (54). PanIN cell lines were derived from PanIN lesions with no 
invasive cancer present within the pancreas of the mouse. OP9-DL1 cells, a 
bone marrow–derived stromal cell line that ectopically expresses the Notch 
ligand Dll1 (55), were cocultured with KrasG12DTnfaΔPdx pancreatic ductal 
cells. Cycloheximide and L685458 were purchased from Sigma-Aldrich. 
Recombinant mouse Tnf-α and Jagged-2/Fc chimeric protein were pur-
chased from R&D Systems.
Histology and immunofluorescence. Histological analysis of pancreases was 
carried out by standard procedures. Specimens were harvested from time-
matched animals, fixed in buffered formalin, and embedded in paraffin. 
Tissue sections (5 μm) were stained with hematoxylin and eosin or used 
for immunostaining. PanIN lesions and PDACs were graded as previously 
described (56). Proliferating cells were assessed by immunohistochemistry 
using an anti-PCNA antibody (BD Biosciences). Trichrome (Masson’s) 
staining was carried out according to the manufacturer’s instructions 
(Sigma-Aldrich). For immunofluorescence staining, cells were stained 
using anti-Hes1  (Santa Cruz Biotechnology  Inc.) or anti–E-cadherin 
(Invitrogen) primary antibodies. Cell nuclei were counterstained with 
DAPI, and cells were visualized under a LSM 510 confocal microscope.
Flow cytometry. Pancreases were minced and digested with 2 mg/ml 
collagenase type IV (Sigma-Aldrich). Single-cell suspensions were pre-
pared and cells were immunolabeled with fluorochrome-conjugated 
antibodies in PBS supplemented with 1% FBS. All antibodies were pur-
chased from eBioscience: anti-F4/80–APC (clone BM8), anti-CD11b–PE 
(M1/70), anti-Ly6G–FITC (RB6-8C5). Flow cytometric data were subse-
quently acquired on a FACSCalibur flow cytometer (BD Biosciences) and 
analyzed using FlowJo software. For sorting of Eyfp-positive pancreatic 
epithelial cells, single-cell suspensions were further digested with 0.05% 
trypsin (Sigma-Aldrich), and EYFP-positive cells were collected using a 
FACSAria II sorter (BD Biosciences).
Real-time PCR analysis, protein expression, and kinase activity assay. Total tis-
sue RNA was prepared using an RNeasy kit (QIAGEN). Quantitative PCR 
was performed as described previously (57). We performed antibody-based 
multiplex cytokine arrays analyzing the abundance of 62 cytokines and 
chemokines (Millipore). Tnf-α levels in cell culture supernatants were 
determined using a commercially available ELISA kit  (R&D Systems) 
according to the manufacturer’s instructions. Cells and tumors were lysed 
and analyzed by SDS-PAGE and immunoblotting (58) with antibodies 
to Hes1 and Rbp-j (both from Santa Cruz Biotechnology Inc.), Ikk2 (Cell 
Signaling Technology), and β-actin (Sigma-Aldrich). In vitro Ikk2 kinase 
activity was assessed using the Kinase Assay Kit (Cell Signaling Technol-
ogy) according to the manufacturer’s instructions.
ChIP. ChIP was performed with the EZ-ChIP Assay Kit (Millipore) in 
accordance with the manufacturer’s instructions. A total of 106 PanIN cells 
were used per condition. Antibodies against phospho–histone H3 at serine 
10 (Cell Signaling Technology), anti–total histone H3 (Cell Signaling Tech-
nology), and control rabbit IgG (R&D Systems) were used.
siRNA transfection. Rbpj-, Ikk2-, and Hes1-specific siRNAs and nontarget-
ing control siRNAs were purchased from Dharmacon. siRNAs were trans-
fected with Lipofectamine RNAiMAX reagent (Invitrogen).
Luciferase reporter assay. For Hes1 reporter gene assays, primary KrasG12D 
TnfaΔPdx and KrasG12DIkk2ΔPdx cells were transfected in duplicate in 24-well 
plates with a Hes1 luciferase reporter construct containing the –194 to +160 
promoter fragment of the Hes1 gene inserted upstream of the luciferase 
gene in pGL2 (gift from Sangram S. Sisodia, Department of Neurobiology, 
University of Chicago, Chicago, Illinois, USA) and an internal control plas-
mid encoding Renilla luciferase (Promega) with Lipofectamine Plus reagent 
from Invitrogen (59, 60). On the next day, cells were stimulated with rTnf-α 
for 6 hours, and cell lysates were prepared and analyzed for firefly and 
Renilla luciferase activity with the Dual-Luciferase Reporter Assay System 
Figure 7
Inhibition of Notch/NF-κB signaling attenuates the inflammatory pro-
file of malignant cells. (A) KrasG12DTnfaΔPdx cells were stimulated with 
1 ng/ml rTnf-α for 6 hours in the presence or absence of L685458 
or Bay11-7082. Hes1 mRNA expression was quantified by real-time 
PCR. Results were normalized to unstimulated KrasG12D cells. Data are 
shown as mean + SD of triplicate determinants and are representative 
of 3 independent experiments. (B) Hes1 mRNA expression in pancre-
ases of 5-month-old untreated KrasG12D and KrasG12DIkk2ΔPdx mice and 
of KrasG12D mice treated with anti–Tnf-α, control IgG, DAPT, Bay11-
7082, or the vehicle control. Results were normalized to Kras pancre-
ases. Data are shown as mean + SD; n = 6. **P < 0.01. The experi-
ment was done in duplicate. (C) KrasG12D PanIN cells were treated with 
DAPT or Bay11-7082. Tnfa mRNA expression and cytokine secretion 
are indicated. Data are shown as mean + SD of triplicate experiments 
and are representative of 3 independent experiments. (D) Cytokine 
and chemokine array on whole pancreases of DAPT or vehicle-treated 
5-month-old KrasG12D mice. The data are represented graphically as 
normalized signal intensity. (E) Tnfa, Il6, Il1b, and Mmp7 expression 
in FACS-sorted EYFP-positive KrasG12D cells treated for 1 week with 
DAPT or vehicle. Data are shown as mean + SD; n = 12. *P < 0.05, 
**P < 0.01, ***P < 0.001. Analysis of Mmp7 expression did not reveal 
statistical significance.
research article
4698	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 12      December 2011
(Promega). The Pparg reporter gene and Hes1 plasmids (gifts from Marc 
Montminy, Salk Institute for Biological Studies, La Jolla, California, USA) 
have been previously described (31). Cells were transfected with the Pparg 
reporter plasmids and an expression plasmid encoding Hes1 or a control 
vector as described for Hes1 reporter gene assays. Results are shown as fire-
fly normalized to Renilla luciferase activity.
Statistics. Results were tested for statistical significance using 1- or 2-way 
ANOVA and Bonferonni’s multiple comparisons test on GraphPad Prism 
version 4.0c software. Tumor incidence was analyzed by Fisher’s exact test. 
P values of 0.05 or less were considered statistically significant.
Study approval. Mice were maintained under specific pathogen–free con-
ditions in the Biological Services Unit, Barts Cancer Institute, Queen Mary 
University of London, and used according to the established institutional 
guidelines under the authority of a UK Home Office project license (Guid-
ance on Operation of Animals [Scientific Procedures] Act 1986; all animal 
studies were approved by the UK Home Office).
Figure 8
Rosiglitazone treatment blocks PanIN progression in KrasG12D mice. (A) Quantification of the percentage or pancreatic parenchyma occupied by 
PanINs in KrasG12D mice treated with rosiglitazone compared with untreated controls. Values are shown as mean + SD; n = 12. (B) Tumor incidence 
and (C) histology grade in rosiglitazone-treated KrasG12D mice compared with untreated KrasG12D and KrasG12DIkk2ΔPdx mice. (D) Percentage of 
F4/80+CD11b+Gr1– cells in the pancreas of 2-, 5-, and 8-month-old KrasG12D mice treated with rosiglitazone or untreated as measured by flow cytom-
etry. Each data point represents an individual mouse. Mean values are depicted by the horizontal lines; n = 10. *P < 0.05, **P < 0.01, ***P < 0.001.
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